| Title | Collaboration Type | HHS Participating Agencies | NIH Participating Institutes, Centers, and Offices | Description |
|---|---|---|---|---|
| 2015 Dietary Guidelines Management Team | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDDK | The Dietary Guidelines Management Team includes federal staff representing the Departments of Health and Human Services and Agriculture throughout the Dietary Guidelines for Americans revision process and supports the Dietary Guidelines Advisory Committee from the planning phase to the final report phase. |
| 9th NICHD Structural Birth Defects Meeting | Meeting/ Workshop | CDC | NICHD, CSR, NHGRI, NHLBI, NIAAA, NIAMS, NIDCR, NIDDK, NIEHS, NINDS | This meeting will bring together 45 researchers funded through the Eunice Kennedy Shriver National Institute of Child Health and Human Development''s (NICHD) Birth Defects Initiatives [PAR-12-034, Developmental Mechanisms of Human Structural Birth Defects (P01) and PA-11-085, Genetic Susceptibility and Variability of Human Structural Birth Defects (R01)], as well as other select NICHD Principal Investigators (PIs) who comprise the Birth Defects Working Group (a total of 56 grantees). The working group is unique in that it includes both basic scientists and clinicians, and the projects they oversee emphasize the translational aspects of birth defects research. These recurring meetings are designed to maintain an interactive special interest working group of investigators who are interested in multidisciplinary approaches to enhancing our understanding of the genetic epidemiology, etiology, pathogenesis, developmental biology, and genetics of structural birth defects. The research areas covered currently include the study of neural tube and other structural central nervous system (CNS) defects, cardiac defects, congenital diaphragmatic hernia, limb defects, skeletal dysplasias, osteogenesis imperfecta, congenital contractures, club foot, Cornelia de Lange Syndrome, pituitary defects, cryptorchidism, and craniofacial defects. The purpose of the meeting is to provide a forum for the investigators to discuss the plans and progress of their research, exchange ideas and information, share resources, and foster synergistic collaborations relevant to the research goals of the NICHD Birth Defects Initiative. It is also an opportunity for the PIs to provide input and advice to NIH Program Staff. There will be an invited keynote speaker (Liliana Solnica-Krezel, Washington University, St. Louis) and a special round table discussion on tissue morphogenesis and biophysical and biomechanical aspects of embryonic development within the context of understanding normal development and structural birth defects. Representatives from the Centers for Disease Control and Prevention (CDC) Birth Defects Branch, National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), NICHD Division of Scientific Review (DSR), and National Institutes of Health (NIH) Center for Scientific Review (CSR) also will be invited. |
| A qPCR-Based Approach to Develop Serological Assays for Influenza Virus: Comparison with Other Assays Using Clinical Samples | Research Initiative | FDA | NIAID | Currently, the assays to measure immunogenicity of a flu vaccine are serologically based hemagglutinin inhibition and microneutralization assays. The assay results vary across laboratories, making it difficult to compare results across multiple sites. FDA standardized the qPCR based neutralization assay and qualified and tested the assay using human samples and compared it to the currently used method (comparability studies). The assay allows for quantitation of results which could be compared across multiple sites using standardized reagents and could have regulatory impact since results from clinical trials evaluating different vaccine candidates can be compared globally. |
| A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews | Research Initiative | CDC | NCI | A cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure. |
| A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation | Committee, Work group, Advisory group, or Task Force | OS | CC | Dr. Marion Danis is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management. |
| A5295 Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects | Research Initiative | CDC | NIAID | This initiative will estimate the sensitivity of a single Xpert MTB/RIF assay (performed on sputum) in TB suspects with at least one acid fast bacilli (AFB) sputum smear positive result and at least one culture result positive for M. tuberculosis. |
| Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) | Research Initiative | FDA | NIDA | ALERTT is part of ACTTION - The mission of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health. |
| Action for Health in Diabetes (Look AHEAD) | Research Initiative | CDC, IHS | NIDDK, NHLBI | This study is a 16-center, randomized clinical trial investigating the long-term health consequences of weight loss. Enrollment occurred between 2001-2004 with a planned follow-up of up to 13.5 years. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. The study intervention was discontinued in Sept. 2012 on the recommendation of the Data and Safety Monitoring Board (DSMB), as there were no differences between the two groups after up to 11 years of follow-up. The study will continue to follow participants for study outcomes. |
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) | Research Initiative | CDC | NHLBI, NIDDK | ACCORD was a large clinical study primarily composed of three clinical trials that tested treatment approaches to determine the best ways to decrease the high rate of major cardiovascular disease (CVD) events – heart attack, stroke, or death from CVD – among people with type 2 diabetes who were at especially high risk of having a CVD event. |
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-up Study (ACCORDION) -- Health Related | Research Initiative | CDC | NHLBI | The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study was primarily composed of three clinical trials that tested treatment approaches to determine the best ways to decrease the high rate of major cardiovascular disease (CVD) events – heart attack, stroke, or death from CVD – among people with type 2 diabetes who are at especially high risk of having a CVD event, like a heart attack or stroke. ACCORDION (the ACCORD Follow-up Study) is a prospective, observational follow-up study of approximately 8000 participants who were treated and followed in the ACCORD Trial. It is designed to further elucidate and clarify the long-term effects of the ACCORD treatment strategy and provide additional data on the long-term relationships among various cardiovascular and diabetic risk factors. ACCORD participants had type 2 diabetes and were at high risk for a CVD event. Those who agree to participate in ACCORDION will continue to be followed through clinic and phone visits for an average of 3.5 years in the period 2011 through 2014. Participants will be seen in 76 clinics across the United States and Canada. The CDC is contributing intellectually and financially to the Health Related Quality of Life and Cost Effectiveness substudies of the trial. |
| Addiction Technology Transfer Center | Resource Development | SAMHSA | NIDA | Accelerating the dissemination of research-based drug abuse treatment into clinical practice is a priority for the National Institute on Drug Abuse (NIDA) and represents the core mission of the Blending Initiative. NIDA and the Substance Abuse and Mental Health Services Administration (SAMHSA) joined together to create the Blending Initiative in 2001 to reduce the gap that exists between the publication of research results and impact on treatment delivery. This initiative incorporates collaboration between clinicians, scientists, and experienced trainers to catalyze the creation of user-friendly treatment tools and products and facilitate the adoption of research-based interventions into front-line clinical settings. Through this initiative, NIDA and SAMHSA’s Addiction Technology Transfer Centers (ATTCs) disseminate treatment and training products based on results from studies conducted by the National Drug Abuse Clinical Trials Network (CTN) as well as other NIDA-supported research. |
| Adjuvant Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID, NCI | Staff from all NIAID Divisions, program staff from BARDA, and regulatory staff from FDA exchange information about ongoing programs related to novel adjuvants for infectious disease vaccines, identify high priority research areas (and gap areas), and discuss ideas to accelerate progress in adjuvant research through better access to information and resources. |
| Administration for Community Living (ACL) - NIA Partnership | Other | ACL | NIA, NIDCR, NIMH, NIMHD, NINDS, NINR | This group is made up of representatives from the Administration for Community Living/Administration on Aging and the National Institute on Aging who are working to identify evidence-based interventions that are ready for dissemination and implementation in community programs and collaboratively support their translation into the community. These efforts may also include setting up ways to evaluate the success of these dissemination and implementation efforts. Areas of interest identified to date include Family Caregiving, Exercise/Physical Activity, Nutrition, Elder Mistreatment/Abuse/Financial Fraud, Falls, Driving, Sleep, Medication Management, Depression/Mental Health, Living with Long-Term Disability, Stroke, and Alzheimer’s Disease. |
| Administration of Comprehensive Assessment of Occupationally-Relevant Exposures | Research Initiative | CDC | NIEHS | This task order provides financial support for NIOSH personnel to travel to, attend, and participate in several National Toxicology Program (NTP) meetings held in Research Triangle Park, NC, and Washington, DC. These included Interagency Committee for Chemical Evaluation and Coordination meetings, NTP Technical Report meetings, NTP Board of Scientific Counselors meetings, Report on Carcinogens meetings, NTP Executive Committee Meetings, and ad hoc meetings addressing specific NTP issues. All of these meetings were aimed at investigating, defining, or reporting hazards associated with exposure to environmental chemicals. Many of the exposures are occupational and NIOSH personnel provide expert opinion on chemical exposures linked to cancer, respiratory disease, development and reproductive disorders, neurotoxicity, and immunological toxicity. |
| Adolescent Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA | NICHD, NIDA, NIMH | The Adolescent Health Working Group was established under the Healthy People 2020 Initiative. The goal of this workgroup is to improve the healthy development, health, safety, and well-being of adolescents and young adults. This interagency workgroup focuses on three current near-term priorities: (1) enrolling eligible adolescents in Medicaid and Children''s Health Insurance Program; (2) preventing and addressing mental disorders and promoting mental wellness in adolescents; and (3) youth engagement. NIMH staff worked with SAMHSA to draft a framework of strategies to address mental disorders and promote mental wellness in adolescents. This framework identified opportunities that could be implemented with existing resources, and proposed ideas would need additional resources. |
| Advanced Anticonvulsant System Interagency Product Team | Committee, Work group, Advisory group, or Task Force | FDA, OS | NINDS, NIAID | The Advanced Anticonvulsant System Interagency Product Team is a Department of Defense-led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure. |
| Advancing Regulatory Science through Novel Research and Science-Based Technologies | Research Initiative | FDA | OD/OSP, NCATS, NEI, NHLBI, NIBIB, NIDDK, NINDS, OD/DPCPSI/OSC | NIH and FDA have formed an interagency partnership to foster regulatory science, a specialized and inter-disciplinary area of biomedical research that serves to generate new knowledge and tools for assessing experimental therapies, preventives, and diagnostics. A key goal of this Regulatory Science program is to accelerate the development and use of new tools, standards and approaches to efficiently develop products and to more effectively evaluate product safety, efficacy and quality. |
| Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP) | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The overall goal of the Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP) is to provide advice that will assist the nation in reducing the incidence and prevalence of childhood lead poisoning. |
| Advisory Committee on Organ Transplantation (ACOT) | Committee, Work group, Advisory group, or Task Force | HRSA | NIAID | The Advisory Committee on Organ Transplantation (ACOT) was established to assist the HHS Secretary in enhancing organ donation, ensuring that the system of organ transplantation is grounded in the best available medical science, and assuring the public that the system is as effective and equitable as possible, thereby increasing public confidence in the integrity and effectiveness of the transplantation system. |
| Agency for Toxic Substances and Disease Registry Seminar Series | Meeting/ Workshop | ATSDR | NIEHS | A seminar series established to communicate Superfund Research Program (SRP) research findings at the Agency for Toxic Substances and Disease Registry (ATSDR) and to provide networking collaborative opportunities for SRP grantees. The series is jointly coordinated with SRP and ATSDR staff. |
| Aging with Disability | Research Initiative | ACL | NIA | The goal of this collaboration among the National Institute on Aging (NIA), Administration for Community Living (ACL) and National Institute on Disability and Rehabilitation Research (NIDRR) is to explore issues of aging with disability through research, policy analysis, and data development, including joint Funding Opportunity Announcements (FOAs). |
| Agricultural Health Study | Research Initiative | CDC | NCI, NIEHS | A study exploring potential causes of cancer and other diseases among farmers and their families and among commercial pesticide applicators. |
| Agricultural Health Study: Health Follow-up Survey (Phase 4) | Health Survey | CDC | NIEHS | A collaboration on long-term follow-up of the Agricultural Health Study Cohort - a cohort of pesticide applicators and their spouses. This project includes active follow-up with participants to identify long-term health effects potentially linked to agricultural exposures. Funding is provided by NIEHS, scientific input by NIOSH and NCI. |
| Agricultural Health Study: Lung Health Study | Health Survey | CDC | NIEHS | This is a field study nested within the Agricultural Health Study to explore genetic and agricultural risk factors for respiratory disease. Participants with and without questionnaire-defined asthma are visited at home to complete clinical studies to classify respiratory disease and quantify extent of respiratory dysfunction, provide additional questionnaire data, and provide environmental and biological samples. |
| AIDS International Training and Research Program (AITRP) Supplements | Training Initiative | CDC | FIC, NCI, NIDA, NINR | The goal of the AIDS International Training and Research Program (AITRP) is to build multi-disciplinary biomedical, behavioral, and social science research capacity for the prevention, care, and treatment of HIV/AIDS and HIV-related conditions in adults and children in low-and middle-income countries. Research training will be provided to scientists at institutions in countries defined by the World Bank criteria as low- and middle-income. In FY13 PEPFAR/CDC-COP funded supplements to parent AITRP awards in Zambia through Vanderbilt; Uganda and Vietnam through Berkeley; Tanzania through Baylor/Dartmouth/Boston University; South Africa through Columbia; and Ukraine through SUNY Medical Center Downstate. |
| AIDSinfo | Public Education Campaign | CDC, CMS, HRSA | OD/DPCPSI/OAR, NIAID, NLM | AIDSinfo, a service of the U.S. Department of Health and Human Services (HHS), offers access to the latest, federally approved HIV/AIDS medical practice guidelines, HIV treatment and prevention clinical trials, and other research information for health care providers, researchers, people affected by HIV/AIDS, and the general public. |
| Alaska Native Tumor Registry | Resource Development | CDC, IHS | NCI | In collaboration with CDC and IHS, NCI, with technical assistance from its Surveillance, Epidemiology, and End Results Program (SEER), collects information on cancer cases among Alaskan Native populations residing in Alaska. |
| Alcohol Clinical Trial Initiative (ACTIVE) | Committee, Work group, Advisory group, or Task Force | FDA | NIAAA, NIDA | Consortium that includes academia and representatives from the FDA, NIAAA, NIDA and the pharmaceutical industry working together to identify and clarify clinical trials methodology to evaluate medications for treating alcohol dependence. |
| All-Hazards Playbook | Resource Development | OS | NLM | This activity is to develop an interactive tool to help state and local health departments prepare for and respond to disasters in their regions. |
| Alternative Methods for Chemical Allergen Identification | Research Initiative | CDC | NIEHS | In chemico alternatives to contact allergen identification are being developed |
| Alzheimer''s Disease Neuroimaging Initiative | Research Initiative | FDA | NIA, NIBIB | This collaboration is meant to develop biomarkers of Alzheimer’s Disease in elderly subjects. A major goal of the study has been to establish and validate MRI and PET images, cerebral spinal fluid, and blood biomarkers as predictors of the disease. |
| America''s Children Forum on Health and Family Statistics | Resource Development | SAMHSA | NIDA | NIDA contributes data from the Monitoring the Future survey on illicit drugs, alcohol and tobacco trends. |
| American Association of Blood Bank (AABB) International Biovigilance Network Task Force | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NHLBI | The task force is a collaboration between the American Association of Blood Banks, the government, and other agencies focused on tracking and analyzing adverse reactions and incidents associated with blood collection and transfusion, as well as organ and cell donation and transplantation. |
| American Association of Pediatrics (AAP) Executive Committee, Section on Perinatal Pediatrics | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The mission of the Section on Perinatal Pediatrics of the American Academy of Pediatrics (AAP) Executive Committee: To improve the health of the pregnant mother, the unborn fetus and the newly-born child through the sponsorship of programs which encourage the professional growth of the neonatal-perinatal providers, continuously improve clinical care delivery, support continuing and postgraduate education, foster basic, clinical and outcomes research and seek to attain federal and local funding for programs directed towards maternal/child health. The Section on Perinatal Pediatrics is the home organization for specialists in Neonatal-Perinatal Medicine and also welcomes affiliate members working in related disciplines. At a membership of nearly 3,500, the Section is the largest specialty subgroup of the AAP. The Section''s highest priority is to ensure the optimal health and well-being of babies and mothers and this is accomplished through the Section''s core activities in the realms of advocacy, education, outreach and support of clinicians and researchers. |
| American Conference for the Treatment of HIV (ACTHIV) | Meeting/ Workshop | CDC | OD/DPCPSI/OAR | The American Conference for the Treatment of HIV (ACTHIV) is a state-of-the-science conference for frontline health care professionals, in scientific collaboration with multiple Federal and independent agencies. The conference is designed for all frontline clinicians providing HIV care for various population groups. |
| Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks | Committee, Work group, Advisory group, or Task Force | FDA | NINDS, NCATS, NCI, NIDA | The mission of the Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership funded by the US Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic treatments for the benefit of the public health. |
| Analysis of Bisphenol A (BPA) Analogs | Research Initiative | CDC | NIEHS | With the Division of Laboratory Sciences, National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) in Atlanta, GA (contacts Antonia Calafat and Sherry Ye), this no cost collaboration aimed to measure BPA analogs in a mouse disposition study. In return, the Fenton lab provided samples with BPAF so that the NCEH lab could develop a method for measuring BPAF for use in the National Health and Nutrition Examination Survey (NHANES) biomonitoring effort. Collaborating labs agreed to co-author research papers. |
| Analysis of Mycotoxins in Dust Samples From a Water Damaged Building | Research Initiative | CDC | NIEHS | These studies are developing methods to quantitate the levels of fungal products in dust samples from water damaged buildings so that biomarkers of effect, such as fungal specific antibodies, can be correlated with biomarkers of exposure. |
| Analysis of Volatile Organic Compound (VOC) Mixtures | Research Initiative | CDC | NIEHS | With the Division of Laboratory Sciences, National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) in Atlanta, GA (contact Ben Blount), this no cost collaboration aimed to measure VOC metabolites in rat biological samples. CDC provided analytical chemistry, dosing instructions, and lab materials to collect the biological samples without contamination. Collaborating labs agreed to co-author research papers. |
| Anti-poliovirus Immune Assays and Testing Revertants from Clinical Trials of V-073, an Antiviral Agent | Research Initiative | FDA | NIAID | This project supports preclinical animal studies to obtain parameters essential for developing antiviral agents against poliovirus and to evaluate potential new antiviral agents. |
| Antiretroviral Pregnancy Registry | Resource Development | CDC, FDA | NICHD | This is a registry of use of antiretroviral drugs in pregnancy that is sponsored by various pharmaceutical companies and has a committee of external experts and government staff from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). |
| Armed Forces Radiobiology Research Institute (AFRRI) Good Laboratory Practices (GLP) Integrated Project Team | Committee, Work group, Advisory group, or Task Force | OS | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) participates on the Armed Forces Radiobiology Research Institute (AFRRI) Good Laboratory Practices (GLP) Integrated Project Team to collaborate and provide subject matter expertise, advice, and guidance on establishing a quality assurance program at AFRRI for GLP compliance. |
| Assistance for Orphans and Other Vulnerable Children in Developing Countries Act of 2005 (PL 109-95) Interagency Work Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA | NICHD, FIC, NIMH | This congressionally mandated workgroup evaluates efforts on behalf of orphans and underserved children worldwide. |
| Asthma Outcomes Workshop | Meeting/ Workshop | AHRQ, CDC, CMS, FDA, HRSA | NHLBI, NIA, NIAID, NICHD, NIEHS, NIMHD, NINR | This March 2010 workshop established standard definitions and data collection methodologies for validated outcome measures in asthma clinical research. The workshop also identified promising outcome measures and discussed the status of their development and validation. |
| Asthma Supplement to the National Ambulatory Medical Care Survey (NAMCS) | Health Survey | CDC | NHLBI, NIAID, NICHD, NIEHS | The National Ambulatory Medical Care Survey (NAMCS) Asthma Supplement is a national survey of physicians’ opinions about and use of the National Asthma Education and Prevention Program (NAEPP) Guidelines for the Diagnosis and Management of Asthma. The National Institutes of Health and the National Center for Health Statistics collaborate on this activity. |
| ATSDR, CDC Toxicological Profile Review Committee | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC | NIEHS | Review draft Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles of Environmental Chemicals |
| Auditory (Hearing) Screening Supplement for Early Childhood Longitudinal Study | Health Survey | CDC | NIDCD | The objective of this Inter-Agency Agreement is to implement a hearing examination protocol in the Early Childhood Longitudinal Study of the Kindergarten Class of 2010–11 (ECLS-K:2010-11). This is a large (n=20,000), nationally representative school-based exam and interview survey sponsored by the National Center for Education Statistics (NCES), U.S. Department of Education. The last NCES longitudinal cohort study of school age children began with the 1998 Kindergarten Class. In this earlier cohort, there were no hearing exams (nor vision exams) and the number of young children with hearing loss (reported by parents or teachers) shrank considerably after the initial enrollment of Kindergarteners. In the U.S., the last comprehensive national study of children with hearing exam measures was the 1963–1965 National Health Examination Survey (National Health and Nutrition Examination Survey predecessor) for children aged 6 to 11 years. A randomly selected sub-sample of about 4500 children were identified for more frequent follow-up and these children have also been selected for the hearing examination; they are also included in a “selected” (protected) subsample for more intensive tracking in follow-up waves of the survey. Children in the selected subsample will be tracked to new schools when possible if they are later enrolled in (moved to) a school that was not in the original school sample, e.g., when families relocate. In addition to hearing, the ECLS-K:2010-11 will track several other outcome measures (e.g., general health, social and physical development, achievement scores, and parental and teacher-reported communication problems) associated with educational performance. Hearing will be tested when the children are examined with achievement testing in the school setting. NCES has awarded a contract to WESTAT to conduct the field operations, including selection of sample schools, data collection, and preparation of user-friendly research data files. The contractor will obtain longitudinal measures of hearing sensitivity and middle ear function of Kindergartners during the fall of Second grade, spring of Third grade, and spring of Fifth grade. Hearing thresholds will be recorded from each ear separately. In addition, the contractor will obtain tympanometric traces to assess middle ear function and, also, wideband reflectometry beginning in the spring of Third grade to improve classification of sensorineural versus conductive hearing loss. |
| Autoimmune Diseases Coordinating Committee (ADCC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NIAID, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR | The purpose of the Autoimmune Diseases Coordinating Committee (ADCC) is to provide a forum for the coordination of research efforts in autoimmunity and autoimmune diseases among various stakeholders including the NIH, other federal agencies such as the FDA and the CDC, and private organizations with an interest in autoimmune diseases. The ADCC meets twice yearly to discuss a broad range of basic, preclinical and clinical endeavors. |
| B-24 Dietary Guidelines | Meeting/ Workshop | CDC, FDA, OS | NICHD | Dietary Guidelines for Americans (DGA) are the official guidelines issued by the U.S. government for health promotion and disease prevention in the American population. Currently, the DGA provides guidelines for ages 2 and above. The “B-24 project” was conceived to evaluate the strength of evidence for the inclusion of infants and children from birth to 24 months in the future iterations of the DGA. The B-24 Prime meeting in February was an important step in the process and it helped the working group members deliberate and develop a final product. The proceedings from the meeting will be published in the American Journal of Clinical Nutrition early next year. An offshoot of the B-24 conference/project is a project where collaboration will occur mostly in FY2014 and will evaluate the evidence to develop guidelines for the nutritional care of preterm infants. |
| Behavioral Aspects of Prep Counseling HIV Prevention Trials Network (HPTN) Protocol #067: The ADAPT Study (Y01-MH-0315) | Research Initiative | CDC | NIMH, NIAID | This behavioral research study is evaluating whether non-daily medication regimens for HIV Pre-Exposure Prophylaxis (PrEP) may be more acceptable and foster better adherence to product. PrEP represents a novel biomedical approach to HIV prevention in which individuals at-risk for HIV take antiretroviral medications to help prevent HIV infection. The HPTN 067 study is conducted through the NIAID-led HIV Prevention Trials Network. An Inter-Agency Agreement between NIMH and CDC supports the implementation of this international research study at a clinical research site in Bangkok, Thailand. |
| Best Pharmaceuticals for Children Act | Research Initiative | FDA, HRSA | NICHD, NHLBI, NIMH | The Best Pharmaceuticals for Children Act (BPCA) Program is a major activity for the Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB) at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). OPPTB is responsible for developing and supporting a comprehensive national research and training effort to increase the knowledge base for understanding how to appropriately treat disease during pregnancy, infancy, and childhood using pharmaceuticals that are appropriately tested within their target populations. NICHD activities related to BPCA are intended to improve pediatric drug therapeutics through preclinical and clinical testing that lead to drug labeling changes. We are performing pediatric clinical trials in order to submit data to FDA for labeling changes. BPCA is a partnership with FDA, to a degree. |
| Best Pharmaceuticals for Children Act Activities | Committee, Work group, Advisory group, or Task Force | FDA | NIMH, NHLBI, NICHD | NIH, FDA, and non-Federal experts in pediatric pharmacology meet several times a year to identify important unmet needs for conducting research on the efficacy and safety of medications in children. |
| Big Data to Knowledge | Meeting/ Workshop | AHRQ, CMS, FDA, OS | OD/DPCPSI, OD/DPCPSI/OSC | The Big Data to Knowledge (BD2K) program aims to facilitate broad use of biomedical big data, develop and disseminate analysis methods and software, enhance training for disciplines relevant for large-scale data analysis, and establish centers of excellence for biomedical big data. In FY 2013, BD2K held a series of workshops on topics of interest in the area of Big Data, including community-based standards, facilitating use of clinical data, and training in big data. Workshop participants included OS, FDA, CMS, and AHRQ. |
| Biomarkers of Nutrition for Development (BOND) Meetings | Meeting/ Workshop | CDC, FDA, HRSA, OS | NICHD, FIC, NCI, NHLBI, NIDDK, OD/DPCPSI/ODP | The National Institute of Child Health and Human Development had meetings concerning an initiative entitled Biomarkers of Nutrition for Development (BOND). The goal of the BOND initiative is to provide information and service to support the entire nutrition research and global health enterprise and to include core elements of discovery, development and delivery/implementation. The Centers for Disease Control and Prevention (CDC) is a member of the Steering Committee and has membership in individual Expert Panels. |
| BioMedical Informatics Coordinating Committee Common Data Elements (CDE) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | This working group conducts initiatives to improve the communication and coordination of efforts to identify, develop, and promote the use of Common Data Elements (CDEs) across NIH and beyond. |
| Bioresource Development, Validation Tools, and Integrating High-Throughput Screening Technology Standards in Complementary and Alternative Medicine (CAM) Product Use in Children | Research Initiative | CDC, HRSA, SAMHSA | NCCAM, NICHD | Collaborative efforts between the FDA/CBER and the NIH/NCCAM for substantiating health benefit claims for probiotics under Investigational New Drug Applications (INDs) were placed in the framework of U01 Cooperative Agreements that began in 2008. The successful evaluation of the initiative has recently developed into an invitation to develop a Memorandum of Understanding (MoU) to promote resource sharing and exchange of research expertise; development of demonstration project(s); and the initiation of trans-agency research initiatives focused on the integration of advanced molecular technologies that lead to harmonization standards and improved diagnostics for safety and substantiation of the health benefits of probiotic interventions. In 2011, a collaboration with FDA/CFSAN was initiated to expand the validation tool. In 2012, a Materials Transfer Agreement [MTA] was approved and the FDA/CFSAN received the entire data collection to undergo testing employing their novel microarray multi-loci sequence testing system [MLST]. |
| Board of Scientific Counselors, CDC''s National Center for Injury Prevention and Control | Committee, Work group, Advisory group, or Task Force | CDC | NIA | A member of the NIA staff serves on the Board of Scientific Counselor''s for the Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control. NIA''s staffer brings expertise in research on older adults. |
| Body Mass and Mortality Relationships | Research Initiative | CDC | NCI | A study of the relationships between categories of body mass and mortality in the U.S. population. |
| Brain Attack Coalition | Committee, Work group, Advisory group, or Task Force | CDC | NINDS | The Brain Attack Coalition (BAC) is a group of public and private entities representing medical, scientific, advocacy, and government professionals from across the stroke continuum. The BAC is dedicated to setting direction, advancing knowledge, and communicating best practices to improve our ability to prevent and combat stroke. |
| Breastfeeding and Human Lactation Research Scientific Interest Group (BALSIG) Special Interest Group | Committee, Work group, Advisory group, or Task Force | FDA, OSG | NICHD, NCI, NIDDK, OD/DPCPSI/ORWH | In August 2012, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) formed a trans-U.S. Department of Health and Human Services (HHS) scientific interest group, Breastfeeding and Human Lactation Research Scientific Interest Group (BALSIG), to provide an intellectual platform for the scientists from HHS agencies interested in breastfeeding and human lactation research activities. |
| Cancer and Women''s Health Interagency Agreement | Research Initiative | FDA | NCI | The overall purpose of this NCI/FDA collaboration is to promote the public health of all women through advancements in cancer research and medical therapies. The parties envision this joint collaborative activity to encompass all the major cancers afflicting the health and well-being for adult women. |
| Cancer Control and Cancer Survivorship in the Sister Studies | Health Survey | CDC | NIEHS | Activities include holding a workshop on research priorities for understanding breast cancer in young women and conducting 2 surveys within the Sister Study: 1) looking at high risk women without breast cancer to understand the impact of breast cancer in a family member on women and their daughters, including screening and lifestyle behaviors; and 2) a survey of young breast cancer survivors to identify issues related to treatment and follow-up, barriers to care, quality of life, discrimination, and other factors post-diagnosis. The study focuses on special needs of young survivors, including fertility. |
| Cancer Control Plan, Link, Act, Network with Evidence-Based Tools (P.L.A.N.E.T) | Resource Development | AHRQ, CDC, SAMHSA | NCI | Cancer control planners, program staff, and researchers have the same goals: to reduce cancer risk, the number of new cancer cases, and the number of deaths from cancer, as well as enhance the quality of life for cancer survivors. While many share the same goals, all do not have easy access to resources that can facilitate the transfer of evidence-based research findings into practice. This Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network with Evidence-based Tools) portal provides access to data and resources that can help planners, program staff, and researchers to design, implement and evaluate evidence-based cancer control programs. |
| Cardiovascular Coordination Team | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI | The purpose of the workgroup is to assess the feasibility of conducting an evidence based review to assess the effectiveness of interventions using community health workers for cardiovascular disease prevention. The final review will be included in The Community Guide sponsored by the Community Preventive Services Task Force. |
| Carrier Screening Work Group | Committee, Work group, Advisory group, or Task Force | HRSA | NICHD | The purpose of the committee is to make recommendations to the Secretary''s Advisory Committee for Heritable Disorders in infants and children related to screenable disorder. |
| CDC Chronic Kidney Disease Surveillance | Health Survey | CDC | NIDDK | NIDDK assists CDC in their surveillance program of chronic kidney disease. |
| CDC Community Guide: Review Various Interventions to Reduce Alcohol-Related Problems | Resource Development | CDC, SAMHSA | NIAAA, NIDA | The Community Guide is a free resource to help people choose the most effective programs and policies to improve health and prevent disease in their communities. |
| CDC Elimination of Pediatric HIV in US Stakeholders Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | Working group of federal and non-federal individuals to assist the Centers for Disease Control and Prevention (CDC) in developing initiatives to eliminate mother to child HIV transmission in the US. |
| CDC Pediatric HIV Case Definition Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | Advises on development of new pediatric HIV surveillance definitions. |
| CDC-NIH Lyme Disease Serum Sample Repository | Resource Development | CDC, OS | NIAID | Initiated in 2008, this resource was made available to the scientific community on a broad basis in late 2011. Lyme disease and related serum samples are available upon request for testing and comparison of new and current diagnostic tests with a common serum sample set for standardization. Samples are distributed by the CDC. CDC and NIH both provided support to acquire the samples and continue to work together to ensure the scientific community has access to samples needed for Lyme disease diagnostic test development. |
| CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment (CHACHSPT) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OAR | The CDC / HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment shall advise the Secretary; the Director, CDC; and the Administrator and Associate Administrator for HIV/AIDS, HRSA, regarding objectives, strategies, policies, and priorities for HIV and STD/hepatitis prevention and treatment efforts including surveillance of HIV infection, AIDS, STDs/hepatitis, and related behaviors; epidemiologic, behavioral, health services, and laboratory research on HIV/AIDS and STDs/hepatitis; identification of policy issues related to HIV/STD/hepatitis professional education, patient healthcare delivery, and prevention services; agency policies about prevention of HIV/AIDS and other STDs, treatment, healthcare delivery, and research and training; strategic issues influencing the ability of CDC and HRSA to fulfill their missions of providing prevention and treatment services; programmatic efforts to prevent and treat HIV and STDs/hepatitis; and support to the agencies in their development of responses to emerging health needs related to HIV and other STDs/hepatitis. |
| CDC/NCHS Balance/Dizziness Problems | Health Survey | CDC | NIDCD | The purpose of this agreement is for NIDCD to provide financial support to the National Center for Health Statistics (NCHS) for the inclusion of a Balance/Dizziness Supplement to a future National Health Interview Survey (NHIS). Previously, NIDCD negotiated an Interagency Agreement (IAA) with NCHS for collaboration and funding of the 2008 Balance/Dizziness Supplement to the NHIS. The FY2013 funds will provide partial support for the renewal of this collaborative effort between NCHS and NIDCD to fund a future Balance/Dizziness Supplement to the NHIS. The new NHIS Supplement will include many of the same questions on Balance/Dizziness included in the earlier 2008 study, although revisions are expected to eliminate some questions in order to consider adding new ones high on the current priority list. These questions on the new Balance/Dizziness Supplement will assist NIDCD to make program planning decisions on priorities with respect to the funding of research on the prevention of falls related to dizziness and balance. The results will also be analyzed for use in tracking the Department of Health and Human Services’ (DHHS) objectives in Healthy People 2020. Results from this nationally-representative survey of the U.S. non-institutionalized, civilian population will help NIDCD make budget allocations to subject areas where needs are found to be most critical. |
| CDC/NIOSH for Audiometric Support for 3 NIDCD-Sponsored, Population-Based Surveys | Health Survey | CDC | NIDCD | The purpose of this agreement is to provide funding for scientific and technical support as well as quality assurance of three large audiometric examination surveys funded by NIDCD. These health surveys are: (i) The National Health and Nutrition Examination Survey (NHANES), (ii) Age, Gene/Environment Susceptibility Study–Reykjavik Study (AGES–RS), and (iii) the Early Childhood Longitudinal Study – Kindergarten Class of 2010/2011 (ECLS–K:2010/2011). The Audiometry Components of all three health examination surveys were previously developed by NIDCD in collaboration with NIOSH and other consultants. NIOSH collaborated on the design of the experimental protocol and provided the equipment specifications, oversight of maintenance and calibration, technician training and oversight, operations manual development, and quality assurance for the NHANES. As well, NIOSH provided similar support to AGES and ECLS–K:2010/2011, including setting-up training sessions and observing/monitoring technical competence in obtaining audiometric measurements, technical assistance as needed, and limited quality assurance. The NHANES scientific goals are to establish a statistically accurate, demographically representative baseline on the general health (including Hearing Health) of the U.S. population. NHANES is now a continuous survey and while general health issues are always under investigation such as height, weight and blood pressure, there are also elements that track individual health outcomes that move in and out of the NHANES as it cycles. NHANES consists of two major components: the household interview and the physical examination in the NHANES Mobile Examination Centers (MECs) that are set up in various areas around the country. The data from the NHANES elements are collected, weighted, and made available to the government and the public as a database on which analysis may be performed. Recently, the data have been released every two years with collaborating agencies receiving the data six months prior to the public release of the data sets. The AGES–RS scientific goals are: 1) to identify genetic and new risk factors for selected diseases including atherosclerosis, cognitive impairment, dementia, stroke, hearing loss, visual impairment, sarcopenia, osteoporosis, and obesity, 2) to characterize phenotypes for these diseases and conditions, and 3) to identify contributory molecular markers associated with these conditions. The proposed ECLS:K-2011 audiometry protocol for the third-grade data collection includes four components: pre-test questions, otoscopy, wideband reflectometry with tympanometry, and pure tone audiometry. (1) Pre-Test Questions: Children will be asked a series of short questions regarding conditions which could affect the test results (cold or earaches, noise exposure within past 24 hours, presence of pe tubes, and whether one ear is better than the other); (2) Otoscopy: Children will receive a brief visual examination of the ear, primarily to assure a clear sound path. In addition, the technicians will note the presence of excessive cerumen or any other gross abnormality which could affect interpretation of audiometric findings. The otoscopic exam will not be diagnostic; it will simply be observational; (3) Wideband Reflectometry, including Tympanometry: An automated wideband reflectometric/tympanometric evaluation of the middle ear will be conducted bilaterally. Analysis and interpretation of the results will be done remotely; (4) Pure Tone Audiometry: Pure tone air conduction thresholds will be obtained bilaterally at 1000, 2000, 3000, 4000, 6000, and 8000 Hz insofar as time and the child’s attention permits. A retest threshold will be obtained in both ears at 2000 Hz as a measure of test reliability. The thresholds will be obtained manually using a modified Hughson-Westlake technique. The first test ear will be alternated to avoid learning effect bias in the thresholds. Frequencies will be tested in a specified order to obtain the more important frequency data first in case time or the child’s attention runs out before all frequencies are completed. All three health surveys share similar hearing exam components, developed collaboratively by NIDCD, NIOSH, NCHS, WESTAT, the Icelandic Heart Association Research Institute, and the Department of Education, National Center for Education Statistics. The hearing component consists of: 1) a set of questionnaires relating to hearing, noise exposure, and other factors relating to hearing, and 2) audiometric examinations consisting of otoscopy, acoustic immittance (bilateral tympanometry or wide-band reflectometry and screening for ipsilateral acoustic reflexes at 1000 and 2000 Hz), and 3) pure-tone, air-conduction audiometry to determine the hearing thresholds in each ear at several frequencies, such as 500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz. A repeat threshold test is obtained at 1000 Hz or 2000 Hz as a measure of test reliability. When significant inter-ear differences are found, then retests may be performed using insert earphones to maximize the inter-aural attenuation rather than using a noise masker of the non-test ear to obtain what is referred to as masked threshold in the test ear to avoid recording of a “shadow audiogram” from the better non-test ear. |
| CDC’s Field Epidemiology Training Program (FELP) Cancer Curriculum | Training Initiative | CDC | NCI | CDC and NCI (Center for Global Health and Cancer Prevention Fellowship Program) are collaborating to add a cancer curriculum to CDC’s Field Epidemiology Training Program. |
| Cell Therapy for Lung Diseases | Meeting/ Workshop | FDA | NHLBI | Acute and chronic lung diseases are leading causes of morbidity, mortality, and health care expenditures. Innovative approaches for therapies are urgently needed. Increasingly, patients who suffer from chronic lung diseases are seeking stem cell therapies outside the U.S. due to limited opportunities to participate in clinical studies of stem cells in the U.S. The current NHLBI portfolio on lung stem and progenitor cells has focused primarily on basic research to build fundamental knowledge of the role of stem/progenitor cells in lung disease and injury/repair. However, clinical application of cell therapy for lung diseases will require a more focused approach that coordinates basic research with translational research to facilitate cell-based clinical trials. Therefore, the NHLBI convened a Cell Therapy for Lung Diseases working group on November 13-14, 2012 to make recommendations for future research directions. The workshop brought together investigators who study basic mechanisms including cell therapy in preclinical models of lung injury/disease along with clinical trial experts in cell therapy for cardiovascular indications and experts from NHLBI’s Production Assistance for Cell Therapy (PACT) program. The overall objective was to discuss the current status of basic investigations in lung cell therapy, identify the scientific gaps in current knowledge regarding cell therapy in the treatment of lung diseases, and develop recommendations to the NHLBI and the research community on scientific priorities that would facilitate high quality, rigorous first-in-human trials of lung cell therapy. |
| Characterizations of Fungal Exposures | Research Initiative | CDC | NIEHS | These studies address the limitations in traditional methods for assessing fungal exposures by using molecular techniques to identify fungi in dust samples and biological fluids |
| Chemical Integrated Program Team (IPT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD | This workgroup is a Public Health Energy Enterprise. The IPT working group provides an end-to-end vision of medical countermeasures needed for a particular threat type (e.g., anthrax, rad/nuc, etc.). The scope of their work includes setting requirements for the stockpiling of Medical Countermeasures (MCMs), MCM delivery and dispensing and monitoring MCM development. The IPTs also advise the Enterprise Executive Committee as to threat- or capability-specific MCM priorities for improving preparedness, to inform leadership consideration of cross-threat prioritizations and strategic goal setting. |
| CHEMM (Chemical Hazards Emergency Medical Management) | Resource Development | ATSDR, CDC, OS | NLM | This activity is to develop and maintain a comprehensive web resource and mobile app (in conjunction with the Wireless Information System for Emergency Responders [WISER]). Chemical Hazards Emergency Medical Management (CHEMM) is a tool designed to provide access to comprehensive sets of information about chemical hazards via a user-friendly interface. |
| Child Abuse and Neglect Working Group (CANWG) | Committee, Work group, Advisory group, or Task Force | ACF, HRSA, SAMHSA | NICHD, CSR, NIAAA, NIDA, NIMH, NINDS, OD/DPCPSI/OBSSR | The NIH Child Abuse and Neglect Working Group (CANWG) was established in response to a recent directive by the House Committee on Appropriations, which requested that NIH report on current NIH efforts, accomplishments, and future plans for research on child abuse and neglect. The CANWG is co-chaired by program staff from NICHD and NIDA (formally NIMH). The working group is also a subcommittee of the Federal Interagency Workgroup on Child Abuse and Neglect. |
| Children''s HHS Interagency Leadership on Disasters (CHILD) Working Group | Committee, Work group, Advisory group, or Task Force | OS | NICHD | The purpose of this workgroup is to document HHS''s steps taken and provide recommendation for next steps regarding the care of children and pregnant women in the event of a disaster. |
| Children''s Mental Health: Surveillance of Mental Disorders Among Children in the United States (CDC MMWR Special Report) | Resource Development | CDC, HRSA, SAMHSA | NIMH | In 2012, The Centers for Disease Control and Prevention (CDC) initiated a special Morbidity and Mortality Weekly Report (MMWR) on child mental health surveillance. This report provides a comprehensive look at surveillance systems that collect data on mental health issues. The report summarizes information about ongoing federal surveillance systems that provide estimates of the prevalence of mental disorders and indicators of mental health among children living in the United States, and presents estimates of childhood mental disorders and indicators from these systems during 2005-2011. |
| Chronic Fatigue Syndrome Advisory Committee (CFSAC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | OD/DPCPSI/ORWH, CSR, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIDCR, NIDDK, NIEHS, NIMH, NINDS, NINR, NLM | The Chronic Fatigue Syndrome Advisory Committee (CFSAC) provides advice and recommendations to the Secretary of Health and Human Services via the Assistant Secretary for Health of the U.S. Department of Health and Human Services on issues related to chronic fatigue syndrome (CFS). These include: 1) factors affecting access and care for persons with CFS; 2) the science and definition of CFS; and 3) broader public health, clinical, research and educational issues related to CFS. |
| Clinical and Translational Research Course for PhD Students | Training Initiative | FDA | CC, NCATS, NCI, NHLBI, NIAID, NIDA, NIDDK, NIGMS, NIMH | The Clinical and Translational Research Course for Ph.D. Students is a two-week intensive introductory course for graduate students in the basic biomedical sciences who have at least one year of graduate study. The purpose of the course is to demonstrate and highlight the roles of PhD scientists in clinical and translational research, to provide an overview and examples of how basic science and clinical observations lead to translational research, and to increase awareness and access to Ph.D. role models, research resources, and potential career opportunities at the NIH. |
| Clinical Investigator Interagency Working Group for the Development of Antiviral Influenza Therapeutics | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | This Working Group discusses a range of issues relevant to the development of antiviral drugs for the treatment of influenza. |
| Clinical Islet Transplantation Consortium | Research Initiative | CMS, FDA | NIDDK, NIAID | "The Clinical Islet Transplantation (CIT) Consortium is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in people with type 1 diabetes. Studies conducted by the CIT Consortium will focus on improving the safety and long-term success of methods for transplanting islets, the insulin-producing cells of the pancreas, in people whose own islets have been destroyed by the autoimmune process that characterizes type 1 diabetes. One clinical trial, in particular, is studying the efficacy of islet transplantation after kidney transplantation. Participants may include Medicare beneficiaries. This study was mandated in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. " |
| Clinical Studies in Fecal Incontinence Committee | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The purpose of this committee was to plan a meeting to present the research world with information on the state of fecal incontinence research and generate discussion about how to move forward research that will improve treatment and outcomes in people with fecal incontinence. |
| Clinical Trials Working Group (CTWG) Steering Committee System | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Scientific Steering Committees (SSCs) are composed of leading cancer experts and advocates from outside the Institute as well as NCI senior investigators who meet regularly to: (1) increase the transparency and openness of the trial design and prioritization process; (2) enhance patient advocate and community oncologist involvement in clinical trial design and prioritization; (3) convene Clinical Trial Planning Meetings to identify critical questions, unmet needs, and prioritize key strategies. |
| Clinical Utilization Plan for Anthrax Medical Countermeasure Use in a Mass Casualty Event (CUPAC) Medical Countermeasures Workgroup | Committee, Work group, Advisory group, or Task Force | CDC | CC | Dr. Marion Danis is participating as a member of the Medical Countermeasures Work Group to provide clinical algorithms that will assist clinicians to evaluate, triage, diagnose and treat large number of patients presenting with symptoms of anthrax. It will also provide a clinical prioritization schema for the use of medical countermeasures specific to anthrax and outline unique critical care issues that may require special consideration. |
| Clinical Vocabulary and Standards Development for Quality Measures | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, OS | NLM | NLM is developing and assessing the feasibility of standards-based quality measures that will utilize Electronic Medical Record (EMR) data. In 2012, NLM developed a system for validating value sets used in Meaningful Use Stage 2 clinical quality measures. |
| ClinicalTrials.gov | Resource Development | FDA | NLM, CC, NCATS, NCCAM, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/OSP | ClinicalTrials.gov is an NLM-operated database containing summary protocol and results information from publicly and privately funded clinical research. As of January 2014, the database included protocol information on more than 160,000 studies conducted in 185 countries, and more than 11,000 summary results records. NLM originally collaborated with FDA on implementing Section 113 of the Food and Drug Administration Modernization Act. It is currently collaborating with FDA and other parts of NIH to implement the statutory requirements of Section 801 of the Food and Drug Administration Amendments Act of 2007. |
| CMS-NIH Data Access Committee | Committee, Work group, Advisory group, or Task Force | CMS | OD/OSP, CC, CSR, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | Observational studies based, in part, on available CMS data could generate important knowledge and policy relevant findings. NIH and CMS established a Data Access Committee to identify and pursue short and long term research priorities. Current initiatives include: implementation of an Inter-Agency Agreement wherein NIH directly purchases blanket access to CMS data from CMS, instead of paying grantees to access these data individually (which incurs high indirect cost rates for NIH); and convening quarterly meetings of the CMS-NIH Data Access Committee to discuss data policy and access issues. Future meetings may include presentations by NIH-funded investigators and in-house CMS data analyses. |
| CMS-NIH Senior Leadership Forum | Committee, Work group, Advisory group, or Task Force | CMS | OD/OSP, NCI, NHLBI, NIA, NIDDK, NINDS | A “CMS-NIH Senior Leadership Forum” comprised of NIH Director Francis Collins, CMS Acting Administrator Marilyn Tavenner, and Senior Staff from both agencies, convenes quarterly. Topics include: • NIH-supported research findings of interest to CMS in high impact conditions such as diabetes, schizophrenia, post-acute stroke care, prevention of pre-term birth, lung cancer CT screening, tobacco cessation, genomics, etc. • Enhancing investigator access to CMS data through the use of Data Enclaves. • Development of common data elements (CDEs) to enhance the conduct of clinical research. • Collaborative development of an RFA with the CMS Innovation Center, “Low Cost, Pragmatic Patient-Centered Randomized Controlled Intervention Trials,” issued and funded by NIH. |
| Collaboration with the Council on Emergency Medical Care | Other | OS | NICHD, NCATS, NHLBI, NINDS | The Council on Emergency Medical Care (CEMC) is a coalition comprised of subject-matter experts and policy makers with representation from organizations across the US Government (USG). The CEMC serves to provide policy level guidance and facilitate inter-agency coordination. This entity contributes to the development and advancement of Federal priorities relating to emergency medical care and informs the development of joint strategies and cohesive policies across the USG to collaborate and coordinate ongoing efforts to improve the nation''s emergency care system. |
| Collaborative Islet Transplant Registry Ad Hoc Scientific Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NIAID | This committee provides scientific direction to the Registry on an ad hoc basis. |
| Collaborative Pediatric Critical Care Research Network (CPCCRN) | Research Initiative | HRSA | NICHD | The goal of the Collaborative Pediatric Critical Care Research Network (CPCCRN) is to develop an infrastructure to have well-designed collaborative clinical trials and meaningful descriptive studies in pediatric critical care medicine. The Network seeks to reduce morbidity and mortality in pediatric critical illness and injury, and to provide a framework for the development of the scientific basis of pediatric critical care practice. |
| Collection and Characterization of HIV Variant Strains in Cameroon for an HIV Panels Project | Research Initiative | FDA | NIAID | This initiative will update the global viral panels to analyze multiple, diverse isolates from different parts of the world. This activity is part of NIAID’s ongoing efforts to develop a well characterized repository for diagnostics, drug, and vaccine studies. |
| Committee on Fetus and Newborn | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The Committee on the Fetus and Newborn (COFN) studies issues and current advances in fetal and neonatal care; makes recommendations regarding neonatal practice; collaborates with the American College of Obstetricians and Gynecologists (ACOG) to consider perinatal issues on which the practices of obstetrics and pediatrics merge; and works cooperatively with ACOG on new editions of Guidelines for Perinatal Care. In 1937, the Academy established the Committee on Neonatal Morbidity and Mortality to collaborate with a similar Committee in the American Pediatric Society. Together, these committees agreed that neonatal mortality and morbidity could be reduced by applying what was already known. The group made a number of recommendations including: collect statistics and develop a standard nomenclature for causes of death, conduct more autopsies to learn about the causes of death, collaborate with obstetricians, and develop standards for protection of newborn infants. In 1938, the committee requested a name change to the Committee on Problems of the Fetus and Newborn Infant and in 1941, the name was changed to its current name, COFN. |
| Committee to Review NIOSH Decisions on Special Exposure Cohorts | Committee, Work group, Advisory group, or Task Force | OS | NCI | NCI was a panel member for administrative review of NIOSH decisions to create special exposure cohorts in response to claimants. |
| Common Data Elements (CDE) for Patient-Centered Outcomes Research | Resource Development | OS | NLM, CC, CIT, NCATS, NCI, NEI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDDK, NIEHS, NIMH, NINDS, NINR, OD/OER | Led by NLM, a work-group of the Trans-NIH BioMedical Informatics Coordinating Committee (BMIC) and others are working to promote the use of common data elements in research, surveillance, and patient registries to facilitate data sharing and reuse. Work has produced a portal of NIH projects that use Common Data Elements (CDEs) and, with the assistance of funding to develop data infrastructure to promote patient-centered outcomes research (OS Patient-Centered Outcomes Research Trust Fund), will contribute to development of a search, retrieval, and repository mechanism that will support and reflect the standards work of the Standards & Interoperability (S&I) Framework Structured Data Capture Initiative. This project contributes to efforts to develop a repository and search tool for identification of CDEs for Patient-Centered Outcomes Research. |
| Community Health Worker Initiative | Public Education Campaign | HRSA, IHS | NHLBI | The Community Health Worker (CHW) Initiative supports activities to reduce disparities in cardiovascular risk factors and asthma in African American, Latino, American Indian, and Filipino population groups. The project uses formative research (literature reviews, focus groups, and workshops) to inform the development and implementation of approaches that integrate CHW activities into the broader health workforce to improve cardiovascular health and reduce asthma disparities. |
| Comparative Effectiveness Research Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CMS, FDA | OD/OSP, CC, CSR, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The NIH Comparative Effectiveness Research Coordinating Committee (CER CC) was established in 2008 at the request of the NIH Director. Its members include NIH Institute and Center (IC) Directors and high level senior staff. Its charge is to coordinate ongoing CER initiatives across the agency, develop a long term research vision for CER, implement collaborative initiatives with sister agencies, determine appropriate definitions, policies and guidance relative to CER, administer the CER funds awarded through ARRA, and track the outcomes of those projects. The CER CC has organized meetings with AHRQ, CMS, the VA, FDA, the Office of the National Coordinator for Health Information Technology (ONC), and PCORI, to discuss potential strategic collaborations. NIH invested $597M in CER in FY2012, and estimates funding $581M in FY 2013. |
| Comparison of Age-Related Macular Degeneration (AMD) Treatment Trials | Research Initiative | CMS | NEI | Head-to-head Comparative Effectiveness Trial between two chemically related ant-VEGF treatments for Age-related Macular Degeneration |
| Computational Toxicology for NIH Medications Discovery | Research Initiative | FDA | NIDA | Through an inter-agency agreement, the FDA provides structure-activity, relationship-based toxicity predictions for compounds that are under evaluation in the NIDA Addiction Treatment Discovery Program. On a limited basis, other NIH ICs may utilize this resource by working through NIDA. |
| Computer-aided Diagnosis for Radiology Images | Research Initiative | FDA | CC | The collaboration focuses on the improvement of computer-aided diagnosis for radiology images. Specific applications include computer-aided polyp detection for CT colonography, improvements in the conduct and analysis of observer performance experiments using radiology images and the use and development of advanced machine learning and receiver operating characteristics methods with application to computer-aided diagnosis. |
| Conducting Comprehensive Toxicological Assessments | Research Initiative | FDA | NIEHS | The purpose of this Agreement is to conduct, at FDA/NCTR, comprehensive toxicological assessments on FDA priority chemicals/agents nominated to the National Toxicology Program. Studies can include range finding sub-chronic and chronic, compound-specific mechanistic studies, and consideration of the use of alternate test systems. This combination of studies is designed to facilitate the interpretation of study results in support of comprehensive quantitative human health risk assessments. The primary goal of this program is to develop a comprehensive scientific data base that can be utilized to reduce the uncertainty in risk assessment/risk benefit analysis for specific chemicals with high FDA impact. |
| Congenital Heart Disease Expert Meeting | Meeting/ Workshop | CDC | NHLBI | The goal of this CDC-sponsored meeting was to develop a public health research agenda for congenital heart disease. An NHLBI representative participated on the committee with CDC members that planned and oversaw the meeting. Fifty invited experts attended the meeting representing diverse expertise in content (congenital heart disease, adult heart disease, statistics), methods (public health strategies), and personal experience. The group included persons from varied backgrounds (physicians, surgeons, epidemiologists, public health officials, advocates, and patients), with a broad representation of public health, professional, and Congenital Heart Disease (CHD) advocacy organizations. The meeting focused on four specific areas including epidemiology, health services, long term morbidity and mortality, and long term psychosocial and neurodevelopmental outcomes. The findings from the meeting were summarized in a manuscript which will be published in a cardiology or public health journal. |
| Congenital Heart Public Health Consortium | Resource Development | AHRQ, CDC | NHLBI | The Congenital Heart Public Health Consortium (CHPHC) is a group of organizations uniting resources and efforts in public health activities. The mission of the CHPHC is to prevent congenital heart defects and improve outcomes for affected children and adults. The consortium achieves its mission by providing leadership and a unified voice for public health priorities, expanding opportunities for surveillance and public health research, and informing public policy priorities that benefit public health and affected persons. The CHPHC represents various federal, state, and community organizations, including those representing patient/family, clinical, and research interests. It is pooling expertise and experience and using a public health model to address Congenital Heart Disease (CHD) issues across the lifespan. |
| Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus | Meeting/ Workshop | AHRQ | OD/DPCPSI/ODP, NICHD | Gestational diabetes mellitus (GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during the third trimester of pregnancy). In collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the NIH Office of Disease Prevention organized a Consensus Development Conference to better understand the benefits and risks of various GDM screening and diagnostic approaches. After weighing the evidence presented by speakers and an evidence report, an unbiased, independent panel prepared and presented a consensus statement addressing the key questions. The conference was held on March 4-6, 2013. |
| Consortium for TB Biomarkers (CTB2) | Research Initiative | FDA | NIAID | The CTB2 seeks to establish a robust biorepository of well-documented clinical specimens to support the discovery and qualification of biomarkers of TB drug effect, especially surrogate markers for stable cure vs. relapse, and to facilitate development of rapid, reliable TB diagnostics, including tests for drug-susceptibility that would be practical for use in resource poor settings. |
| Council on Emergency Medical Care | Committee, Work group, Advisory group, or Task Force | AHRQ, CMS, HRSA, OS | NIMH, NHLBI, NICHD, NINDS, NLM | The Council on Emergency Medical Care (CEMC) is a coalition comprised of subject-matter experts and policy makers in emergency medical care from organizations across the Federal Government. The CEMC provides strategic and operational support to the HHS Emergency Care Coordinating Committee (ECCC) through policy-level guidance and interdepartmental and interagency collaboration for ongoing and future Federal efforts that address daily emergency medical care issues in the US. This entity contributes to the development, advancement, and coordination of Federal strategies, policies, and priorities relating to emergency medical care to improve the nation''s emergency care system. |
| Countermeasures Against Chemical Threats (CounterACT) Research Network Annual Symposium | Meeting/ Workshop | CDC, FDA, OS | NINDS, NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS | This workshop was organized by NINDS as part of the Countermeasures Against Chemical Threats (CounterACT) Research Network, a group formed to conduct basic, translational, and clinical research aimed at the discovery and/or identification of better therapeutic and diagnostic medical countermeasures against chemical threat agents. The 3-day meeting allowed researchers to share information, encouraged collaboration, and enabled NIH staff to evaluate the group’s progress on themes such as nerve agents, seizure detection technology, cyanide, and sulfur mustard. |
| Countermeasures Against Chemical Threats (CounterACT) Research Network Working Group | Committee, Work group, Advisory group, or Task Force | OS | NICHD, NHLBI, NIAID, NIAMS, NIEHS | An OB-Pediatric representative is on the program staff of the Countermeasures Against Chemical Threats (CounterACT) section of NINDS. The collaboration''s function is to prioritize/fund/manage studies focusing on the development of medical countermeasures (MCMs) for protection against chemical agents. |
| Country Stakeholder Meeting – Kenya | Other | CDC | NCI, FIC, NIAID | Kenya has an estimated population of over 42 million. Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have a significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M. USAID invested $700 million in Kenya in FY2011. At least 6 NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment, to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH), in partnership with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012. |
| Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone, National Hormone and Pituitary Program (NHPP) | Resource Development | CDC, FDA | NIDDK | From 1963 to 1985, the National Hormone and Pituitary Program (NHPP), funded by the U.S. Department of Health and Human Services (HHS), sent Human Growth Hormone (HGH) made from human pituitary glands to hundreds of doctors across the country. As a part of research studies, doctors used the hormone to treat nearly 7,700 children for failure to grow. In 1985, the HHS learned that three people treated with pituitary HGH died of Creutzfeldt-Jakob Disease (CJD), a rare, incurable brain disease. The HHS immediately stopped distributing the hormone and began a national study to learn more about how pituitary HGH treatment may have caused this problem. |
| DAIDS (NIH/NIAID) and DTBE (CDC/NCHHSTP) Partnership for TB and TB/HIV Research | Research Initiative | CDC | NIAID | This research initiative will conduct pyrazinamide (PZA) resistance profiling. |
| DailyMed | Resource Development | FDA | NLM | DailyMed provides high quality information about marketed drugs, including FDA labels (package inserts). The Web site provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. NLM provides this DailyMed as a public service, free of advertising. |
| Data Access for Grantees | Resource Development | CMS | NIA | NIA developed a Memorandum of Understanding (MOU) to assist grantees with accessing Centers for Medicare & Medicaid Services (CMS) data. It is anticipated that this initiative will create a more user friendly and more cost efficient means for grantees to access CMS data especially the need to access Part D data. Specifically, this MOU gives CMS''s Privacy Board justification to release Part D data to NIA grantees with Data Use Agreements. Researchers pay for data use. This includes activities for remote access data enclave. |
| Data to Action Research Capacity Building Workshops | Meeting/ Workshop | CDC | NCI | NCI and CDC co-organized a preconference workshop at the 1st International Conference on Public Health in the 21st Century: The End-Game for Tobacco. The workshop, ‘Data to Action,’ was aimed at building capacity for research and data collection among Low and Middle Income Countries (LMICs). The preconference was attended by 50 participants representing India, State Health Officers, Epidemic Intelligence Service (EIS) participants, and several countries (including Indonesia, Bangladesh, Turkey, Thailand, Ukraine, and Nigeria). |
| Demand Reduction Interagency Working Groups | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS, SAMHSA | NIAAA, NIDA | These working groups aim to prevent substance abuse and related negative consequences by implementing a prevention framework to serve as a foundation for collaboration among Federal agencies in the development of joint initiatives that serve States and communities across the Nation. |
| Department of Defense Resuscitation and Transfusion Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC | CC, NHLBI | Oversees DoD research in resuscitation and transfusion. |
| Determining Autism in Somali Immigrants in the Minneapolis Region | Research Initiative | CDC | NICHD, NIEHS, NIMH, NIMHD | Several Institutes and Centers at NIH are providing funds to CDC to support surveillance of Autism Spectrum Disorder (ASD) in select children who live in Minneapolis, with the goal of determining whether children of Somali descent have a higher ASD prevalence. This research initiative originated due to concerns in the Minneapolis community about the unexpected high number of Somali children in preschool programs for children with autism. While that study had a number of limitations, it was an important first step towards understanding autism prevalence in the Somali community. In response to concerns about the number of Somali children with autism living in Minneapolis, the CDC, NIH, and Autism Speaks funded the University of Minnesota through a competitive announcement from the Association of University Centers on Disabilities (AUCD) to estimate the number of children with autism living in Minneapolis and to examine whether autism is more common among Somali children than non-Somali children. The adopted study methods were developed by the CDC and are used by the Autism and Developmental Disabilities Monitoring (ADDM) network. The ADDM network reviews health and special education records to identify school-aged children with autism. Data collected using this method can help explain if certain groups are more likely to be identified with autism than others. The project was initially funded for 1 year to encourage a timely response to community concerns. However, the State of Minnesota did not have an existing autism monitoring system in place, so an infrastructure for autism monitoring needed to be built, which took 8 months. Because building the infrastructure took so much time and resulted in delays, a 1-year cost extension to complete the autism monitoring activities was requested and approved. An important component of the project has been community engagement, including establishing a community advisory board, hiring Somali community facilitators, hiring a Somali leadership liaison, and conducting outreach through community resources and meetings as well as through immigrant media sources. In addition, after hearing the community''s concerns about disparities, additional research questions were added that will address potential differences in the level of functioning and service delivery between Somali and non-Somali children. CDC, NIH, and Autism Speaks have monitored the University of Minnesota''s efforts throughout the project to ensure adherence to the CDC methodology. The next step plans were to finish the data collection and review and prepare the data for analysis. A communications workgroup was established to prepare a community report that summarizes the findings in an understandable and useful way. Not only will this project help understand how often autism occurs in Somali and non-Somali children in Minneapolis, but results could also promote awareness of autism, help plan and coordinate service delivery, and inform future research and advocacy efforts. In response to concerns about the number of Somali children with autism living in Minneapolis, the CDC, NIH, and Autism Speaks funded the University of Minnesota through a competitive announcement from the Association of University Centers on Disabilities (AUCD) to estimate the number of children with autism living in Minneapolis and to examine whether autism is more common among Somali children than non-Somali children. The adopted study methods were developed by the CDC and are used by the Autism and Developmental Disabilities Monitoring (ADDM) network. The ADDM network reviews health and special education records to identify school-aged children with autism. Data collected using this method can help explain if certain groups are more likely to be identified with autism than others. The project was initially funded for 1 year to encourage a timely response to community concerns. However, the State of Minnesota did not have an existing autism monitoring system in place, so an infrastructure for autism monitoring needed to be built, which took 8 months. Because building the infrastructure took so much time and resulted in delays, a 1-year cost extension to complete the autism monitoring activities was requested and approved. An important component of the project has been community engagement, including establishing a community advisory board, hiring Somali community facilitators, hiring a Somali leadership liaison, and conducting outreach through community resources and meetings as well as through immigrant media sources. In addition, after hearing the community''s concerns about disparities, additional research questions were added that will address potential differences in the level of functioning and service delivery between Somali and non-Somali children. CDC, NIH, and Autism Speaks have monitored the University of Minnesota''s efforts throughout the project to ensure adherence to the CDC methodology. The next step plans were to finish the data collection and review and prepare the data for analysis. A communications workgroup was established to prepare a community report that summarizes the findings in an understandable and useful way. Not only will this project help understand how often autism occurs in Somali and non-Somali children in Minneapolis, but results could also promote awareness of autism, help plan and coordinate service delivery, and inform future research and advocacy efforts. |
| Developing Clinical Vocabulary Standards for Public Health Reporting | Resource Development | CDC | NLM | This collaboration between NLM and CDC is to develop Logical Observation Identifiers Names and Codes (LOINC) codes for use in public health reporting, including tumor registry reporting, and reportable disease reporting. |
| Development and Use of a Non-human Primate Model of Pertussis Diseases and Transmission | Research Initiative | FDA | NIAID | NIH has been working with the FDA toward development and use of a non-human primate model of pertussis disease and transmission. |
| Development of a High Throughput Quantitative PCR Assay to Detect Neutralizing Antibody to Human Respiratory Syncytial Viruses | Research Initiative | FDA | NIAID | Improvements in neutralization assays, in terms of standardization and throughput potential, for Respiratory Syncytial Virus (RSV) would facilitate the development of novel vaccines and therapeutics and enhance the ability to perform large-scale seroepidemiological studies. FDA developed a qPCR based assay which considerably shortens the testing time and increases the output compared to the standard neutralization assays. Because a standardized assay for measuring neutralization would have an impact on regulatory decisions, research conducted by the Food and Drug Administration (FDA) can have significant impact on establishing guidelines and standards that can be used by the outside community during product development. |
| Development of Chemical Emergency Medical Management Website | Resource Development | OS | NICHD, NEI, NIA, NIDA, NINDS | This website''s development is under the auspices of the National Library of Medicine (NLM) Specialized Information Services Division. Additional funding is provided by the Biomedical Advanced Research and Development Authority (HHS). NICHD staff is detailed to assist the NLM in the website''s development with primary responsibility for the creation of the medical management guidelines component. |
| Development of Filovirus BSL-D Neutralization and Enzyme-Linked Immunosorbent Assay (ELISA) Tests for Licensing of Vaccines and Immunoglobulin Preparations | Research Initiative | FDA | NIAID | NIH has been working with the Food and Drug Administration (FDA) to develop standardized BSL2 neutralization and enzyme-linked immunosorbent assay (ELISA) tests to evaluate nonhuman primate immune responses to filoviruses. These standardized tests can be used by all filovirus vaccine developers to assess these surrogate markers for vaccine efficacy in preclinical studies and for studies performed to obtain FDA licensure of a vaccine under the Animal Rule. |
| Development of Live Biotherapeutics Workshop | Meeting/ Workshop | FDA | NIAID, NCI | Workshop participants will discuss the regulatory pathway for live biotherapeutics constituted of live microorganisms (such as bacteria or yeast) that may be naturally occurring, recombinant, or clonally selected; are applicable to the prevention, treatment, or cure of a disease or human condition; and are not an immunogen-specific vaccine. |
| Development of the HHS Framework for Guiding Funding Decisions about Research Proposals with the Potential for Generating Highly Pathogenic Avian Influenza H5N1 Viruses that are Transmissible among Mammals by Respiratory Droplets | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Development of HHS policy regarding the funding of research with the potential for generating HPAI H5N1 viruses that are transmissible among mammals by respiratory droplets. |
| DHHS Health Care Personnel Influenza Vaccination Interagency Working Group | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee is charged with developing strategies to improve the fraction of healthcare professionals who are vaccinated with the influenza vaccine. |
| DHHS Healthcare Infection Control Practices Advisory Committee (HICPAC) | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee serves as the major policy advisory committee in the nation for healthcare epidemiology. |
| DHHS Steering Committee for the Prevention of Healthcare-Associated Infections | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee is charged with developing a national action plan for addressing the important problem of healthcare-associated infections. |
| DHHS Women''s Health and the Environment Interagency Committee | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA, HRSA, IHS, OS | NIEHS, NCI, NICHD | There is abundant evidence that environmental factors may contribute to a variety of diseases in women, including breast and ovarian cancers, osteoporosis, endometriosis, uterine fibroids and autoimmune diseases. Many Federal agencies and offices are working to address these environmental and often preventable threats to women''s health. The DHHS Office on Women''s Health established the Federal Interagency Working Group on Women''s Health and the Environment (FIWGWHE) in 1994 to coordinate and focus Federal action in this area. |
| Diabetes Mellitus Interagency Coordinating Committee (DMICC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NIDDK, CSR, NCATS, NCCAM, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM | The DMICC facilitates cooperation, communication, and collaboration on diabetes among these government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other’s expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate. |
| Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS) | Research Initiative | CDC, IHS | NIDDK, NCATS, NCMHD, NEI, NHLBI, NIA, NICHD | The DPP showed that lifestyle change or metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP. |
| Diabetic Retinopathy Clinical Research Network | Research Initiative | OS | NEI, NIDDK | The Diabetic Retinopathy Clinical Research Network (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the NEI, and co-funded by OS, through NIDDK, with the Special Funding Program for Type 1 Diabetes Research. |
| Diagnosis, Treatment, and Medical Service Utilization in Medicare and Medicaid Population | Research Initiative | CMS | CC | CMS and NIH CC Rehabilitation Medicine (RMD) agreed to collaborate in data-sharing for research the results of which may be helpful to improve medical-service quality, utilization, and effectiveness for Medicare and Medicaid beneficiaries. CMS will provide electronic data to NIH CC/RMD who will perform analyses that are agreed to by both parties. |
| Diet-Induced Hypomethylation in Preneoplastic Liver | Research Initiative | FDA | NCI | The FDA National Center for Toxicological Research and the NCI Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that predetermine individual susceptibility to development of hepatocellular carcinoma and to provide evidence that epigenetic alterations may be used as markers of susceptibility to disease development and correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies. |
| Dietary Guidelines for Americans 2015 | Resource Development | OS | NCI, NIDDK, OD/DPCPSI/ODP | DHHH''s Office of Disease Prevention and Health Promotion has the administrative leadership for the 2015 edition of the Dietary Guidelines for Americans and is supported by USDA''s Center for Nutrition Policy and Promotion. The departments jointly review the Dietary Guideline Committee''s recommendations and develop and publish the policy document. |
| Dietary Guidelines for Mothers and Infants | Research Initiative | OS | NICHD | This Interagency Agreement is to support the Project "Dietary Guidelines for Mother and Infants 0-2 years: Exploring the Evidence." |
| Dietary Supplements Ingredient Database (DSID) | Resource Development | CDC, FDA | OD/DPCPSI/ODP, NCI, NHLBI, NIDDK | The database provides statistical estimates—based on chemical analysis—of the nutrient content of selected ingredients in dietary supplements, compared with label-reported ingredient levels. Currently the DSID provides estimated levels of 18 vitamin and mineral ingredients derived from analytical data for 115 representative unspecified adult multivitamin/multimineral supplements (MVMs). Additional dietary supplement ingredients will be included in future releases of the database. . |
| Digital Quantitation of Plasma Cells in Marrow Biopsies | Research Initiative | FDA | CC | Collaboration with M Choi, WC Cheng and A Badano from the Imaging Physics Lab, Div of Imaging and Applied Mathematics Office of Science and Engineering Labs, Center for Devices and Radiological Health, FDA. The project consists of developing software and establish validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis and therapy monitoring of marrow disorders. |
| Disaster Research Response Project | Research Initiative | ATSDR, CDC, FDA, OS | NIEHS, NLM | The NIH Disaster Research Response (DR2) Project is a pilot project aimed at creating an environmental health disaster research system through platforms of ready-to-go research data collection tools and a network of specially trained research responders. This project was developed and will be administered by the NIEHS and NLM. Elements of the system include epidemiologic questionnaires and clinical protocols, specially trained disaster researchers, environmental health disaster research networks, a reach-back roster of subject matter experts, and a support infrastructure that can be activated and deployed during public health emergencies and declared disasters. This effort will not only serve as a model for enhancing environmental health research responses, but will also provide invaluable lessons and platforms for others interested in advancing timely post-disaster research activities. |
| Domestic Scheduling to Control New Drugs of Abuse, with NIDA-Funded Testing Conducted in Support of DEA Scheduling Recommendations to the FDA | Research Initiative | FDA, OS | NIDA | HHS depends upon NIDA contracts to generate the in vitro and animal behavioral data that are required to support the domestic scheduling of new street drugs. The long-standing agreement is that DEA provides the drugs (or the funds to cover drug synthesis) to NIDA, and NIDA covers the cost of pharmacological testing. |
| Dominantly Inherited Alzheimer''s Network (DIAN): International Network for the Identification, Evaluation, and Follow up of Families with Early Onset of Dominantly Inherited Alzheimer''s Disease | Research Initiative | FDA | NIA | This collaboration aims to set up an international network consisting of a consortium of scientific investigators that will have the responsibility to identify, recruit, evaluate, and follow-up individuals from families with early onset dominantly inherited Alzheimer’s disease [i.e., families with the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) mutations or duplications or others still to be discovered]. |
| Drug Induced Liver Injury Network (DILIN) | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK | Both a prospective and retrospective database containing cases of drug-induced liver disease, DILIN is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. One of the goals of DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Three employees of FDA serve as ad hoc members on the committee overseeing the network activities. |
| Early Hearing Detection and Intervention | Meeting/ Workshop | CDC | NIDCD | Teleconference sponsored by CDC. |
| Early Learning Interagency Policy Board (IPB) | Committee, Work group, Advisory group, or Task Force | ACF | NICHD, NIDA | The purpose of the Early Learning Interagency Policy Board is to coordinate and align efforts, where possible, around early learning and development, across the Department of Health and Human Services and the Department of Education. |
| Electronic Research Administration (eRA) | Other | AHRQ, CDC, FDA, SAMHSA | OD/OER, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM | The Electronic Research Administration (eRA) provides information technology solutions and support for the full life cycle of grants administration functions for the NIH as well as the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Veterans Health Administration (VHA). eRA offers vital solutions to manage the receipt, processing, review, award and monitoring of over $30 billion in research and non-research grants awarded annually by NIH and other grantor agencies in support of the collective mission of improving human health. eRA helps NIH meet a vital mission: the support of cutting-edge biomedical research via grants to scientists at universities and other research institutions. Over 4,600 NIH staff, 700 partner agency staff, and 166,000 active external users depend on eRA daily. Used by Federal staff and applicants at over 12,500 research institutions worldwide, eRA has helped eliminate the hundreds of millions of pieces of paper previously required to: • Record, review and process over 80,000 applications each year. • Support more than 3,500 review meetings held annually. • Administer more than 55,000 awarded competing and non-competing grants. • Maintain patent and invention records for 25 Federal agencies (see the iEdison website). • Support thousands of applicant interactions with the Federal Government before and after the grant award, through the eRA online interface. eRA''s focus is on supporting the mission of serviced agencies by providing tools to electronically manage and report on grants in a way that maximizes efficiencies, provides a strong and scalable infrastructure, is responsive to evolving customer needs and employs sound management controls. eRA systems align with Grants.gov (the one-stop web portal for finding and applying for federal grants), allowing for full electronic processing of grant applications from application submission through closeout of the grant award and reporting thereafter. eRA operates as a fee for service activity to OPDivs and other federal agencies. |
| Emergency Care Research Interagency Program Officer Working Group | Committee, Work group, Advisory group, or Task Force | HRSA | NICHD, NHLBI, NINDS | This working group aims to share common challenges in conducting emergency care research, identify innovative solutions amongst the projects in IC portfolios for common problems; discuss performance evaluation of emergency care networks; and discuss models for funding and evaluating data coordinating centers. (Ad hoc) |
| Emergency Preparedness, Medical Countermeasures | Resource Development | OS | NCI | NCI provides expertise in radiation biology and radiation oncology to help guide the research and development for medical countermeasures for radiation injury and for biomarkers for assessing injury, dose and who needs treatment. |
| Endocrinologic and Metabolic Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the FDA for drug approval. |
| Enhanced Comprehensive HIV Prevention Planning (ECHPP)/12-Cities Initiatives | Research Initiative | CDC, HRSA, IHS, SAMHSA | NIMH, NIAID | NIMH staff have participated in workgroups to inform the implementation of the Enhanced Comprehensive HIV Prevention Planning (ECHPP)/HHS Twelve Cities Project. This project is funded by the CDC''s Division of HIV/AIDS Prevention. The project aims to maximize the impact of HIV prevention in the twelve metropolitan areas with the highest AIDS prevalence in the United States. |
| Enhanced Comprehensive HIV/AIDS Prevention Plan Cross-Agency Programmatic Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, IHS, OS | NIAID, NIMH | The purpose of this group is to enhance federal coordination in support of the National HIV AIDS Strategy, specifically related to the Enhanced Comprehensive HIV/AIDS Prevention Plan funded by the CDC. |
| Enhancing the National Death Index (NDI) | Resource Development | CDC | NIA, NCI, NHLBI | This agreement will enable the Centers for Disease Control and Prevention/National Center for Health Statistics to expedite the processing of state death certificate data for annual updates to the NDI. |
| Environmental Tobacco Smoke Exposure and Mortality Among Nonsmokers | Research Initiative | CDC | NCI | An investigation of environmental tobacco smoke exposure and mortality among nonsmokers in the National Health and Nutrition Examination Survey (NHANES) study. |
| Ethical, Legal and Social Issues (ELSI) Sub-study in the Biospecimen Pre-Analytical Variables (BPV) Project | Research Initiative | OS | NCI, CC | This Substudy is part of ongoing efforts by the Cancer Human Biobank (caHUB) program to improve effectiveness and generate best practices for the biospecimen research community. The Biospecimen Pre-Analytical Variables (BPV) Ethical Legal and Social Implications (ELSI) Substudy is a study of the ethical, legal and social implications related to the informed consent process for biobanking. The ELSI study will be designed to address current issues related to informed consent for biobanking, particularly the issue of consent for broad future research use, and will be approached in a two-step fashion. The objective of the ELSI Substudy is to assess research participant comprehension and concerns related to informed consent for biobanking across the diverse patient populations included in the BPV program. The intent of this evaluation is to improve our understanding of the issues that impact donor participation in such programs and to identify factors that may result in decreased rates of donor participation. This study will provide a unique and unprecedented opportunity to address these issues in a diverse patient population of actual biospecimen contributors approached for consent using a highly harmonized informed consent document. Each Biospecimen Source Site (BSS) collecting tumor tissue from surgical procedures shall ensure participation in the ELSI study. Both BPV participants and decliners will be surveyed, using two different survey instruments. |
| European-US Pediatric Formulations Excipients Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | Multinational academic, industry and regulatory group convened to determine toxicity of excipients in pediatrics. Accomplishments include developing a database that will be tested both in the EU and US this year |
| Evaluate the Efficacy of an Antiviral Drug, Tenofovir | Research Initiative | CDC | NICHD | The purpose of this Interagency Agreement is to continue to establish a formal working relationship between CDC and NICHD as co-sponsors of a multicenter clinical study to evaluate the efficacy of an antiviral drug, tenofovir, for prevention of hepatitis B virus (HBV) mother-to-child transmission from HBV-infected mothers with high HBV viral load. The study evaluates the critical issue of prevention of mother-to-child transmission (MTCT) of HBV in the high risk situation of elevated maternal HBV virus load [HBV e antigen positive (HBeAf+] mothers). Infants infected at birth with HBV are at high risk of both cirrhosis and liver cancer during adulthood. |
| Evaluation of Patient Reported Outcomes Following LASIK Surgery. | Research Initiative | FDA | NEI | This will be a prospective, questionnaire-based study conducted by the U.S. Navy Refractive Surgery Center San Diego in collaboration with the U.S. Food and Drug Administration’s Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices. The primary purpose is to quantify the satisfaction and health related quality of life of 500 active duty patients over a period of six months following state-of-the-art laser in situ keratomileusis (LASIK). The questionnaire to be used will be a new instrument which, once validated in this study, might be employed in future clinical studies that include civilian refractive surgery centers in the U.S. |
| Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome | Meeting/ Workshop | AHRQ | OD/DPCPSI/ODP, NICHD | The Office of Disease Prevention coordinates the development of Evidence-based Methodology Workshops (EbMW) that seek to identify methodological and scientific weaknesses in a scientific area and move the field forward through an unbiased and evidence-based assessment of a complex clinical issue. The first workshop in this program focused on polycystic ovary syndrome (PCOS), a common hormone disorder that affects approximately 5 million reproductive-aged women in the United States. The workshop was designed to clarify: 1) benefits and drawbacks of using the Rotterdam Criteria, 2) the condition’s causes, predictors, and long-term consequences, and 3) optimal prevention and treatment strategies. The workshop was sponsored by the Office of Disease Prevention and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. A multidisciplinary steering committee developed the workshop agenda. The NIH Library created an extensive, descriptive bibliography on PCOS to facilitate workshop discussion. During the 2½-day workshop, invited experts discussed the body of evidence and attendees provided comments during open discussion periods. After weighing the evidence, an unbiased, independent panel prepared a report that summarized the workshop and identified future research priorities. The workshop was held on December 3-5, 2012. |
| Evidence-Based Review & Report Program | Resource Development | AHRQ | OD/DPCPSI/ODP, NCCAM | This Congressionally mandated program reviews current scientific evidence on the efficacy and safety of dietary supplements; identifies research needs; and prepares reports of their findings. |
| Exposure Assessment of Engineered Nanoparticles | Research Initiative | CDC | NIEHS | The purpose of this project is to identify workplaces engaged in the synthesis, manufacture and use of engineered nanomaterials, and to characterize the potential for worker exposure to selected engineered nanoparticles. |
| Extracellular RNA Communication | Research Initiative | FDA | OD/DPCPSI, NCATS, OD/DPCPSI/OSC | Recent advances have indicated that RNAs can play a role in a variety of complex cellular functions, including newly discovered mechanisms of cell-to-cell communication. RNA can be exported from cells in extracellular vesicles or bound to lipids or proteins, to circulate through the body and affect cells at a distance. However, the actual impact of the extracellular RNAs, or exRNAs, is currently unknown. NIH and FDA intend to collaborate and coordinate efforts towards the preclinical and clinical use of exRNAs to address human health and disease. |
| Family Health History | Health Survey | OSG | NCI, NHGRI | The "My Family Health Portrait" tool is a Web-enabled program that runs on any computer that is connected to the Web and running an up-to-date version of any major Internet browser. The Web-based tool helps users organize family history information and then print it out for presentation to their family doctor. In addition, the tool helps users save their family history information to their own computer and even share family history information with other family members. |
| FDA Arthritis Drugs Advisory Committee Meeting | Meeting/ Workshop | CDC, FDA | NIMH | An NIMH Program Officer (PO) was invited to serve as a voting ad hoc member of one of the FDA Arthritis Drugs Advisory Committees, which met to review a new drug application for the treatment of Chronic Fatigue Syndrome (CFS). Subsequently, the NIMH PO has been invited as the sole NIH representative to a follow-up meeting planned at the FDA among FDA staff, a CDC representative, and the sponsor to discuss further steps in Myalgic Encephalomyelitis/CFS drug development. |
| FDA Blood Products Advisory Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NHLBI, CC | The FDA Blood Products Advisory Committee advises the FDA regarding issues of blood safety and efficacy. The committee reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum, or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases. |
| FDA Cancer Diagnosis Program (CDP) Monthly Meeting | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Participants discuss proposed integral markers and process for regulatory input into integral markers/assays for clinical trials. |
| FDA Cancer Imaging Program (CIP) Bi-annual Meeting | Meeting/ Workshop | FDA | NCI | This collaboration is a bi-annual meeting to enhance communication between the Cancer Imaging Program (CIP) and the Division of Medical Imaging Products of CDER in the FDA. This allows for a two-way exchange of information and discussion of issues that are important for each side. Topics that have been discussed include CIP''s standardization efforts of medical imaging scanners in NCI Cancer Centers, presentation and discussion of specific new molecular imaging modalities, and discussion of recent FDA decisions regarding new medical imaging innovations. |
| FDA Center of Drug Evaluation and Research (CDER) Workgroup | Committee, Work group, Advisory group, or Task Force | FDA | CC | The joint CC-CDER collaborative working team is aimed at developing new processes to consider exceptions to existing CDER policies and procedures for extraordinary clinical circumstances. Over the past few years, CC investigators have encountered instances in which regulatory barriers may have precluded novel pharmacological interventions for severely ill patients. Leaders at the FDA CDER became aware of the concern of some NIH intramural investigators and approached CC leadership to understand the issues. |
| FDA Drug Safety Oversight Board | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | OD/OSP, NCI | The FDA Drug Safety Oversight Board (DSB), created in 2005 and mandated by law in the FDA Amendments Act of 2007, advises the FDA''s Center for Drug Evaluation and Research (CDER) Center Director on the handling and communicating of important and often emerging drug safety issues and regulatory science. The DSB is composed of representatives from two FDA Centers and eight other federal government agencies: the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Centers for Medicare and Medicaid Services (CMS), Department of Defense (DOD), Health Resources and Services Administration (HRSA), Indian Health Service (IHS), National Institutes of Health (NIH), and Department of Veterans Affairs (VA). An important role of the DSB is to help FDA assess the impact of their safety decisions on the healthcare systems of its Federal Partners. The Board, with its broad representation from federal healthcare organizations, can provide valuable input and allows FDA to hear other perspectives on drug safety issues. |
| FDA Medical Countermeasures initiative (MCMi) Regulatory Science Steering Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This committee provides guidance to MCMi stakeholders. |
| FDA Memorandum of Understanding with NHLBI [Docket No. FDA–2008–N–0043] | Committee, Work group, Advisory group, or Task Force | FDA | NHLBI | The group meets quarterly at alternate sites to discuss stem cell research, cell therapy research, and clinical trials related to these areas. Group members are invited to and attend CBER or NHLBI working groups and workshops on these topics. |
| FDA Pediatric Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | This is a committee of ad hoc pediatric clinical pharmacologists and pediatricians. |
| FDA-NCI Monthly Meeting | Meeting/ Workshop | FDA | NCI | A monthly meeting to enhance communication between the two agencies, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure; as well as an understanding of the operations of the sister agencies. |
| Fecal Microbiota for Transplantation | Meeting/ Workshop | FDA | NIAID | This workshop provided a forum for the exchange of information, knowledge, and experience among FDA, NIH, and the scientific - medical community regarding fecal microbiota for transplantation |
| Federal Breastfeeding Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The purpose of this workgroup is to develop strategies to implement the Surgeon General''s call to action to support breastfeeding. |
| Federal Dietary Reference Intakes Steering Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, OS | NIDDK | This committee serves as an interagency forum to provide oversight on the process used to establish the Dietary Reference Intakes. These values serve as a basis for many federal nutrition programs and policies. |
| Federal Education and Training Interagency Group | Committee, Work group, Advisory group, or Task Force | HRSA | NICHD, NLM | This group''s mission is to oversee the development of national standards for disaster preparedness education and training. |
| Federal HIV/AIDS Web Council (AIDS.gov) | Resource Development | CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OAR, NCI, NIAID, NIDA, NLM | The goals of this collaboration are to: expand visibility of timely and relevant Federal HIV policies, programs, and resources to the American public; increase use of new media tools by government, minority, and other community partners to extend the reach of HIV programs to communities at greatest risk; and increase knowledge about HIV and access to HIV services for people most at-risk for, or living with, HIV. |
| Federal Interagency Committee on Relationships | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC | NICHD | Interagency group established to improve the information base about children and families. |
| Federal Interagency Committee on Traumatic Brain Injury | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, HRSA, SAMHSA | NCCAM, NIDA, NIDCR, NIMH, NINDS | The charge of the Interagency Committee includes promoting collaboration among federal agencies. A goal of this committee is to develop a national “Roadmap” for Traumatic Brain Injury (TBI). This strategic planning effort will represent the collective expertise of providers, educators, advocates, federal/state/national organizations, and individuals with TBI and their families and will result in a consensus document outlining the critical elements of a successful system of care for TBI service delivery. Another goal is to build and maintain an interagency site like the envisioned www.TBI.gov. |
| Federal Interagency Forum on Aging Related Statistics | Resource Development | ACL, AHRQ, CDC, CMS, OS, SAMHSA | NIA | This Interagency Forum was formed with the goal of bringing together Federal agencies that share a common interest in improving aging-related data. The specific goals of the Forum are to improve both the quality and use of data on the aging population. |
| Federal Interagency Reentry Council: Health Care Access Reentry Workgroup Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, CDC, CMS, HRSA, IHS, OS, SAMHSA | NIMH, NIDA | The Subcommittee is convened by HHS/ASPE to address issues pertaining to the reentry to the community from incarceration. Participants discuss behavioral and mental health policy and research, and how best to reduce health disparities within and among vulnerable populations. |
| Federal Interagency Task Force on the Arts and Human Development | Committee, Work group, Advisory group, or Task Force | ACF, ACL, SAMHSA | NIA, NCCAM, NICHD, NIMH, OD/DPCPSI/OBSSR | Beginning in 2011, the NEA has convened a Federal Interagency Task Force on the Arts and Human Development to encourage more and better research on how the arts can help people reach their full potential at all stages of life. Task force members represent multiple units across federal government, including the U.S. Department of Health and Human Services, the National Institutes of Health, the National Science Foundation, and the U.S. Department of Education, among others. To date, the Task Force has met quarterly to share ideas and information about research gaps and opportunities for understanding the arts'' role in improving health and educational outcomes throughout the lifespan. The Task Force has conducted a series of public webinars on compelling research and practices. Additionally, the group has begun a literature review of research on the arts and human development. And in November 2012, four Task Force member agencies hosted a first-ever convening at the National Academy of Sciences to review the current state of research on the arts, health, and well-being in older Americans. |
| Federal Interagency Traumatic Brain Injury Research (FITBIR) Working Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, OS, SAMHSA | NINDS, CIT, NCATS, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIGMS, NIMH | The FITBIR network facilitates communication, coordination, and collaboration of Traumatic Brain Injury (TBI) research across agencies. Data sharing policies and strategies are developed by this working group. |
| Federal Interagency Workgroup on Child Abuse and Neglect | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, HRSA, IHS, OS, SAMHSA | NICHD, NIDA, NIMH | The Federal Interagency Workgroup on Child Abuse and Neglect meets to provide a forum through which staff from relevant Federal agencies can communicate and exchange ideas concerning the prevention of child maltreatment and other related issues. The Workgroup collects information about Federal child maltreatment activities and provides a basis for collective action through which funding and resources can be maximized. |
| Federal Interagency Workgroup on Teen Dating Violence (TDV) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, OS, SAMHSA | NIAAA, NICHD, NIDA, NIMH | The federal government is coordinating efforts to address the problem of teen dating violence (TDV) through this workgroup, which serves as a forum for information sharing, cooperation, and collaboration. It meets every 6 weeks to monitor research on TDV and consider how federal agencies might contribute to fighting TDV. In 2009, this working group produced a trans-NIH program announcement (PA) on Research on Teen Dating Violence (TDV). |
| Federal Interagency Working Group on Vitamin D | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA | NICHD, NEI | Workgroup supports research on the importance of vitamin D for health. |
| Federal mHealth Collaborative | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/DPCPSI/OBSSR, NCI, NHLBI, NIBIB, NIDA, NLM | Federal working group of agencies interested in mHealth technology and its potential for enhancing health care. Also involves resource development. |
| Federal Partners Committee on Women and Trauma | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, SAMHSA | NIDA, NIAID, NIMH, OD/DPCPSI/ORWH | Led by the Department of Labor (DOL) and Substance Abuse and Mental Health Services Administration (SAMHSA), the Women and Trauma work group includes more than three dozen federal agencies, departments, and offices. It is one of the largest inter agency collaborations in federal government history. The work group published a recent report in September 2013 summarizing the specific progress that participating agencies have made over the past three years (2010-2013). |
| Federal Partners in Bullying Prevention, Intervention, and Recovery | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, IHS, SAMHSA | NIMH, NIAAA, NICHD, NIDA, OD/DPCPSI/ODP | This workgroup meets to provide a forum through which staff from relevant Federal agencies can communicate and exchange ideas concerning how to prevent or stop bullying in schools and communities. |
| Federal Primary Care Medical Home Collaborative (PCMH) | Committee, Work group, Advisory group, or Task Force | AHRQ, CMS, HRSA, IHS, SAMHSA | OD/DPCPSI/OBSSR, NCI, NHLBI, NIA, NIDA, NIDDK, NIMH | Federal working group designed to share information and develop multi-agency scientific and funding opportunities. Also includes resource development. |
| Federal Sudden Unexpected/Unexplained Infant Death (SUID) Sudden Infant Death Syndrome (SIDS) Workgroup | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, IHS, OS | NICHD | This workgroup is a collaboration of Federal Partners to coordinate efforts to reduce infant mortality from Sudden Infant Death Syndrome (SIDS) and Sudden Unexpected/Unexplained Infant Death (SUID), and to make the Federal effort to address SIDS and SUID more efficient and effective by assuring complete and consistent communication, avoiding duplication of effort, and integrating the varied perspectives and efforts of the different agencies. This workgroup addresses the public health challenges of SIDS and SUID and opportunities for prevention in the United States. The purpose of the partnership is to establish and enhance relationships among Federal agencies with responsibilities for SIDS and SUID. The partner agencies intend to work together to improve communication and coordination, and to collaborate on a range of activities designed to reduce, and, ultimately, eliminate SIDS and SUID, including the elimination of racial, ethnic and socio-economic disparities. |
| Federal Supply and Demand of Isotopes | Committee, Work group, Advisory group, or Task Force | FDA | NIBIB, NCI | This workgroup was formed as follow-up to the Inaugural Workshop on Isotope Federal Supply and Demand, a workshop now held annually. The workgroup consists of representatives of Federal agencies with the aim of providing a forum for interaction between agencies and departments to communicate about potential shortages of isotopes that are of strategic importance to the nation including the availability of medical isotopes. DOE is charged with the production of isotopes that are not commercially available, and coordinates the informational and production efforts. Dr. Roderic Pettigrew, Director of NIBIB is the NIH point of contact on this topic. The workgroup holds an annual workshop that includes all Federal agencies that use isotopes; the workshop promotes discussion on the use, supply and demand of isotopes in various areas including homeland defense, medicine, agriculture, and basic and applied research, |
| Federal Working Group on Bone Diseases | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, OS | NIAMS, CSR, NCATS, NCCAM, NCI, NEI, NIA, NIAAA, NICHD, NIDCR, NIDDK, NIEHS, NIMH, OD/DPCPSI/ORWH | An interagency committee focusing on osteoporosis, Paget''s disease, and other bone disorders. It offers a forum for sharing information, learning from each other and invited speakers, and facilitating the development, early in the planning stages, of collaborative research activities based on each agency''s mission. Serves to develop and foster collaborative activities among the government agencies on bone diseases. |
| Federal Working Group on Dietary Supplements | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA | OD/DPCPSI/ODP, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OBSSR | The Federal Working Group on Dietary Supplements (FWGoDS) is comprised of individuals from federal agencies that share information and discuss issues, initiatives, and research related to dietary supplements. The FWGoDS meets twice a year and serves as a means of communication between the Office of Dietary Supplements (ODS) and its federal partners. |
| Federal Working Group on International Migration Statistics and Research | Committee, Work group, Advisory group, or Task Force | ACF, CDC, OS | NICHD | This working group brings together agencies from across the Executive Branch to share current work and to collaborate on joint projects to advance the federal government''s contribution in the area of international migration. |
| FedTel: Cross-Federal work group on telehealth | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NIBIB, NLM, OD/DPCPSI/OBSSR | The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies. Current topics of emphasis include Telehealth and Health Information Technology (HIT); Technology, Innovation and Standards; Public Education of Telehealth; and Access to Health Care. |
| Filovirus Animal Non-Clinical Group (FANG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The Filovirus Animal Non-Clinical Group focuses on the advanced development of Filovirus Medical Countermeasures (MCM), both vaccines and therapeutics. The FANG will focus on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories. |
| Food Safety and Nutrition Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIDDK, NIEHS | The Food Safety and Nutrition Working Group (FSNWG) aims to highlight and promote awareness of an integrated approach to nutrition and food science in academia, and among nutritionists and food scientists; facilitate the alignment of research priorities to address food safety, food quality, and nutrition in single studies; and identify future research areas that can mesh food safety, food quality, and nutrition together. |
| Forum on Child and Family Statistics | Resource Development | ACF, AHRQ, CDC, HRSA, SAMHSA | NIMH, NICHD, NIDA | The Federal Interagency Forum on Child and Family Statistics, or the Forum, is a working group of Federal agencies that collect, analyze, and report data on issues related to children and families. The Forum''s signature report, America''s Children: Key National Indicators of Well-Being, provides annual updates on the well-being of children and families in the United States across a range of domains. |
| Gain-of-Function Research on Highly Pathogenic Avian Influenza H5N1 Viruses: An International Consultative Workshop | Meeting/ Workshop | CDC, FDA, OS | OD/OSP, NIAID | International consultative workshop convened on December 17-18, 2012 on Gain-of-Function Research on Highly Pathogenic Avian Influenza H5N1 Viruses. The purpose of this workshop was to provide a forum for sharing multidisciplinary international perspectives on the risks and benefits of research on highly pathogenic avian influenza (HPAI) H5N1 viruses, and possible oversight strategies. |
| Genetic, functional, and epidemiologic studies of chronic hepatitis C | Research Initiative | FDA | NCI | Interdisciplinary studies to determine the molecular and immunological mechanisms of action of interferon lambda region genetic variants in HCV infection. |
| Genetics in Environmental and Occupational Diseases | Research Initiative | CDC | NIEHS | These studies evaluate unique cohorts of individuals from professions associated with immune-mediated occupational diseases including asthma, respiratory and contact allergy, chronic beryllium disease, rhinitis, and silicosis. Occupational cohorts are being studied for a number of endpoints including, impact of genetic polymorphisms on inflammatory disease development and clinical outcomes, the role that genetic variations play in environmental and workplace related diseases and identification of unique immunological biomarkers for disease. |
| Genome in a Bottle Consortium | Resource Development | CDC, FDA | NHGRI, NCI, NLM | The "Genome in a Bottle Consortium" was organized to develop the reference materials, reference data, and reference methods needed to assess performance of human genome sequencing. |
| Genomic Nursing State of the Science Advisory Panel | Committee, Work group, Advisory group, or Task Force | HRSA | NHGRI, NINR | A Genomic Nursing State of the Science Advisory Panel was convened in 2012 to develop the nursing research blueprint. The Advisory Panel, which met via two webinars and two in-person meetings, considered existing evidence from evidence reviews, testimony from key stake-holder groups, presentations from experts in research synthesis, and public comment. |
| Global Change Research Program (GCRP) Interagency Climate Change and Human Health Group (CCHHG) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIEHS, FIC | NIEHS co-chairs along with CDC and NOAA the interagency working group under the Global Change Research Program (GCRP) that plans, coordinates and executes many federal science activities on climate change and human health. |
| Global Environmental and Occupational Health (GEOHealth) | Other | CDC | FIC, NIEHS | FIC, in collaboration with NIEHS and NIOSH/CDC, launched this program in order to support the development of leading institutions in the developing world that serve as regional hubs for collaborative research, data management, training, curriculum development and policy support in environmental and occupational health. The goal of the program is to catalyze a multi-national network of regional Global Environmental and Occupational Health (GEOHealth) Hubs that are the lead resources for environmental and occupational health, attract and retain the best talent in the region, and provide the scientific evidence for policy formulation. |
| Global Health Security Advisory Group (GHSAG) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIAID, NINDS | The Global Health Security Advisory Group (GHSAG) is a committee composed of high level representatives of the national health authorities for the G-8 block of countries. The GHSAG was formed to develop and implement concrete actions to improve global health security and serve as a network for rapid response to chemical, biological, radiological, and nuclear (CBRN) terrorism crises. |
| Global Strategic Plan to Prevent Harms Associated with Alcohol Misuse | Meeting/ Workshop | CDC, SAMHSA | NIAAA | NIAAA represented HHS at the World Health Organization coordinating with officials at CDC and SAMHSA to review Global Strategies to Prevent Harms Associated with Alcohol Misuse. |
| Go4Life | Public Education Campaign | ACL, AHRQ, CDC, OS, OSG | NIA, NCCAM, NEI, NHLBI, NIAMS, NIDDK, NIMH, NINDS | Go4Life, is an exercise and physical activity campaign from the National Institute on Aging at the National Institutes of Health (NIH), and is designed to help individuals fit exercise and physical activity into their daily life. Motivating older adults to become physically active for the first time, return to exercise after a break in their routines, or build more exercise and physical activity into weekly routines are the essential elements of Go4Life. Go4Life offers exercises, motivational tips, and free resources to help individuals get ready, start exercising, and keep going. The Go4Life campaign includes an evidence-based exercise guide in both English and Spanish, an exercise video, an interactive website, and a national outreach campaign. |
| Guidelines for Prevention of Mother to Child HIV Transmission; Guidelines for Pediatric Antiretroviral Treatment; Guidelines for Adult Antiretroviral Treatment; Guidelines for Prevention and Treatment of Opportunistic Infections in Adults | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, NIAID | These are separate Working Groups for development of U.S. guidelines related to HIV infection and its treatment. These Working Groups are composed of external experts in the various areas covered as well as federal agency representatives, including CDC, HRSA, and FDA. |
| Guidelines for Prevention of perinatal group B streptococcal disease-neonatal evaluation | Research Initiative | CDC | NICHD | This Interagency Agreement requires the technical assistance of the National Institute of Child Health and Development (NICHD) Neonatal Research network for development of current guidelines for prevention of group B streptococcal disease calling for a limited neonatal evaluation including blood culture at birth and initiation of empiric antibiotic therapy for all newborns born to mothers with chorioamnionitis |
| Harmonization of soluble transferrin receptor (STIR) measurements | Research Initiative | CDC | NICHD | This Interagency Agreement is intended to conduct activities that will harmonize assays measuring soluble transferrin receptor (STfR), an important indicator to assess the global burden of iron deficiency in children and women of childbearing age. The goal of the harmonization process is to generate comparable data across multiple laboratories using currently available methodologies for measuring STfR. |
| Health and Retirement Study (HRS) | Health Survey | CDC, CMS | NIA | This survey follows more than 20,000 men and women over 50, offering insight into the changing lives of the older U.S. population. Launched in 1992, this multidisciplinary, longitudinal study has become known as the Nation''s leading resource for data on the combined health and economic conditions of older Americans. |
| Health Behavior in School-Aged Children, 2009-2010 Survey (HBSC) including NEXT as an option | Health Survey | HRSA | NICHD | This Interagency Agreement (IAA) is to fund the Electronic Health Record (EHR) Pediatric Practice Based Research Network (PBRN) initiative. The purpose of this IAA is to fund, oversee, and manage a research grant on a topic of mutual interest to the agencies. The funds will be used to conduct comparative effectiveness research (CER) and epidemiologic assessments of the use of selected psychotropic medications and the most commonly prescribed asthma medications in pediatric populations, as well as possible associations between these medications and side effects in this population in an existing electronic health record (EHR) based pediatric practice-based research network. This agreement provides needed supplemental funding and HRSA staff experience to conduct the U.S. survey component according to the HBSC study protocol developed in collaboration with the World Health Organization. The NEXT study was included as an option in FY2012. NEXT is a 7-year longitudinal assessment of a representative sample of U.S. adolescent and young adults, starting when they are in in 10th grade. This research initiative involves collaboration with the Best Pharmaceuticals Act for Children. |
| Health Literacy Work Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG | NICHD, NCI, NEI, NHGRI, NHLBI, NIBIB, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINR, NLM, OD/DPCPSI/OBSSR, OD/OCPL | This Workgroup is comprised of various HHS agencies that work towards meeting the Department’s prevention goals and to accomplish the National Action Plan and the Healthy People 2020 Objective: Improve the health literacy of persons with inadequate or marginal literacy skills. |
| Health Services and Technology Assessment Text (HSTAT) | Resource Development | AHRQ, CDC, OSG, SAMHSA | NLM | NLM provides a free, web-based resource of full-text documents that provide information on health-care decision making. |
| Healthcare Systems (HCS) Research Collaboratory | Research Initiative | AHRQ, CDC, FDA | NIDCR, NCATS, NCCAM, NCI, NHGRI, NHLBI, NIA, NIAMS, NICHD, NIDA, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR, OD/DPCPSI/OSC | The overall goal of the Common Fund’s Health Care Systems (HCS) Research Collaboratory program is to strengthen the national capacity to implement cost-effective large-scale research studies that engage health care delivery organizations as research partners. The aim of the program is to provide a framework of implementation methods and best practices that will enable the participation of many health care systems in clinical research, not to support a defined health care research network. Research conducted in partnership with health care systems is essential to strengthen the relevance of research results to health practice. |
| Healthy People 2010 - Kidney Disease | Public Education Campaign | CDC, CMS, FDA, HRSA, OS | NIDDK | The Office of the Secretary of HHS leads the Healthy People 2010 initiative. The lead agency for most data activities is the CDC. However, for the kidney area, most of the information is provided by NIDDK through the US Renal Data System. |
| Healthy People 2010/2020 Partnership | Other | AHRQ, CDC, CMS, HRSA, IHS, OS | NHLBI, NINDS | The Partnership provides the opportunity for several units of the Federal government to work on activities related to the Heart Disease and Stroke (HDS) components of the Healthy People initiative. In particular, the purpose of the activity is to catalyze progress toward achieving the Healthy People goals through the various phases of prevention, including prevention of the development of risk factors for HDS; detection and treatment of risk factors for HDS; early identification and treatment of HDS especially in the acute phases; and prevention of recurrence and complications of HDS. |
| Healthy People 2020 - Blood Diseases, Disorders, and Safety | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS | NHLBI | The purpose of this agreement is to support development and implementation of survey questions and measures to assess progress made toward the achievement of the Healthy People 2020 national objectives for blood diseases/disorders and safety. |
| Healthy People 2020 - Environmental Health and Respiratory Disease Topic Areas | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, OS | NIEHS, NHLBI | Led workgroups, coordinated meetings, developed goals, reported to DHHS, and collaborated with other Federal agencies. |
| Healthy People 2020 - Environmental Health Topic Area | Committee, Work group, Advisory group, or Task Force | AHRQ, ATSDR, CDC, FDA, OS | NIEHS | Healthy People provides science-based, 10-year national objectives for promoting health and preventing disease. Since 1979, Healthy People has set and monitored national health objectives to meet a broad range of health needs, encourage collaborations across sectors, guide individuals toward making informed health decisions, and measure the impact of our prevention activity. Currently, Healthy People 2010 is leading the way to achieve increased quality and years of healthy life and the elimination of health disparities. Healthy People 2020 is currently assessing the objectives of the past decade, measuring the impact of its prevention activity, and developing new 10-year targets. |
| Healthy People 2020 - Respiratory Diseases | Health Survey | CDC | NHLBI, NIAID, NIEHS | The purpose of the collaborative activity is to support development and implementation by the National Health Interview Survey (NHIS) of measures that could be used to assess progress towards achieving Healthy People 2020 respiratory/asthma objectives. The NHLBI and the National Center for Health Statistics collaborate on this activity. |
| Healthy People 2020 - Sleep Health | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA, OSG | NHLBI, NCCAM, NIA, NICHD, NINDS, NINR | This activity supports the development and implementation of survey questions and measures to assess progress on achieving the Healthy People sleep health objectives. |
| Healthy People 2020 Partnerships for Heart Disease and Stroke | Committee, Work group, Advisory group, or Task Force | CDC, OS | NHLBI, NINDS | The purpose of this collaborative activity is to support the development by the National Health Interview Survey (NHIS) of measures that can be used to assess progress toward achieving Healthy People 2020 (HP2020) Heart Disease, Blood Pressure, and Cholesterol Objectives. This work group is dedicated to HP2020-related activities that will: improve cardiovascular health and quality of life through prevention, detection, and treatment of risk factors for heart attack and stroke; promote early identification and treatment of heart attacks and strokes; and prevent repeat cardiovascular events. The NIH and CDC''s National Center for Health Statistics collaborate on this activity. |
| Healthy People 2020, Disability and Health Objective on Epilepsy Care (DH-6) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NINDS, NICHD | Working group to coordinate Healthy People 2020 objectives on epilepsy care in US adults, based on National Health Interview Survey data. In 2013, the group converted the objective from developmental to measurable status. |
| Healthy People 2020-Dementias, Including Alzheimer''s Disease | Committee, Work group, Advisory group, or Task Force | CDC | NIA, NIMH, NINDS | This Healthy People 2020 topic will focus on increasing the awareness of the diagnosis of Alzheimer’s disease, and reducing the proportion of preventable hospitalizations in persons with diagnosed Alzheimer’s disease and other dementias. The goal is to reduce the morbidity and costs associated with, and maintain or enhance the quality of life for, persons with dementia, including Alzheimer’s disease. |
| Healthy People 2020-Older Adults | Committee, Work group, Advisory group, or Task Force | ACL, CDC | NIA | This Healthy People 2020 topic is designed to develop an understanding of the health and health care needs and implications for older adults. The objectives overall will promote healthy outcomes in this population. The goal of these objectives is to improve the health, function, and quality of life of older adults. |
| Healthy Vision Month | Public Education Campaign | CDC | NEI | Each May, the NEI sponsors Healthy Vision Month (HVM) which is a national observance designed to elevate eye health as a priority for Americans. NIH worked closely with CDC for the 2010 observance and worked together to create a Morbidity and Mortality Weekly Report (MMWR) article, develop information for their Vision Initiative website and provided online banners and buttons linking to the HVM site and to the NEI for additional information. |
| Hematopoietic Stem Cell Transplantation Interagency Working Group | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NCI, CC, NHLBI, NIAID, NIDDK | This working group reviews matters associated with hematopoietic stem cell transplantation. |
| Hemoglobinopathy Uniform Medical Language Ontology Project | Resource Development | AHRQ, CDC, FDA, HRSA, OS | NHLBI, NIAMS, NICHD, NLM | The purpose of the project is to create a uniform medical language ontology for hemoglobinopathies. The ontology would be a resource for federal programs and extramural communities (e.g., researchers) to use when developing data systems that incorporate data elements related to hemoglobinopathies. |
| Hepatitis B Research Network | Research Initiative | CDC | NIDDK | The Hepatitis B Research Network (HBRN) was established in 2008 to advance understanding of disease processes and natural history of chronic hepatitis B, as well as to develop effective approaches to treatment with currently available therapies. The Network brings together clinical centers from throughout the U.S. and Canada. This multi-center Network is enrolling patients in multiple clinical trials in both adults and children with hepatitis B. |
| HHS Action Plan for the Prevention, Care and Treatment of Viral Hepatitis Interagency Implementation Group (VHIG) | Research Initiative | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIDA, NIAID, NIDDK | HHS agencies review the Institute of Medicine (IOM) recommendations and develop a comprehensive strategic viral hepatitis action plan that would: address IOM recommendations for viral hepatitis prevention, care, and treatment; set forth actions to improve viral hepatitis prevention and ensure that infected persons are identified and provided care and treatment; and improve coordination of all activities related to viral hepatitis across HHS and promote collaborations with other government agencies and nongovernmental organizations. |
| HHS Advisory Committee on Blood & Tissue Safety & Availability (ACBTSA) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, OS | NHLBI | This federal advisory committee advises the Secretary of the Department of Health and Human Services and the Assistant Secretary for Health on a number of issues related to blood (and tissue) safety including, public health parameters related to the safety and availability of blood and blood products; broad public health, ethical, and legal issues related to transfusion and transplantation safety; and the effect of various economic factors on blood (and tissue) safety and availability (and infectious disease concerns for organ transplantation). The ACBTSA is a Federal Advisory Committee (i.e., a FACA) seated with industry representatives, physicians/scientists, consumer advocates, and federal ex-officio members from the HHS Agencies, the Department of Defense, and the Department of Veteran''s Affairs. |
| HHS Advisory Council for the Elimination of Tuberculosis | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, IHS, OS, SAMHSA | NIAID | The Council advises and makes recommendations to the DHHS Secretary, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis. |
| HHS Behavioral Health Coordinating Committee (BHCC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIMH, NIAAA, NIDA, OD/DPCPSI/OBSSR, OD/OCPL | The HHS Behavioral Health Coordinating Committee is a coordinating body within HHS that identifies and facilitates collaborative, action-oriented approaches to addressing the HHS behavioral health agenda. Co-chaired by the Assistant Secretary for Health, Howard Koh, and the Administrator of the Substance Abuse and Mental Health Services Administration, Pam Hyde, the Committee has five subcommittees: Communications; Early Intervention/Institute of Medicine Implementation; Prescription Drug Abuse; Primary Care/Behavioral health Integration; and Underage Drinking and Alcohol Policy. The subcommittees develop projects with clear goals, provide guidance to achieve steady progress and measurable outcomes, and develop key policy messages. The projects and activities build upon existing activities in the proposed areas and are consistent with other important HHS and Federal strategies and initiatives, such as Healthy People, the U.S. Preventive Task Force, and the National Drug Control Strategy. |
| HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Communications | Committee, Work group, Advisory group, or Task Force | ACL, OS | NIDA, NIMH | Committee of communication professionals to collaborate on inter-departmental behavioral health initiatives and promotional efforts. |
| HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Prescription Drug Abuse | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIDA | NIDA Serves as Co-Chair with FDA on this inter-agency subcommittee addressing prescription drug abuse. |
| HHS Biannual Dual Use Research of Concern (DURC) Inventory | Resource Development | CDC, FDA, OS | OD/OSP, CC, FIC, NCATS, NCCAM, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI | Development of the HHS biannual Dual Use Research of Concern (DURC) inventory reports, as required by the USG Policy for Oversight of Dual Use Research of Concern. |
| HHS Biomedical Advanced Research and Development Authority (BARDA) Radiological/Nuclear Integrated Program Team | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | This Interagency Working Group, established under the Biomedical Advanced Research and Development Authority (BARDA), determines overall radiation countermeasures strategy and priorities. The National Institute of Allergy and Infectious Diseases (NIAID) provides subject matter expertise, advice and guidance on medical countermeasure development, requirements, and preparedness/response. |
| HHS Biovigilance Committee | Committee, Work group, Advisory group, or Task Force | CDC | CC, NHLBI | This committee develops systems for reporting adverse events resulting from blood transfusion or donation. |
| HHS Blood, Organ, and Tissue Senior Executive Council (BOTSEC) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | NHLBI, CC | The mission of the HHS Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is to serve as the Department''s internal executive leadership coordination mechanism across all the staff and operating divisions involved in blood, organ, and tissue safety and blood product availability. The BOTSEC is chaired by the Assistant Secretary for Health and voting members are the senior-most heads of the relevant Staff divisions and Operating divisions of HHS (e.g., the Director of CDC and NIH, Administrator of CMS, and Commissioner of FDA). The BOTSEC is an internal council chartered to consider significant issues and make decisions that require cross-Agency input, including resources. In important aspect of the BOTSEC is the formation of HHS-wide (i.e., multi-Agency) working groups to explore significant public health items such as re-examining the lifetime blood donor deferral policy for MSM, and the creation of hemovigilance systems to collect and analyze data on adverse events that occur during the blood donation and utilization processes. The internal committee is also responsible for looking at providing timely recommendations on emerging issues that are taking place. It also provides decisional elements on proposed policies, public health threats, and issues related to blood, organ, and tissue safety and availability. The staff of the Public Health Service (PHS) operating divisions involved in blood, organ and tissues safety (BOTS) meet monthly by a teleconference call. |
| HHS Climate Adaptation Strategies | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | NIEHS has been partnering with the Assistant Secretary for Administration (ASA) and more recently the Assistant Secretary for Preparedness and Response (ASPR) and other operating and staff divisions of HHS to respond to White House directives on climate change adaptation at the agency level. This includes production of the HHS Climate Adaptation Plan and the coordination and production of deliverables under the President''s Climate Action Plan. |
| HHS Diagnostics Integrated Program Team (DxIPT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The DxIPT was established by the USG Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Executive Committee. The DxIPT will advise leadership on investments in human health diagnostics, medical countermeasures to improve the response to chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. Members include Federal employees or contractors to the Federal Government with diverse expertise in diagnostics. In 2012, DxIPT was charged with two tasks: 1) to reevaluate the feasibility of anthrax diagnostics for asymptomatic infections and 2) to develop Quantitative Technological Readiness Levels (Q-TRLs) for diagnostics to represent milestones and activities for the product development lifecycle from discovery through post-approval. |
| HHS Dietary Guidance Review Committee | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS | NIDDK | This committee reviews draft nutrition materials developed by all federal agencies and fulfills the legislative mandate (1990 NNMRRA) to ensure that Federal dietary guidance is consistent with the Dietary Guidelines for Americans and is scientifically accurate. |
| HHS Disability and Health Workgroup for Healthy People 2020 | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The purpose of this workgroup is to discuss the measurement of health and the targets for persons with disabilities. |
| HHS Environmental Justice Team | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS, NIMHD, NLM | Collaboration of HHS Operational Divisions under the leadership of OASH. The group works together to help advance HHS progress toward the HHS Environmental Justice (EJ) Strategy. It shares updates about EJ issues and concerns. The group also plans EJ-focused meetings and sessions for national conferences. |
| HHS Global Health Collaboration | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, SAMHSA | OD/DPCPSI/OAR | Federal working group established to communicate and share information related to global health activities within HHS. |
| HHS H5N1 Gain-of-Function Review Group (HHG Review Group) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | The Framework for Guiding HHS Funding Decisions about Research Proposals with the Potential for Generating Highly Pathogenic Avian Influenza (HPAI) H5N1 Viruses that are Transmissible among Mammals by Respiratory Droplets requires that certain research proposals undergo additional review at both the funding agency and Departmental (HHS) levels prior to funding. The HHS Department-level review is performed by the HHG Review Group, which brings to bear multidisciplinary interagency expertise in science, countermeasure development and availability, national security, law, public health preparedness and response, biodefense, select agent regulations, and science and public health policy. The purpose of the HHS Department-level review includes review of the funding agency''s risk assessment, consideration of whether additional factors may alter assessment of whether the research can be funded, determination of which measures are needed to mitigate risks, consideration of the overall HHS influenza research portfolio, and determination of whether the proposal is acceptable for HHS funding. |
| HHS Influenza Diagnostics Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | This Working Group shares information on influenza diagnostics initiatives and programs funded across different Federal agencies. |
| HHS Initiative on Multiple Chronic Conditions | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | OD/OSP, NIA, OD/DPCPSI/OBSSR | Recognizing the importance of Multiple Chronic Conditions (MCC) to patients, caregivers, and the health care system, the Assistant Secretary for Health convened an HHS-wide work group on MCC to identify options for improving the health of this population. The work group, in conjunction with other stakeholders, developed Multiple Chronic Conditions: A Strategic Framework. The Framework serves as a national-level roadmap for assisting HHS programs and public and private stakeholders to improve the health of individuals with MCC. |
| HHS Intersection of HIV/AIDS, Violence Against Women and Girls (VAWG), & Gender-Related Health Disparities Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, OS, SAMHSA | NIMH, NIAAA, NICHD, NIDA | This inter-agency workgroup focuses on working with the White House on a report on the Intersection of HIV/AIDS, Violence Against Women and Girls (VAWG), and Gender-Related Health Disparities, providing updates to the report and advancing research in this area. |
| HHS Lyme and Tick Borne Diseases Work Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | This work group involves members from agencies including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health (NIH) with the purpose of continued coordination and communication of activities, policy updates, events, agency highlights and other shared interests relating to Lyme Disease and other tick-borne diseases. |
| HHS National HIV/AIDS Strategy Implementation Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG | OD/DPCPSI/OAR | Trans DHHS Committee charged with addressing issues of and/or related to AIDS. |
| HHS National Promotores de Salud Initiative | Public Education Campaign | AHRQ, CDC, CMS, HRSA, SAMHSA | NHLBI | Community health workers (CHWs) and promotores de salud are frontline public health workers who serve as a link between health/social services and communities to facilitate access to services and improve the quality and cultural competence of service delivery. The purpose of the collaborative activity was to establish the National Promotores de Salud Initiative in partnership with HHS agencies to: establish a steering committee, develop a national recognition for promotores, and develop a HHS Portal for promotores and a national database system to connect with the promotores networks. |
| HHS Nutrition Policy Board | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS, SAMHSA | NIDDK | This Board coordinates the Department''s nutrition policy development and program implementation and is the principle point of contact with USDA for nutrition policy. |
| HHS Tissue and Organ Donor Epidemiology Study (TODES) Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NHLBI | The Working Group supports the design and conduct of TODES. |
| HHS Violence Against Women Steering Committee | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/ORWH, NIA, NIAAA, NICHD, NIDA, NIMH, NLM, OD/DPCPSI | The HHS Violence Against Women Act (VAWA) steering committee is chaired by the Office on Women''s Health (OWH). The VAWA committee has the responsibility for coordinating the Department of Health and Human Services (HHS) response to issues related to violence against women and their children, and also coordinates HHS violence related activities with those of other Federal agencies. This committee collaborates with the Department of Justice to implement the VAW Act. |
| HHS Viral Hepatitis Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIDDK, CC, NCCAM, NCI, NHLBI, NIAAA, NIAID, NICHD, NIDA, NIMHD, OD/DPCPSI/OAR | The HHS Viral Hepatitis Interagency Working Group was created by the Office of the Assistant Secretary for Health to address a recent report sponsored by the Institute of Medicine entitled Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The group meets to discuss collaborations and activities directed at achieving the goals for viral hepatitis research and control highlighted in the IOM report. |
| HHS Working Group on the Epilepsies | Committee, Work group, Advisory group, or Task Force | ACL, CDC, CMS, FDA, HRSA, OS | NIA, NICHD, NIMH, NINDS | The purpose of this group, which is led by the Office of the Assistant Secretary for Health, Department of Health and Human Services (HHS), is to increase communication among agencies sponsoring epidemiology-related activities and explore opportunities for increased coordination. The National Institute of Neurological Disorders and Stroke (NINDS) is the lead Institute representing the National Institutes of Health on the Working Group. |
| HHS-Trauma, Emergency Care and Emergency Medical Services working group | Committee, Work group, Advisory group, or Task Force | OS | NICHD | This workgroup documents HHS wide emergency related activities (including research) for the Assistant Secretary''s informational purposes |
| HIV/AIDS Cancer Match Study | Research Initiative | CDC | NCI | Investigators have used data from the NCI HIV/AIDS Cancer Match Study, in conjunction with data from the CDC surveillance program on the number of HIV-infected people in the U.S., to estimate the contribution of the HIV epidemic to the occurrence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer. |
| HIV/AIDS Prevention Research Synthesis (PRS) Project | Resource Development | CDC, HRSA | NIMH, NIDA | The HIV/AIDS Prevention Research Synthesis (PRS) is a collaboration between NIH, CDC, and HRSA involving the development of criteria for identifying evidence-based behavioral interventions for HIV medication adherence. These criteria were finalized in 2010 after a series of consultations with methodologists, HIV prevention researchers, and key federal partners. The revised criteria focus on quality of study design, quality of study implementation and analysis, and strength of evidence of efficacy. |
| Hospice to Palliative Care: Maximizing Patient Preferences and Cost Savings | Research Initiative | AHRQ | CC | The goal of the study is to provide rational, patient-defined, evidence-based recommendations to inform the redesign of the Medicare hospice benefit, transitioning policy from the current hospice benefit to a more patient-centered palliative care model. |
| HPV Working Group for the Advisory Committee on Immunization Practices (ACIP) | Committee, Work group, Advisory group, or Task Force | CDC | NCI | ACIP Work Groups (WGs) serve in a key scientific role in support of vaccine policy development by the ACIP. ACIP WGs conduct extensive background reviews of relevant research data to develop options for recommendations for use of vaccines in the civilian population of the United States. WGs are convened solely to gather scientific information related to vaccines and the diseases they prevent, to analyze relevant issues and data, and to draft policies or options for review, deliberation and vote by the ACIP. The duties of this position include participation in teleconferences and meetings, as well as preparation time for these meetings. |
| HRSA-Supplemental funding-NEXT STUDY | Research Initiative | HRSA | NICHD | In this Interagency Agreement (IAA), HRSA supports NICHD in performance of the NEXT Generation Health study. This IAA provides needed supplemental funding and HRSA staff experience to conduct this longitudinal study of a nationally representative cohort of 10th grade students in the US. NEXT is a 7-year longitudinal assessment of a representative sample of US adolescent and young adults, starting when they are in 10th grade. |
| Human Nutrition Research Information Management (HNRIM) System | Resource Development | CDC, FDA, HRSA | NIDDK | HNRIM is a searchable database of nutrition research and research training activities supported by the Federal government and maintained by the NIH Division of Nutrition Research Coordination (DNRC). |
| IAA with CDC for HPTN 052: A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples | Research Initiative | CDC | NIAID | These clinical studies are based on data collected in Africa and Thailand. There is a correlation between HIV viral load (blood levels) and HIV transmission. Specifically, the higher the viral load in the blood, the more likely the chance for transmission. Antiretroviral therapy (ART) reduces the viral load in the blood, as well as in genital secretions (for both men and women), and the drugs can be detected in semen and vaginal and cervical secretions. This information strongly suggests that ART may reduce the risk that HIV-infected people will transmit HIV. HPTN 052 compares the HIV-infection rates of two groups of HIV-serodiscordant couples. |
| ICARE: Interagency Collaborative to Advance Research in Epilepsy | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NINDS, FIC, NCATS, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NIBIB, NICHD, NIDA, NIGMS, NIMH, NINR | The Interagency Collaborative to Advance Research in Epilepsy (ICARE) is an interagency epilepsy working group that includes broad representation across the NIH ICs involved in epilepsy-related research, as well as across HHS and other Federal agencies and multiple epilepsy research and patient advocacy groups with a primary focus on biomedical research. The purpose of this group, which is led by the National Institute of Neurological Disorders and Stroke, is to increase communication among institutes and agencies sponsoring epilepsy-related research and explore opportunities for increased coordination. The group’s annual meetings provide a forum for sharing information about ongoing and planned epilepsy research activities, highlighting advances, discussing needs and opportunities, and promoting increased collaboration toward common research goals. |
| Image-guided Interventional Therapeutics | Research Initiative | FDA | CC, NCI | This collaboration will lead to safer and more effective treatment planning and performance of image-guided interventions and therapeutic drug delivery. The results of all of these studies of image guided interventions and related technologies and the models used to study them will have a direct impact on the effectiveness and consistency of the FDA Center for Devices and Radiological Health''s preclinical review of device applications while meeting the primary research goal of optimizing image guided interventions and pre-clinical modeling of those interventions. Regulatory science and translational therapeutics have overlapping goals when it comes to drugs and devices combination therapies. |
| Implementation Barriers to Screening, Brief Intervention and Referral to Treatment (SBIRT) in Federally Qualified Health Centers (FQHCs) | Research Initiative | HRSA | NIDA | This project will examine the use of SBIRT for substance use disorders in Federally Qualified Health Centers (FQHCs) to identify barriers to implementation and effective strategies for overcoming these challenges. The purpose of the project is to inform policy makers and providers regarding best practices and implementation strategies to overcome identified barriers. There has yet to be a systematic evaluation of SBIRT implementation challenges in FQHCs. With joint participation from the National Institute on Drug Abuse (NIDA) and the Health Resources and Services Administration (HRSA), this project will investigate SBIRT implementation at FQHCs to learn about best practices and implementation strategies that have been critical to supporting implementation of SBIRT, as well as the challenges that present barriers to implementation. Findings from this project may help inform efforts to increase SBIRT uptake among FQHCs and other primary care settings. |
| Improving Community Health through Land Reuse | Committee, Work group, Advisory group, or Task Force | ATSDR | NIEHS | Workgroup to discuss and provide input on Brownfields land reuse activities. NIEHS participates in this workgroup and were involved in the planning and writing of an online book being produced by the Agency for Toxic Substances and Disease Registry. |
| Improving Technical Standards and Molecular Tools for Probiotics Research and Development | Research Initiative | FDA | NCCAM | In 2008, the USDA Agricultural Service initiated a Memorandum of Understanding (MOU) with NCCAM to exchange expertise in technology development and partner research initiatives to advance the field of probiotic biology and role in human health. The MOU consists of a five year plan defining common mission goals; expected benefits from the exchange of research expertise and resources; and demonstration projects based on NIH/NCCAM funded U01 cooperative agreements. The long-term goal of the MOU is to develop trans-agency networked initiatives. In 2012, the unique resources of the USDA Agricultural Research Service and the Human Microbiome Project investigators were successfully implemented as a parallel comparative biotechnologies validation and standardization prototype with targeted molecular approaches. |
| IMS Health Contract | Research Initiative | CDC | NIDA | NIDA and the HHS Assistant Secretary for Planning and Evaluation (ASPE) are working collaboratively to analyze prescribing trends of opioid analgesics and stimulants under the terms of a Third Party Agreement (TPA) between IMS Health, NIDA, and ASPE. |
| Industry Wide Exposure Assessment Study of Workers to Carbon Nanotubes and Nanofibers | Research Initiative | CDC | NIEHS | This study will measure workplace exposures to Carbon nanotubes and Carbon nanofibers among a representative sample of US manufacturers and downstream users. |
| Influenza (Flu) Risk Management Meeting (FRMM) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Influenza (Flu) Risk Management Meeting (FRMM) meetings provide members with a venue to discuss issues relating to the U.S. Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v. |
| Influenza Vaccine Manufacturing Improvement Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Influenza Vaccine Manufacturing Improvement Group aims to optimize donor strains, improve sterility assays, and develop alternative potency assays. |
| Inter-Agency Committee on Drug Control (ICDC) | Committee, Work group, Advisory group, or Task Force | FDA, OS, SAMHSA | NIDA | The Inter-Agency Committee on Drug Control (ICDC) serves to facilitate communication between government agencies, including NIDA, FDA, DEA, and SAMHSA regarding drug control policies and initiatives. |
| Inter-Agency Working Group on Technology Transfer | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/OIR/OTT, OD/OER | This working group recommends opportunities for improving technology transfer (TT) from Federal laboratories, including: (i) current technology transfer programs and standards for assessing the effectiveness of these programs; (ii) new or creative approaches to technology transfer that might serve as model programs for Federal laboratories; (iii) criteria to assess the effectiveness and impact on the Nation’s economy of planned or future technology transfer efforts; (iv) an assessment of cooperative research and development venture programs; and (v) policy and guidance statements to support all Federal Agencies'' TT programs. |
| Inter-Society Coordinating Committee (ISCC) for Practitioner Education in Genomics | Committee, Work group, Advisory group, or Task Force | HRSA | NHGRI, NCI, NEI, NHLBI, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIGMS, NIMH, NINDS, NLM | The purpose of this group is to facilitate interactions among professional societies that will enhance efforts to increase the understanding and expertise of practitioners in applying genomic results to clinical care. Current focus is on physicians with the goal to expand to other allied healthcare team members. |
| Interactive Publications | Resource Development | CDC | NLM | NLM collaborated with the CDC National Center for Vital Health Statistics to convert the CDC''''s Health US in Brief to interactive form, which can be viewed using NLM''''s Panorama software. Interactive Publications are scientific multimedia documents that give readers more information from an article than is available in the published form (electronic or print) by enabling interaction with the included media (tables, graphs, images, videos, biomedical image studies, etc.) NLM conducts research into models for highly interactive multimedia documents that could transform the next generation of publishing in biomedicine. We focus on the standards, formats, authoring and reading tools necessary for the creation and use of such interactive publications that, in addition to text, contain media objects relevant to biomedical research and clinical practice: video, audio, bitmapped images, interactive tables and graphs, and clinical digital imaging and communications in medicine (DICOM) images such as x-rays, CT, MRI, and ultrasound. |
| Interactive Training Tool to Teach Health Care Providers About Reducing Prescription Opioid Abuse | Research Initiative | AHRQ, CDC, FDA, OS, SAMHSA | NIDA, NINDS | The purpose was to create an online training tool to teach health care providers about reducing prescription opioid abuse. |
| Interagency Agreement for Communications on Prevention of Underage Tobacco Use | Public Education Campaign | FDA | NCI | The FDA Center for Tobacco Products (CTP) and the NCI Office of Communications and Education are collaborating on an Interagency Agreement in which CTP will provide funds to NCI to provide planning, formative research, target messaging, creative content, outreach strategies, and communications support for a campaign to prevent underage tobacco use as it relates to FDA’s authorities under the Tobacco Control Act. Primary focus areas include multi-ethnic journalist training and outreach; development of a partnership strategy, digital strategy, and social marketing tools; digital gaming best practices; and formation of a CTP communications workgroup comprised of subject matter experts. |
| Interagency Artificial Pancreas Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, NIBIB, NICHD | The Interagency Artificial Pancreas Working Group is a group of multi-disciplined scientists and clinicians from the FDA and NIH to support the Artificial Pancreas Initiative. The goals of this initiative are to provide infrastructure for narrowing the gap between basic biomedical knowledge and clinical application of novel technologies, and to cross-fertilize and partner with stakeholders in order to identify and overcome the clinical and scientific challenges to the development of an artificial pancreas. Through collaborative efforts, such as workshops, the group strives to develop innovative strategies to achieve their goals. |
| Interagency Autism Coordinating Committee (IACC) | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, FDA, HRSA | NIMH, NICHD, NIDCD, NIEHS, NINDS | In accordance with the Combating Autism Act and the Combating Autism Reauthorization Act, the Interagency Autism Coordinating Committee (IACC), a Federal advisory committee, is charged with coordinating all efforts with the Department of Health and Human Services concerning autism spectrum disorder (ASD). The IACC mission is to: (1) provide advice to the Secretary of Health and Human Services regarding Federal activities related to ASD; (2) facilitate the exchange of information on and coordination of ASD activities among the member agencies and organizations; and (3) increase public understanding of the member agencies'''' activities, programs, policies, and research by providing a public forum for discussions related to ASD research and services. |
| Interagency Chemical Hazards Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NINDS | Working group on chemical hazards led by the Office of Science and Technology Policy (OSTP). |
| Interagency Chemical Risk Assessment Working Group | Committee, Work group, Advisory group, or Task Force | OS | NINDS, NIAID | Department of Homeland Security led effort to determine chemical hazards and develop Chemical Risk Threat Assessment list of priority chemicals. |
| Interagency Committee on Emergency Medical Services for Children Research (ICER) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS, SAMHSA | NICHD, NIAID, NIAMS, NIDCR, NIGMS, NIMH, NINR | ICER is a federal collaborative effort begun in the mid-1990’s to improve the quality and quantity of Emergency Medical Services for Children (EMSC) research, to foster collaboration between federal agencies in highlighting EMSC research topics during development of research agendas, and to reduce barriers to the production of high quality EMSC research. |
| Interagency Committee on Human Growth Hormone | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD, NIDDK, NINDS | The committee was instituted to follow up recipients of human growth hormone derived from pituitary glands that was distributed by NIH under and IND. |
| Interagency Committee on Smoking and Health | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD, NCI, NHLBI, NIDA | The Interagency Committee on Smoking and Health (ICSH) coordinates Department of Health and Human Services research, educational programs, and other smoking and health effects with similar activities of other federal, state, local, and private agencies. |
| Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, SAMHSA | NIAAA, NICHD | The ICCFASD was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that NIAAA chair an effort to coordinate Federal activities on fetal alcohol syndrome (FAS) and other disorders associated with prenatal alcohol exposure. The ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FAS and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and frequently arranges special conferences; the most recent was Oct. 31-Nov. 2, 2011 on Recognizing Alcohol-related neurodevelopmental disorder (ARND) in Primary Health Care of Children. |
| Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt-Jakob Disease | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDDK, NICHD, NINDS | Coordinates federal efforts to understand how pituitary human growth hormone may have led to the development of Creutzfeldt-Jakob Disease in participants of the National Hormone and Pituitary Program. |
| Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, IHS, OS, OSG, SAMHSA | NIDA, NIAAA | The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency. |
| Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) | Research Initiative | ATSDR, CDC, FDA | NIEHS, NCI, NEI, NIAID, NLM | The Interagency Coordinating Committee on the Validation of Alternative Methods is an interagency committee of 15 Federal agencies that carries out specific duties prescribed by the ICCVAM Authorization Act, P.L. 106-545. The ICCVAM is administered by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), a component of the NIEHS. NICEATM in collaboration with ICCVAM and its international collaborators in Japan, the EU, and Canada conducts research studies to evaluate the scientific validity of proposed new safety testing methods. NICEATM and ICCVAM also conduct international scientific peer review evaluations of proposed safety methods, and forward recommendations on scientific valid methods to Federal agencies, which must adopt the proposed methods or provide a basis for not adopting it. NICEATM and ICCVAM also organize scientific workshops to evaluate the current state of the science on a wide range of toxicological and other safety endpoints. |
| Interagency Group on Alzheimer''s Disease and Related Dementias for implementation of the National Alzheimer''s Project Act | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA | NIA | This interagency group was established by HHS in response to the Congressional directive to address Alzheimer''s disease. Under the National Alzheimer''s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran''s Administration, National Science Foundation, and Department of Defense are also involved in this effort. |
| Interagency Midazolam Product Coordination Team | Committee, Work group, Advisory group, or Task Force | FDA, OS | NINDS, NIAID | HHS-led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure. |
| Interagency Modeling and Analysis Group (IMAG) | Committee, Work group, Advisory group, or Task Force | FDA | NIBIB, CSR, FIC, NCATS, NCI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI/OBSSR | The Interagency Modeling and Analysis Group (IMAG) is comprised of program directors from ten government agencies in the U.S. and Canada, including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the United States Department of Agriculture (USDA), the Canadian federal research network for Mathematics of Information Technology and Complex Systems (MITACS), the National Aeronautics and Space Administration (NASA), the United States Department of Veterans Administration (USDVA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological and behavioral systems. IMAG has promoted and supported a wide variety of modeling over the past 10 years, notably the multi-scale modeling (MSM) initiative, which was originally a multi-agency funding opportunity announcement and continued on by different IMAG agencies through separate funding opportunity announcements. The MSM Consortium Meeting scheduled for 2013 was cancelled due to the government shutdown. |
| Interagency Pain Research Coordinating Committee (IPRCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, IHS, OS, SAMHSA | NINDS, NCCAM, NIDA, NIDCR, NINR | The Interagency Pain Research Coordination Committee (IPRCC) was mandated by the Affordable Care Act to coordinate pain research activities across the government. The initial charge to the committee includes: 1) develop a summary of major advances in pain care research supported by Federal Agencies relevant to the diagnosis, prevention, and treatment of pain; 2) identify critical gaps and duplications in basic and clinical pain research across Federal Agencies; 3) make recommendations on how best to disseminate information on pain care; and 4) make recommendations on how to expand public-private partnerships to expand collaborative cross-cutting research. Federal and non-federal committee representatives and NIH staff developed a survey to address item 1 above and performed a portfolio analysis to address item 2 above. The committee was charged in 2012 with an additional task: to create a comprehensive, population health level strategy for pain prevention, treatment, management, and research. Volunteers from the IPRCC and professional associations established a working group to address the 2012 charge to the committee. |
| Interagency Select Agent Review Group (ISARG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID, OD/OSP | The ISARG, composed of members from FDA and relevant federal agencies, including CDC, Department of Justice, and Department of State, recommends to NIAID whether facilities and procedures (e.g., registration, security risk assessments, safety plans, security plans, emergency response plans, training, transfers, record keeping, laboratory inspections, notification, etc.) at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed. |
| Interagency Subcommittee on Disability Statistics (ISDS) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIDCD | A Government-wide group, the Federal Interagency Subcommittee on Disability Statistics (ISDS), meets monthly to discuss the issues related to identifying people with disabilities and coordinate research in this area. |
| Interagency Subcommittee on Education (ISED) of the Interagency Committee on Disability Research (ICDR) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA | NICHD | The Interagency Committee on Disability Research (ICDR) is mandated to promote interagency coordination, collaboration, and communication. It must identify, assess, and seek to coordinate all Federal programs, activities, and projects, and plans for such programs, activities, and projects with respect to the conduct of research (including assistive technology research and research that incorporates the principles of universal design) related to rehabilitation of individuals with disabilities. The committee facilitates the effective exchange of information on disability and rehabilitation research activities among its member agencies. We coordinate activities that span the areas of assistive technology and universal design; medical rehabilitation; data and statistics; employment; health disparities, and education. The Interagency Subcommittee on Education (ISED), a subcommittee of ICDR, focuses on issues related to the education of persons with disabilities by collecting input from stakeholders to inform planning; identifying emerging research areas; assessing research gaps, synergies and duplications; and making recommendations to inform the federal research agenda. |
| Interagency Subcommittee on Medical Rehabilitation (ISMR) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC | NICHD, NCATS, NCI, NEI, NHLBI, NIAMS, NIBIB, NIDA, NIDCD, NIMH, NINDS | The Interagency Subcommittee on Medical Rehabilitation (ISMR) is composed of representatives from Federal agencies involved in disability and related research, including rehabilitation research. After receiving input from targeted individuals, the Committee shall identify, assess, and seek to coordinate all Federal programs, activities, and projects, and plans for such programs, activities, and projects with respect to the conduct of research (including assistive technology research and research that incorporates the principles of universal design) related to rehabilitation of individuals with disabilities. |
| Interagency Task Force on Antimicrobial Resistance (ITFAR) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | NIAID | ITFAR is a coordinating committee within the USG for research on antimicrobial resistance. |
| Interagency Working Group on Neuroscience | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIMH, NIA, NIDA, NINDS, NINR, OD/DPCPSI/OBSSR | "By Executive Order, the White House Office of Science and Technology Policy (OSTP) established the Interagency Working Group on Neuroscience by action of the National Science and Technology Council (NSTC) to foster collaboration across agencies and to coordinate Federal investments in neuroscience research. The Interagency Working Group on Neuroscience will coordinate activities in neuroscience research across the Federal government with a focus on the fundamental understanding of learning, brain development and plasticity, and brain health and recovery. The working group will enhance Federal efforts related to: improving our understanding of learning and cognition and applying that to improvements in education and other areas; improving our understanding of a variety of neurological conditions and injuries; and developing appropriate resources, tools, techniques, interventions, and therapies to assist in research, treatment, and recovery. The NSTC working group includes members from the Departments of Agriculture, Defense, Education, Energy, Health and Human Services, Homeland Security, Justice, and Veterans Affairs, as well as the Central Intelligence Agency, Environmental Protection Agency, National Aeronautics and Space Administration, the National Science Foundation, and the Office of the Director of National Intelligence." |
| Interagency Working Group on Youth Programs | Committee, Work group, Advisory group, or Task Force | ACF, CDC | NIAAA, NIDA | The Interagency Working Group on Youth Programs (IWGYP), which is composed of representatives from 12 Federal Departments and 5 Federal Agencies that support programs and services focusing on youth. The IWGYP promotes the goal of positive, healthy outcomes for youth. |
| INTERMACS - Interagency Registry for Mechanically Assisted Circulatory Support | Resource Development | CMS, FDA | NHLBI | The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) is a national registry for patients who are receiving mechanical circulatory support device therapy to treat advanced heart failure. This registry was devised as a joint effort of the National Heart, Lung, and Blood Institute, the Centers for Medicare and Medicaid Services, the U.S. Food and Drug Administration, clinicians, scientists, and industry representatives, in conjunction with the University of Alabama at Birmingham and the United Network for Organ Sharing. |
| International Cancer Control Partnership | Other | CDC | NCI | The National Cancer Institute and the Union for International Cancer Control convened global partners including CDC to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal. ICCP partners will assist countries by: creating a searchable database of current cancer control plans from around the globe; performing analysis of gaps and highlighting priority areas for inclusion in plans; training appropriate personnel to develop plans with targets and evaluation strategies; providing planners with relevant existing materials and tools; and offering technical assistance. ICCP partners will use their collective state, country and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets. |
| Intradepartmental Council for Native American Affairs (ICNAA) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIMHD | To support activities of the ICNAA, including tribal consultation sessions, and development of the annual tribal consultation report. |
| Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | The ISATTAC is a working group of subject matter experts from the Federal Government formed by the CDC Director to provide recommendations to the CDC''s Division of Select Agents and Toxins in three technical areas: 1) review requests for exclusion of attenuated strains, 2) review requests to conduct restricted experiments, and 3) review of select agents and toxins. The Committee conducts a biannual review, required by the Select Agent Rule of the Select Agents and Toxins list for HHS. Expert input from the ISATTAC and public comments are the primary inputs into this process. |
| Investigations into Health Effects Caused by Exposure to Indoor Air Reaction Products | Research Initiative | CDC | NIEHS | Ongoing studies are identifying and quantifying the volatile reaction products of gas-phase compounds present in the indoor environment, especially dicarbonyls, and investigating immunotoxic and hypersensitivity effects of these reaction products in both in vitro and in vivo models. |
| Investigations of Early Life Determinants of Pediatric and Adult Malignancies in a Population | Research Initiative | CDC | NCI | In collaboration with investigators from the U.S. CDC and the China CDC, NCI is assessing risk of pediatric leukemia and other pediatric cancers in a large population of offspring of mothers enrolled in a community intervention program of peri-conception folic acid supplementation in China. Pediatric cancer risks will be compared in offspring of mothers treated vs offspring of mothers not treated with folic acid supplements. |
| Iron and Malaria Research Project | Research Initiative | CDC, OS | NICHD, NIAID | In November 2007, the NICHD launched the Iron and Malaria Project to identify and examine factors that affect the safety and effectiveness of interventions to prevent iron deficiency in the context of malaria and other infections. The Project is funded, in part, by the Bill and Melinda Gates Foundation with additional support from the NIH Office of Dietary Supplements. The Project aims not only to generate new data to address this high-priority global health issue, but also to support efforts of the World Health Organization (WHO) to develop evidence-based guidelines with specific regard to the use of iron interventions. The Project and its goals grew out of new research that examined historical concerns about the safety of iron supplementation and, in particular, evidence of an increased risk for poor health outcomes among those (primarily young children) who were not iron deficient, but who received iron supplementation as part of “universal” supplementation programs in regions where malaria and other infections are common. The objective of this meeting was to assess progress of the funded grants and discuss the research project. This project has 3 sub-projects with direct collaborations with CDC: Inflammation and nutrition science for programs/policy and interpretation of research evidence (INSPIRE); Soluble transferrin receptor (sTfr) standard material development project to help provide standards to evaluate reliability and validity of assays to measure sTfr, a biomarker of iron status - Biomarkers reflecting inflammation and nutritional determinants of anemia (BRINDA) |
| Joint Committee and Joint Commission Meetings | Meeting/ Workshop | CDC, FDA, OS | NCI, FIC, NIAID | US State Department establishes collaborative agreements with foreign governments in fields of science and technology. These Joint Committee and Joint Commission Meetings (JCMs) facilitate discussion on selected topics creating cross-talk among the equivalent government agencies leading towards future collaborations. The OS through OGA organizes the DHHS OP/DIVs; FIC facilitates NIH ICs participation. For FY2011, JCMs were convened for Brazil, Colombia, and Mexico. |
| Joint Fellowship Program | Training Initiative | FDA | NCI | The objective of the NCI-FDA fellowships is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set that bridge the two disparate processes. Fellows will learn to build awareness of regulatory requirements into the early stages of the medical product development process and develop strategies to improve planning throughout research and regulatory review. |
| Kaposi Sarcoma and HHV8 in Sickle Cell and Other Ugandan Populations | Research Initiative | CDC | NCI | Epidemiological studies are being conducted to assess small-area variation of HHV8 and to learn about socio-demographical and environmental risk factors for HHV8 and Kaposi sarcoma in Uganda. |
| Kidney Interagency Coordinating Committee (KICC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NIDDK, NHLBI, NIA | The goal of the Kidney Interagency Coordinating Committee (KICC) is to encourage cooperation, communication, and collaboration among all federal agencies involved in kidney research and other activities. The KICC Consists of Federal representatives involved in chronic kidney disease (CKD) programs. The National Kidney Disease Education Program (NKDEP) convenes KICC annually to share information on various agencies'' programs and activities related to CKD and to discuss ways to improve the coordination of Federal responses to CKD. |
| Know Stroke in the Community | Public Education Campaign | CDC | NINDS | The NINDS developed the Know Stroke campaign to help educate the public about the symptoms of stroke and the importance of getting to the hospital quickly. The campaign includes outreach to consumers and health care professionals using mass media, grassroots outreach, partnerships, and community education. |
| Leprosy Research Support and Maintenance of an Armadillo Colony | Resource Development | HRSA | NIAID | This interagency agreement helps to establish and maintain a colony of wild caught armadillos that are infected with M. leprae. Infected organs and tissues are used to develop and make available standardized research reagents to investigators worldwide. This project also includes studies to optimize infection of armadillos for maximum yield, early identification of animals that were successfully infected, and studies to assess the timecourse and location of infection to create additional samples for disease studies. The project also maintains the mouse footpad model and other methods to amplify M. leprae bacteria from human specimens before they can be used to infect armadillos. |
| Let''s Move/HHS Healthy Weight Task Force | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIDDK, NHLBI | The HHS Healthy Weight Task Force aims to improve dietary and physical activity behaviors through targeted sector initiatives |
| Long-term Oxygen Treatment Trial | Research Initiative | CMS | NHLBI | The Long-term Oxygen Treatment Trial is a randomized controlled clinical trial to assess the efficacy of around-the-clock, supplemental oxygen therapy in subjects with chronic obstructive pulmonary disease and moderately severe hypoxemia. NHLBI will administer and oversee the study, and Medicare will cover the costs of items and medical services that are generally available through that program to beneficiaries enrolled in the trial. |
| Lupus Federal Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NIAMS, NCCAM, NEI, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIMHD, NINDS | The Lupus Federal Working Group, established on behalf of the HHS Secretary by the NIH, facilitates collaboration among NIH components, other Federal agencies, voluntary and professional organizations, and industry groups with an interest in lupus. These agencies exchange information on new developments and take advantage of new scientific opportunities in the field of lupus research. |
| Malaria Transmission | Research Initiative | FDA | NIAID | This collaboration is designed to develop new ways of detecting malaria parasites in mosquitoes to facilitate studies of transmission blocking. |
| Maternal and Child Health (MCH) Research Pediatric Practice Based Research Network (PBRN) Initiative | Research Initiative | HRSA | NICHD | This Intra-Departmental Delegation of Authority (IDDA) provides money to HRSA to fund the following activities: Electronic Health Record (EHR) Pediatric Practice Based Research Network (PBRN) Initiative; and Comparative Effectiveness Research (CER) and epidemiologic assessments of the use of selected psychotropic medications and the most commonly prescribed asthma medications in pediatric populations, as well as the possible association between these medications and side effects in this population. |
| Medical Education Partnership Initiative (MEPI) | Training Initiative | CDC, HRSA | FIC, NCATS, NCCAM, NCI, NHGRI, NHLBI, NIAAA, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OAR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC | The Medical Education Partnership Initiative (MEPI) supports foreign institutions in Sub-Saharan African countries that receive PEPFAR support and their partners to develop or expand and enhance models of medical education. These models are intended to support PEPFAR’s goal of increasing the number of new health care workers by 140,000, strengthen medical education systems in the countries in which they exist, and build clinical and research capacity in Africa as part of a retention strategy for faculty of medical schools and clinical professors. |
| Medical Expenditure Panel Survey (MEPS) | Health Survey | AHRQ | NCI | The Medical Expenditure Panel Survey (MEPS) is a set of large-scale surveys of families and individuals, their medical providers, and employers across the United States. MEPS is the most complete source of data on the cost and use of health care and health insurance coverage. |
| Medical Planning and Response to a Nuclear Detonation Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NCI | This group developed educational materials related to emergency planning for nuclear detonations for government use and publication. |
| Medicare benefit postcard developed by NEI and CMS | Public Education Campaign | CMS | NEI | NEI worked with CMS to develop and disseminate a Medicare benefit card in English and Spanish which describes eligibility for the Medicare benefit for glaucoma and diabetic eye disease. The postcards are distributed to Medicare beneficiaries, the general public, and to health professionals. |
| Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS | Other | FDA | NINDS | This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and FDA approval and licensure. |
| Mental Health Surveillance Study | Health Survey | SAMHSA | NIMH | Since 2008, the Substance Abuse and Mental Health Services Administration (SAMHSA) has produced national and state estimates of serious mental illness among adults using the National Survey on Drug Use and Health (NSDUH). The estimates are based on the Mental Health Surveillance Study (MHSS) which provides estimates of serious mental illness among adults aged 18 or older at both national and state levels. The MHSS builds upon established federal survey platforms in order to expand the NIMH research portfolio in population-based mental health studies. The purpose of the MHSS was to conduct additional calibration work on the survey data; to assess the feasibility of developing a longitudinal component for future surveys; and to produce reports related to mental health. In FY2013, NIMH participated in 23 data analysis activities related to the development of a population measure of Serious Mental Illness (SMI); mental illness correlates in adults and youth; disparities in mental health service use; suicidality in the general populations; and smoking among persons with mental illnesses. |
| Microphysiological Systems for Drug Efficacy and Toxicity Testing | Research Initiative | FDA | NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI, OD/DPCPSI/ORWH | The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration (FDA), is leading this initiative to improve the process for predicting whether drugs will be safe in humans. |
| Microsystems Team | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, NINDS | The NIH has identified a critical need for improved model systems to predict efficacy, safety, bioavailability, and toxicology outcomes for candidate therapeutics. This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund and participating NIH IC''''s, invites applications for projects that will develop accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity. By definition, these cellular and organ microsystems will have a multicellular architecture representing the characteristics and functions of the tissue of origin and will demonstrate a reproducible and viable operation under physiological conditions over a long culture period. It is anticipated that these bio-engineered human tissue models could lead to the development and commercialization of microsystems that will enable rapid and high fidelity evaluation of safety and efficacy for candidate therapeutics. |
| Minneapolis Somali Autism Spectrum Disorder Prevalence Project | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS, NICHD, NIMH | Participated in working groups that provided oversight and advice to study investigators regarding analysis and dissemination plans for the study. |
| Mobile Applications for Data Collection on Adverse Events of Medication or Device During Public Health Emergencies | Resource Development | FDA | NLM | NLM and the U.S. Food and Drug Administration (FDA) established a partnership to explore the development, assessment, and utilization of mobile applications to disseminate and exchange scientific information and data concerning reported adverse events from the use of a medication or medical device approved under the Emergency Use Authorization in a public health emergency or disaster. |
| Models of Infectious Disease Agent Study (MIDAS) (RFA) | Research Initiative | CDC | NIGMS, FIC | Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models will be useful to policymakers, public health workers and other researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid public officials in their decision-making processes. |
| mPOWER mHealth Group | Research Initiative | CDC, CMS, FDA, HRSA, IHS | OD/DPCPSI/OBSSR, CIT, FIC, NCCAM, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR, NLM | Mobilizing Research supports the development, promotion, and dissemination of a wireless health research recruitment and data platform. In addition to being a primary data collection mechanism, the platform would be a data repository for both basic and applied health science, making validation and standardization of mobile health tools accessible. |
| Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIBIB, NHLBI, NIAMS, NICHD, NIDCD, NIDCR | This Interagency Working Group, organized under the auspices of the Subcommittee on Biotechnology of the National Science and Technology Council (NTSC), enables Federal agencies involved in tissue engineering to stay informed of each other’s activities and coordinate efforts in a timely and efficient manner. In 2007, the Working Group published their Federal-wide strategic plan for advancing tissue science and engineering. The Working Group is formally recognized by NIH/OD as a collaborative trans-NIH working group and is actively engaged with other agencies to accelerate progress in the tissue engineering field. |
| Multi-Payer Claims Database | Resource Development | AHRQ, OS | NIA, OD/OSP | The goals of the Multi-Payer Claims Database (MPCD) Pilot is to evaluate the value of a multi-payer claims database for comparative effectiveness research. The database will combine public and private claims data, providing investigators with access to data on a broad patient population. |
| Multinational Influenza Seasonal Mortality Study (MISMS) Research | Research Initiative | OS | FIC, NHLBI, NIAID, NLM | The Multinational Influenza Seasonal Mortality Study (MISMS) was originally initiated to analyze national and global mortality patterns associated with influenza virus circulation. The focus of MISMS has since expanded to evaluate the interaction between the epidemiology, ecology, and evolutionary dynamics of influenza, including natural selection, reassortment, migration, and antigenic change. Multinational and bilateral collaborations developed by MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. Our research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 30 countries (representing ~3.2 billion people), resulting in over 100 publications. |
| Muscular Dystrophy Coordinating Committee (MDCC) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA | NINDS, NHLBI, NIAMS, NICHD | This Committee coordinates activities across NIH and with other Federal health programs and activities relevant to the various forms of muscular dystrophy. |
| Naloxone Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDA | The goal of this Workgroup is to discuss ways to implement the use of naloxone as emergency treatment for opioid overdose. |
| Nanomaterial Registry | Resource Development | FDA | NCI, NIBIB, NIEHS | The Nanomaterial Registry is an authoritative, fully curated resource available to the public that archives research data on nanomaterials and their biological and environmental implications. |
| Nanotechnology Characterization Laboratory | Research Initiative | FDA | NCI, NIEHS | The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the preclinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers and facilitates the development and translation of nanoscale particles and devices for clinical applications. |
| National Action Alliance for Suicide Prevention (NAASP) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, HRSA, IHS, OS, OSG, SAMHSA | NIMH, NIAAA, NIDA, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The National Action Alliance for Suicide Prevention (NAASP) is a public-private partnership for advancing the National Strategy for Suicide Prevention. The mission of the NAASP is to champion suicide prevention as a national priority; to catalyze efforts to implement high priority objectives of the NAASP; and to cultivate the resources needed to sustain progress. The NIMH Director is an ex officio member of the NAASP Executive Committee and Co-Chair of the NAASP Research Task Force. Additional NIMH staff serve on task forces pertaining to LGBT Youth, Military and Veterans, Youth in Justice Settings, and American Indian/Alaska Natives. |
| National Advisory Board for Medical Rehabilitation Research | Committee, Work group, Advisory group, or Task Force | CDC, CMS | NICHD, CSR, NCATS, NCI, NHLBI, NIA, NIAMS, NIBIB, NIDCR, NINDS, NINR | The Board meets twice a year to advise the directors of NIH, NICHD, and the National Center for Medical Rehabilitation Research (NCMRR) on matters and policies relating to the Center''s programs. The Board comprises 12 members representing health and scientific disciplines related to medical rehabilitation and 6 members representing persons with disabilities. |
| National Ambulatory Medical Care Survey (NAMCS) Asthma Supplement - Interagency agreement with CDC/NCHS | Health Survey | AHRQ, CDC | NIEHS, NHLBI, NIAID, NICHD | Developed a survey of a national sample of primary care health providers and specialists likely to see asthma patients to gauge implementation of the NHLBI Guidelines for the Diagnosis and Management of Asthma. |
| National Amyotrophic Lateral Sclerosis (ALS) Registry | Resource Development | ATSDR, CDC | NINDS | The National ALS Registry is a congressionally mandated registry for persons in the U.S. with ALS. It is the only population-based registry in the U.S. that collects information to help scientists learn more about who gets ALS and its causes. |
| National Asthma Control Initiative (NACI)/National Asthma Education and Prevention Program (NAEPP) | Public Education Campaign | CDC, FDA | NHLBI, NIAID, NIEHS | The National Asthma Control Initiative (NACI) is a national effort to facilitate implementation of the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. The NAEPP, which was initiated in 1989, seeks to enhance the quality of life for patients with asthma and decrease asthma-related morbidity and mortality by improving asthma awareness, diagnosis, and treatment. |
| National Asthma Education and Prevention Program Federal Liaison Group on Asthma (FLGA) | Committee, Work group, Advisory group, or Task Force | AHRQ, ATSDR, CDC, CMS, FDA, HRSA, OS | NHLBI, NIA, NIAID, NICHD, NIEHS, NIMHD, NINR | The Federal Liaison Group on Asthma is a subcommittee of the National Asthma Education and Prevention Program that is charged with addressing ways to strengthen and improve the coordination of asthma-related activities across agencies of the Federal Government. The group provides a forum for Federal Agencies with major interest in asthma to exchange ideas and explore collaborative activities. |
| National Blood Disorders Program | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | NHLBI, NIMHD | The National Heart, Lung, and Blood Institute established the National Blood Disorders Program in accordance with the Institute’s strategic plan of moving scientific discovery from causes to cures. The program’s purpose is to coordinate a national effort to improve the management of hematological disorders focused on the implementation of evidence-based clinical practice guidelines to prevent, detect, and treat, complications. |
| National Children''s Study Interagency Coordinating Committee | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NIEHS | Initiated in 2000-2001, the National Children''s Study (NCS) Interagency Coordinating Committee represents the lead agencies for the Study and oversees broad Study issues and ensures interagency collaboration. The representatives assure that at a high level, the mission and goals of the NCS are maintained over time and that they reflect the scientific priorities of the Study''s four lead agencies. The committee is made up of staff from the U.S. Department of Health and Human Services (including the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences, of the National Institutes of Health, and the Centers for Disease Control and Prevention), and the U.S. Environmental Protection Agency. |
| National Collaborative on Childhood Obesity Research (NCCOR) Committee | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NCI, NHLBI, NIDDK, OD/DPCPSI/OBSSR | The mission of the National Collaborative on Childhood Research is to improve the efficiency, effectiveness, and application of childhood obesity research, and to halt-and reverse-childhood obesity through enhanced coordination and collaboration. |
| National Collaborative on Childhood Obesity Research (NCCOR) Initiatives | Research Initiative | CDC | NIDDK, NCI, NHLBI, NICHD | The National Collaborative on Childhood Obesity Research (NCCOR) brings together four of the nation’s leading research funders – the Centers for Disease Control and Prevention, the National Institutes of Health, the Robert Wood Johnson Foundation, and the U. S. Department of Agriculture – to address the problem of childhood obesity in America. NCCOR focuses on efforts that have the potential to benefit children, teens, their families, and the communities in which they live. A special emphasis is put on the populations and communities in which obesity rates are highest and rising the fastest. NCCOR''s goals are to identify intervention needs, improve child obesity surveillance, improve research and evaluation methodologies, and provide national leadership to implement evidence-based practice and policy. NCCOR also works with many non-health partners to develop sustainable environmental design and food systems strategies to reach high risk populations and communities. |
| National Committee for Quality Assurance | Committee, Work group, Advisory group, or Task Force | AHRQ | NICHD | This committee advises on quality assurance measures related to HIV. |
| National Consortium for Child and Adolescent Mental Health Services | Research Initiative | SAMHSA | NICHD | The purpose of this research initiative is for research collaboration to address child and adolescent mental health issues and services. |
| National Diabetes Education Program (NDEP) | Public Education Campaign | CDC | NIDDK | "Established in 1997, the National Diabetes Education Program is a federally-funded program sponsored by the U.S. Department of Health and Human Services’ National Institutes of Health and the Centers for Disease Control and Prevention and includes over 200 partners at the federal, state and local levels, working together to improve the treatment and outcomes for people with diabetes, promote early diagnosis, and prevent or delay the onset of type 2 diabetes." |
| National Drug Facts Chat Day | Public Education Campaign | CMS | NIDA, NIAAA, NIMH | The National Institute on Drug Abuse (NIDA) and several partner U.S. Department of Health and Human Services agencies and National Institutes of Health Institutes "Chat" in real time with high school students across the country. The students ask questions (anonymously) on drugs and get research-based responses directly from NIDA and other government scientists. |
| National Food and Nutrient Analysis Program (NFNAP) | Research Initiative | CDC, FDA, IHS | NCI, NEI, NHLBI, NIA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ODP, OD/DPCPSI/ORWH | This U. S. Department of Agriculture (USDA)-based program provides basic information about the nutrient content of highly consumed foods and dietary supplements in the U.S. The five Specific Aims of the National Food and Nutrient Analysis Program (NFNAP) are to: 1) establish a monitoring program for Key Foods and critical nutrients. Key Foods are frequently consumed foods and ingredients, which contributed, collectively, more than 75% of the intake of any specific nutrient for the U.S. population; 2) conduct comprehensive analyses of selected Key Foods; 3) develop databases for high priority foods consumed by U.S. ethnic subpopulations; 4) develop databases for new bioactive components; and 5) develop a validated database for ingredients in dietary supplements. Approximately 1,100 food items have been sampled and analyzed in the last 7 years. The National Cancer Institute Division of Cancer Prevention coordinates a U.S. Department of Health and Human Services-USDA collaboration that focuses on the content of bioactive food components that are consumed as foods or dietary supplements. These components, such as Vitamin D, trans and omega-3 fatty acids, and sodium, will be characterized and measured for their content and contribution to total daily intake. New databases have also been added for flavonoid content of selected foods and sulfur-containing bioactive compounds. |
| National Forum for Heart Disease and Stroke Prevention | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI, NHGRI, NINDS | The Forum was founded to implement a public health action plan to prevent heart disease and stroke. |
| National Health and Aging Trends Study (NHATS) | Health Survey | CMS, OS | NIA | The National Health and Aging Trends Study will examine how the daily lives of older adults change as they age. This research will help scientists understand the social and economic consequences of late-life disability for individuals, families, and society. |
| National Health and Nutrition Examination Survey (NHANES) | Health Survey | CDC, FDA, OS | OD/DPCPSI/ODP, NCI, NHLBI, NIA, NIDDK, OD/DPCPSI | A program of studies designed to assess the health and nutritional status of adults and children in the United States. The survey is unique in that it combines interviews and physical examinations. |
| National Health and Nutrition Examination Survey (NHANES) Cardiovascular Component | Health Survey | CDC | NHLBI, NCI, NIA, NIAAA, NICHD, NIDCD, NIDCR, NIDDK | The purpose of this collaboration is to inform the National Institutes of Health (NIH) and the Nation on the status of key measures of cardiovascular, pulmonary, and sleep health, such as blood pressure, serum lipid levels, risk factors for disease, airway flow limitation, reports of efforts to control weight, and reports of sleep disturbances, and disease prevalence in the US civilian population. NIH identifies key cost-effective basic measures for these conditions and behaviors, relevant to its mission and amenable to being utilized in a mobile hospital setting. NIH staff work with National Center for Health Statistics (NCHS) staff to implement the most cost-effective of the measures, to monitor and help manage the survey in progress, and to evaluate and publish the resulting data. |
| National Health and Nutrition Examination Survey (NHANES) components | Research Initiative | CDC | NCI, NHLBI, NIA, NIDDK, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | For the National Health and Nutrition Examination Survey (NHANES) 2011-14, the National Cancer Institute proposed and coordinated funding from multiple National Institutes of Health Institutes and the Department of Defense for two components: a new technology physical activity monitor to be worn on the wrist and a measurement of muscle strength using a hand-grip dynamometer. The wrist-worn accelerometer will provide the first objective measurement of sleep duration in a nationally representative sample, in addition to measuring physical activity movement. The muscle-strength measure will provide an indicator of total body strength for children, adults, and older adults who are NHANES participants. |
| National Health and Nutrition Examination Survey (NHANES) Oral Health Component | Health Survey | CDC | NIDCR | The periodic oral health component of the National Health and Nutrition Examination Survey (NHANES); enamel fluorosis imaging study for inclusion in future NHANES |
| National Health Interview Survey (NHIS) | Health Survey | CDC | NCI, NCCAM, NHLBI, NIA, NIDDK, NIMH, NINDS | The National Health Interview Survey (NHIS), carried out by the CDC, is a national survey that annually monitors the Nation’s health through personal interviews of a representative sample of the civilian, non-institutionalized U.S. population. The National Cancer Institute periodically sponsors a Cancer Control Supplement (CCS) which is administered to a randomly selected sample of 39,000 adults. The National Institute of Diabetes and Digestive and Kidney Diseases provides support for the development of the diabetes interview components and funding for collection of data. Complementary and Alternative Medicine (CAM) related questions are posed to about 30,000 randomly selected NHIS participants every 5 years. The data from the survey provides many fascinating insights into the types of CAM people use, the reasons for which they turn to CAM, and changes that have occurred since the last time CAM questions were included in the survey. |
| National Health Interview Survey (NHIS): 2013 Heart Attack, Blood Pressure, and Cholesterol Questions | Health Survey | CDC | NHLBI | The purpose of the collaborative activity is to support the development by the National Health Interview Survey (NHIS) of measures that can be used to assess progress toward achieving Healthy People 2020 Heart Attack, Blood Pressure, and Cholesterol Objectives. The National Institutes of Health and the National Center for Health Statistics collaborate on this activity. |
| National Health Interview Survey (NHIS): 2013 Respiratory/Asthma Questions | Health Survey | CDC | NHLBI | The purpose of the collaborative activity is support development and implementation by the National Health Interview Survey (NHIS) of measures that could be used to assess progress towards achieving Healthy People 2020 respiratory/asthma objectives. The National Heart, Lung and Blood Institute and the National Center for Health Statistics collaborate on this activity. |
| National Health Interview Survey (NHIS): 2014 Hearing Supplement | Health Survey | CDC | NIDCD | The purpose of this agreement is for the National Institute on Deafness and Other Communication Disorders (NIDCD) to provide financial support to the National Center for Health Statistics (NCHS). The FY2012 funds provide partial support for the National Health Interview Survey (NHIS) and contribute to the development, testing, and 2014 implementation of the Hearing questions. The Hearing questions for the 2014 NHIS will be similar in scope to the 2007 NHIS Hearing supplement for the "sampled" adult and, also, will include some questions for report by the parent/caregiver on the hearing of their “sampled” child (age range: birth to 17 years old). This project is a collaborative effort between NCHS and NIDCD. |
| National Hispanic Science Network (NHSN) | Meeting/ Workshop | AHRQ, CDC, SAMHSA | NIDA, NIAAA, NIMH | The National Hispanic Science Network is dedicated to improving the health equity of Hispanics. It has broad representation from academic and government agencies, including several National Institutes of Health Institutes and Centers, the Centers for Disease Control and Prevention, the Substance Abuse and Health Services Administration, and the Agency for Healthcare Research and Quality. |
| National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations | Resource Development | AHRQ, CDC, CMS | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations is designed to encourage networking among individuals and organizations with an interest in the diseases and disorders of human communication. The directory is maintained in an online database accessible to the public from the NIDCD website. The NIDCD pays to maintain the directory, however several U.S. Department of Health and Human Services agencies are featured in it. |
| National Interagency Confederation for Biological Research | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIAID | The mission of the National Interagency Confederation for Biological Research is to develop unique knowledge, tools, and products by leveraging advanced technologies and innovative discoveries to secure and defend the health of the American people. |
| National Kidney Disease Education Program | Public Education Campaign | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NIDDK, NHLBI | The National Kidney Disease Education Program (NKDEP) is an initiative of the National Institutes of Health, designed to reduce the morbidity and mortality caused by kidney disease and its complications. NKDEP aims to improve early detection of chronic kidney disease (CKD), facilitate identification of patients at greatest risk for progression to kidney failure, promote evidence-based interventions to slow progression of CKD, and support the coordination of Federal responses to CKD. |
| National Longitudinal Mortality Study | Health Survey | CDC | NIA, NCI, NHLBI | A national, longitudinal, mortality study to study the effects of differentials in demographic and socio-economic characteristics on mortality. |
| National Partnership for Action to End Health Disparities (NPA): Federal Interagency Health Equity Team (FIHET) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIMH, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMHD, NINR, OD/DPCPSI/ODP | Federal leadership for the National Partnership for Action to End Health Disparities (NPA) is provided by the Federal Interagency Health Equity Team (FIHET). The FIHET was established to foster communications and activities of the NPA within federal agencies and their partners; and to increase the efficiencies and effectiveness of related policies and programs at the national, state, tribal, and local levels. NIMH staff serve on the FIHET, including co-chairing the Leadership Subcommittee and participating on the Data, Research, and Evaluation Subcommittee. NICHD team members serve on various committees to provide input/recommendations on maternal and child health equity. |
| National Program to Reduce Cardiovascular Risk (NPRCR) Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NHLBI | The National Program to Reduce Cardiovascular Risk (NPRCR) Coordinating Committee is the leadership body for the broader NPRCR. The Committee seeks to reduce risk of cardiovascular disease through a national effort to implement evidence-based clinical practice guidelines and interventions to control cardiovascular risk factors (including high blood pressure, high blood cholesterol, and overweight/obesity) in clinical practice settings. Coordinating Committee members engage their respective organizations in program activities. |
| National Program to Reduce Cardiovascular Risk (NPRCR) Federal Subcommittee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NHLBI, NCI, NIDDK, NIMHD, NINDS, OD/DPCPSI/ODP | The subcommittee provides a forum for Federal Agencies within the U.S. Department of Health and Human Services (including within the National Institutes of Health) to coordinate and collaborate on Federal efforts aimed at reducing cardiovascular risk in the nation. |
| National Research Action Plan (NRAP) | Research Initiative | CDC | NIDA, NIAAA, NIMH, NINDS | This Executive Order directed the Department of Defense, Veterans Affairs, Health and Human Services, and Department of Education to develop a National Research Action Plan on post-traumatic stress disorder, other mental health conditions and traumatic brain injury to improve the coordination of agency research into these conditions and reduce the number of affected men and women through better prevention, diagnosis and treatment. |
| National Robotics Initiative | Research Initiative | FDA | NIBIB, NEI, NIA, NICHD, NIDCD, NINDS, NINR | The Office of Science and Technology Policy (OSTP) created a "National Robotics Initiative" to promote research in a variety of robot-related topics. The National Institutes of Health (NIH) joined as a major civilian aspect of this coordinated interagency plan which incorporates the following funding agencies: NIH, National Science Foundation (NSF), National Aeronautics and Space Agency (NASA), U.S. Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA). |
| National Science Advisory Board for Biosecurity (NSABB) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Advises the U.S. government on oversight of dual use life sciences research. |
| National Security Staff Dual Use Research of Concern Interagency Policy Committee (NSS DURC IPC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP, NIAID | Develops policy options for U.S. government oversight of dual use research of concern (DURC). |
| National Security Staff Dual Use Research of Concern Sub-Interagency Policy Committee (NSS DURC Sub-IPC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP, NIAID | Develops policy options for U.S. government oversight of dual use research of concern (DURC). |
| National Survey of Family Growth | Health Survey | ACF, CDC | NICHD | The National Survey of Family Growth (NSFG) gathers information on family life, marriage and divorce, pregnancy, infertility, use of contraception, and men''s and women''s health. The survey results are used by the U.S. Department of Health and Human Services and others to plan health services and education programs, and to do statistical studies of families, fertility, and health. |
| National Toxicology Program (NTP) Executive Committee | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA | NIEHS, NCI | The National Toxicology Program (NTP) was established as a department-wide effort within the Public Health Service (PHS) on November 15, 1978. The program is comprised of the relevant PHS activities within the U.S. Food and Drug Administration, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention, and the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health. The NIEHS Director serves as NTP Director and reports to the Assistant Secretary for Health. The NTP Executive Committee reviews progress on NTP activities directed toward carrying out its mission. |
| Native American Research Center for Health (NARCH) Program | Research Initiative | AHRQ, HRSA, IHS, OS | NIGMS, CSR, NCATS, NCCAM, NCI, NHGRI, NHLBI, NIAAA, NIAID, NIAMS, NIDA, NIDCR, NIDDK, NIMH, NIMHD, OD/DPCPSI/OBSSR | Native American Research Center for Health is a grant program that provides funds to enhance research, research infrastructure and training among American Indian and Alaska native programs and academic partners. This National Institutes of Health-wide program supports partnerships between American Indian (AI), Alaska Native (AN), or Tribally-based organizations and institutions that conduct intensive academic-level biomedical, behavioral and health services research in an effort to build a research infrastructure of core components for capacity building and to reduce health disparities in AI/AN communities. This funding mechanism develops opportunities for conducting research, research training and faculty development to meet the needs of American Indian/Alaska Native (AI/AN) communities. As a developmental process, Tribes and Tribal organizations are able to build a research infrastructure, including a core component for capacity building and the possibility of reducing the many health disparities so prevalent in AI/AN communities. |
| Natural Experiments and Effectiveness Studies in the Prevention and Control of Diabetes | Research Initiative | CDC | NIDDK | This project will focus on population-targeted interventions that health systems, communities, and governments can undertake to reduce the incidence of diabetes and its complications. This project will also strengthen the capacity of CDC and NIDDK to conduct vital health services and health policy research related to diabetes prevention and care. |
| NCI Clinical Trials and Translational Research Advisory Committee (CTAC) | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NCI | The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process. |
| NCI National Cancer Informatics Program (NCIP) Nanotechnology Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NHLBI, NIBIB, NIEHS | The National Cancer Institute National Cancer Informatics Program (NCIP) Nanotechnology Working Group (NCIP Nano WG) was established in 2008 for researchers with a specific interest in informatics and computational approaches to nanotechnology, with a particular emphasis on nanomedicine. The goal of this Working Group is to demonstrate the scientific potential of federating nanotechnology databases through pilot projects aimed at integrated semantic search and retrieval of nanomedicine and nanotoxicology datasets that are applicable across nanoscience. The NCIP Nano WG comprises over 20 active participants from academia, government and industry with diverse interests. |
| NCI/FDA Federal Investigator Registry of Biomedical Information Research Data (FIREBIRD) | Resource Development | FDA | NCI | An agreement has been reached by the U.S. Food and Drug Administration and the National Cancer Institute to manage and share information about clinical investigators using the Federal Investigator Registry of Biomedical Information Research Data, or FIREBIRD, system. Drug makers are encouraged to also submit information about investigators electronically to the new registry. FIREBIRD is the first module of an expected suite of software programs that will comprise a system called the Clinical Research Information Exchange (CRIX). CRIX is intended to support the biomedical and biopharmaceutical research community by streamlining the document and data exchange process. The resulting reduction of paperwork is expected to increase the efficiency and lower the cost of conducting clinical trials. |
| NCI/FDA Memorandum of Understanding for Drug related information | Resource Development | FDA | NCI | The National Cancer Institute (NCI) Enterprise Vocabulary Services is working with the U.S. Food and Drug Administration (FDA) to develop and support controlled terminology in several areas. More than 10,000 FDA terms and codes are stored in the NCI Thesaurus. |
| NCI/FDA Memorandum of Understanding for Proteomics | Research Initiative | FDA | NCI | The purpose of this Memorandum of Understanding (MOU) is to create a framework to foster scientific and programmatic collaborations. The collaborations envisioned by this MOU involve proteomics science and technology applications such as instrument/technology validation, informatics, biological sample preparation, diagnostics, and discovery and validation of biomarkers for cancer development, therapeutics, and response. This MOU sets forth the basic principles under which the Agencies intend to work together to foster partnership in: research and education; the exchange of ideas, information, and data; the development and use of proteomics technologies that may be used by the National Cancer Institute and other sponsors in clinical applications. |
| Nested case-control study of lung cancer and diesel exhaust among non-metal miners | Research Initiative | CDC | NCI | A retrospective cohort mortality and nested case-control study of about 12,315 non-metal miners (278,041 person-years) to investigate risk of lung cancer in relation to quantitative measures of exposure to diesel exhaust. |
| Network for Improvement of Access to Treatment (NIATx) | Research Initiative | SAMHSA | NIDA, NIMHD | Research grant focused on helping drug abuse treatment organizations develop practice improvement procedures to get patients enrolled in treatment. |
| Neural Interfaces Conference | Meeting/ Workshop | FDA | NIBIB, CSR, NEI, NIA, NICHD, NIDCD, NINDS | The Neural Interfaces research community consists of investigators, supported by grants or contracts, who are working in areas that include functional neuromuscular/electrical stimulation, auditory prosthesis, cortical prosthesis, neuromodulation, microelectrode array technology, brain computer/machine interfaces and other related areas. Conferences were held in 2010 and 2012. Planning is underway for a conference in 2014. |
| Newborn Drug Development Planning Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, NHLBI, NLM | Primary responsibility for administering, contracting, and monitoring studies to develop Investigational new drug application data for potential label modification. |
| Newborn Screening Coding and Terminology Guide | Resource Development | CDC, HRSA, OS | NLM, NHGRI, NHLBI, NICHD | This ongoing collaboration develops, supplements and publicizes a free online resource with guidance to help promote efficient electronic exchange of standardized newborn screening data. Related efforts include studying the screening process for diseases including severe combined immunodeficiency (SCID), lysosomal storage disorders (LSDs), and critical congenital heart disease (CCHD), and developing standard codes for ordering and reporting the results of newborn screening for SCID, CCHD, and other conditions added to the Uniform Recommended Screening Panel by the Secretary''s Advisory Committee on Heritable Disorders in Newborns and Children. |
| Newborn Screening Committee | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD, NHLBI, NLM | The National Institutes of Health, Health Resources and Services Administration, Centers for Disease Control and Prevention (CDC), the American College of Medical Genetics and the Genetic Alliance meet monthly, in person or online, to discuss and coordinate current activities and initiatives in newborn screening. Topics include the activities of the Newborn Screening Translational Research Network Coordinating Center, the Clearinghouse of Newborn Screening Information, Sickle Cell Screening Programs, the CDC Newborn Screening Quality Assurance Program, and the Regional Newborn Screening Collaboratives. |
| Newborn Screening Technical Assistance and Evaluation Program (NewSTEPs) Steering Committee | Committee, Work group, Advisory group, or Task Force | HRSA | NICHD | Steering committee for the Newborn Screening Technical Assistance and Evaluation Program (NEWSteps). NEWSteps is a cooperative agreement related to newborn screening that the Health Resources and Services Administration funds. |
| NEXT Generation Health Study - Health Behavior in School-Age Children | Research Initiative | HRSA | NICHD, NHLBI, NIAAA | NEXT is a 7-year longitudinal assessment of a representative sample of U.S. adolescent and young adults, starting when they are in the 10th grade. The goals of the NEXT longitudinal study include: to identify the trajectory of adolescent health status and health behaviors from mid-adolescence through the post high school years; to examine individual predictors of the onset of key adolescent risk behaviors and risk indicators during this period; to identify genetic, personal, family, school, and social/environmental factors that provide or sustain positive health behaviors; to identify transition points in health risk and risk behaviors and changes in family, school, and social/environmental precursors to these transitions; and to examine the role of potential gene-environment interactions in the development of health status and health behaviors. |
| NHLBI Federal COPD Workshop | Committee, Work group, Advisory group, or Task Force | ACL, CDC, CMS, FDA, HRSA, IHS | NHLBI, NCCAM | The Senate Appropriations Committee in FY2012 encouraged the National Heart, Lung and Blood Institute (NHLBI) "to work with community stake-holders and other Federal Agencies, including CDC, to develop a national action plan to respond to the growing burden of this disease". In response to this congressional encouragement, NHLBI hosted in Bethesda, Maryland, on May 3, 2013, a forum of representatives from Federal Agencies and Institutes to share information about current activities related to Chronic Obstructive Pulmonary Disease (COPD) and discuss opportunities for further cooperation and enhanced effectiveness of the Federal response to this serious public health problem. |
| NIAID International tuberculosis (TB) Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, IHS, OS | NIAID, FIC, NHLBI, NICHD, NIDA | The working group focuses on coordinating tuberculosis (TB) research, which includes: studies to characterize drug resistance; the identification, preclinical development and clinical evaluation of new drugs, diagnostics, and vaccines; and studies of the epidemiology and transmission of TB, including research addressing HIV/TB co-infection and TB in high-risk populations. |
| NIAID-CDC Joint U.S. Partnership Implementing TB Elimination Research (JUPITER) | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | Through weekly teleconferences, the Joint U.S. Partnership Implementing TB Elimination Research (JUPITER) facilitates cooperation, communication, and collaboration on tuberculosis between the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention. This approach helps ensure that Federal activities are coordinated and not duplicated, and stimulates collaborations where appropriate. |
| NIAID/CDC Select Agents Laboratory Inspections | Other | CDC | NIAID | The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins laboratory inspectors visit foreign National Institute of Allergy and Infectious Diseases (NIAID) grantees on behalf of NIAID to ensure that foreign select agents laboratories follow safety, security, and training standards comparable to those for U.S. institutions. |
| NICHD-Electronic Health Record Pediatric Practice Based Research Network (PBRN) | Research Initiative | HRSA | NICHD | This Interdepartmental Delegation Authority (IDDA) (NIH-13-030) funds the following activities: Electronic Health Record (EHR) Pediatric Practice Based Research Network (PBRN) Initiative; and Comparative Effectiveness Research (CER) and epidemiologic assessments of the use of selected psychotropic medications and the most commonly prescribed asthma medications in pediatric populations. |
| NICHD-Maternal and Child Health (MCH) Electronic Health Record (EHR) | Research Initiative | HRSA | NICHD | This Interdepartmental Delegation Authority (IDDA) (NIH-13-031) provides funds for the Maternal and Child Health (MCH) Electronic Health Record (EHR) Pediatric Practice Based Research Network (PBRN) Initiative. |
| NIEHS Patterns of Co-Exposure in Danish Women of Reproductive Age | Research Initiative | CDC | NIEHS | This study characterizes exposure to National Health and Nutrition Examination Survey (NHANES) chemicals in a set of 50 Danish women participating in a time to pregnancy study that will also include follow-up of offspring. |
| NIH Guide for Grants and Contracts | Resource Development | AHRQ, CDC, FDA | OD/OER, CIT, CSR | The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines and funding opportunities, and is used by other U. S. Department of Health and Human Services (HHS) agencies to disseminate Funding Opportunity Announcements (FOAs) to its 50,000 subscribers. |
| NIH Recombinant DNA Advisory Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NCI, NHGRI, NIAID, NINDS | The Recombinant DNA Advisory Committee (RAC) advises the National Institutes of Health on the safe and ethical conduct of basic and clinical research involving recombinant DNA. It reviews protocols and provides recommendations for each protocol to enhance the scientific and ethical design. The RAC also discusses safety data and other emerging issues for the field of gene therapy. This year the RAC hosted a meeting to develop biosafety guidelines for gain-of-function research with H5N1 which led to the amendment of the NIH Guidelines for Research with Synthetic and Recombinant Research. The RAC also hosted a meeting of mid-level investigators to examine the scientific and other challenges that gene therapy will face in the next decade and a meeting to discuss optimization of the design of clinical trials using gene modified T cells in order to realize the potential of this immunotherapy while minimizing the risk to subjects. |
| NIH Translational Research Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, CC, CIT, CSR, NCATS, NCCAM, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/OER, OD/OIR, OD/OSP | As Chair of the National Institutes of Health (NIH) Translational Research Interest Group (TRIG), the National Cancer Institute (NCI) staff has coordinated Forums, Workshops, NIH Bench-to-Bedside Awardees’ Lecture Series, and Monthly Seminar Series to help bridge the gap between laboratory research and clinical applications; suggestions of topics and speakers for the Annual NIH Research Festivals; and nominations of speakers for the NIH Wednesday Afternoon Lecture Series and the NIH Director’s Lecture Series. NCI staff has informed TRIG members of scientific events coordinated with other NIH Scientific Interest Groups and Working Groups. |
| NIH-CDC-HRSA Working group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | Working group to coordinate activities related to care of HIV in adolescents in the US. |
| NIH-CDC-IDSA Guidelines for Treatment of HIV Related Opportunistic Infections Among Adults and Adolescents | Committee, Work group, Advisory group, or Task Force | CDC | CC | The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention (CDC) have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immunodeficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-infected children and previously published guidelines for prevention of OIs in these populations. |
| NIH-CMS Coordinating Committee for trials and data sharing | Committee, Work group, Advisory group, or Task Force | CMS | NIDDK, NCATS, NCI, NIA | The National Institutes of Health (NIH) and the Centers for Medicare & Medicaid Services meet periodically to discuss areas of common interest with respect to both clinical trials and research data. |
| NIH-FDA Interagency Clinical Outcome Assessments Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, CC, NCCAM, NHLBI, NIA, NIAMS, NICHD, NIDA, NIDDK, NIMH, NINDS, OD/DPCPSI | The Interagency Clinical Outcome Assessments Working Group (ICOA WG) works to foster the development, evaluation and qualification of Clinical Outcomes Assessments (COAs) for use in both medical product development and clinical research. Leveraging the unique strengths, knowledge, and resources at both the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH), the objectives of the ICOA WG are: 1) To increase communication between the relevant groups at FDA and the many separate efforts at NIH to advance measurement science by exchanging information about specific COA projects of common interest, thereby improving the knowledge base for COA development; 2) To clarify and disseminate information about the regulatory processes for evaluation of medical product development tools; 3) To foster appropriate interagency scientific efforts to generate evidence toward the development and potential qualification of novel COAs; and 4) To leverage public and private efforts toward consensus and standards development in this area. The ICOA WG is composed of representatives and selected senior staff of each agency. |
| NIH-FDA Leadership Council | Committee, Work group, Advisory group, or Task Force | FDA | OD/OSP, NCI, NHLBI, NIAID, NIDDK, NIGMS, NIMH, NINDS | The Joint Leadership Council will work together to help ensure that regulatory considerations form an integral component of biomedical research planning, and that the latest science is integrated into the regulatory review process. Such collaboration and integration will advance the development of new products for the treatment, diagnosis and prevention of common and rare diseases and enhance the safety, quality, and efficiency of the clinical research and medical product approval enterprise. The formation of the Leadership Council represents a commitment on the part of both agencies to forge a new partnership and to leverage the strengths of each agency toward this common goal. |
| NIH-FDA Tobacco Regulatory Science Workgroup | Committee, Work group, Advisory group, or Task Force | FDA | NIGMS, CSR, FIC, NCI, NEI, NHGRI, NHLBI, NIAAA, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINDS, NINR, NLM, OD/DPCPSI/OBSSR | The Food and Drug Administration (FDA)-National Institutes of Health (NIH) Tobacco Regulatory Science Workgroup was established in June 2011 through an NIH interagency partnership with the FDA''s Center for Tobacco Products. The FDA-NIH Tobacco Regulatory Science Workgroup is comprised of NIH staff and staff from the FDA Center for Tobacco Products. The purpose of the group is to coordinate, develop, and disseminate information about the Tobacco Regulatory Science Program and to leverage the research experience and capability of NIH to maximize the opportunity available in authorities given in the Family Smoking Prevention and Tobacco Control Act to reduce tobacco related morbidity and mortality. The Working Group meets quarterly. |
| NIH/PEPFAR Collaboration for Advancing Implementation Science in Prevention of Maternal-Child HIV Transmission | Research Initiative | CDC | OD/DPCPSI/ORWH, FIC, NICHD, NIMH | 2010 World Health Organization (WHO) recommendations to provide antiretroviral prophylaxis or treatment to mothers or infants during the breastfeeding period have not been adopted in resource poor countries. The goal of this study is to evaluate the effect of a "feeding buddy" to support mothers to adhere to prevention of mother to child HIV transmission. This is a prospective cohort intervention study set within a comprehensive ongoing national program addressing maternal and child health. |
| NIH/PEPFAR Collaboration for Implementation Science and Impact Evaluation | Research Initiative | CDC | NIAID, NCI, NICHD, NIMH, OD/DPCPSI/OAR | In FY11 a National Institutes of Health (NIH)/President''s Emergency Plan for AIDS Relief (PEPFAR) Request for Application (RFA) was issued for 3-year grant projects on Implementation Science in PEPFAR. Funding began in FY12. This RFA went out concurrently with a Centers for Disease Control and Prevention (CDC) RFA. The two agencies worked together to ensure awards were complementary and that there was no overlap. |
| NNI Nanotechnology Signature Initiative on Nanotechnology for Sensors and Sensors for Nanotechnology: Improving and Protecting Health, Safety, and the Environment | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB | Interagency effort to coordinate and stimulate creation of the knowledge, tools, and methods necessary to develop and test nanosensors and to track the fate of engineered nanomaterials in the body, consumer products, the workplace, and the environment. |
| NNI Nanotechnology Signature Initiative on Nanotechnology Knowledge Infrastructure: Enabling National Leadership in Sustainable Design | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB | Interagency effort to provide a community-based, solutions-oriented knowledge infrastructure to accelerate nanotechnology discovery and innovation. |
| Non-Allergic Rhinitis Workshop | Meeting/ Workshop | FDA | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) and the Food and Drug Administration (FDA) collaborated on this workshop, which comprised 13 experts in the field of non-allergic rhinitis (NAR), representatives from seven stakeholder organizations, and National Institutes of Health (NIH) and FDA staff. The goal of this workshop was to better define NAR, clinical testing, phenotypes and pathophysiology for NAR, as well as to identify future clinical research opportunities and the potential for drug development. |
| North American Plan For Animal and Pandemic Influenza | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | North American Plan for Avian and Pandemic Influenza (NAPAPI) is a comprehensive document designed to prepare for avian and pandemic influenza in North America. Coordinated by the Division of International Health Security in the Office of Policy and Planning at the Office of the Assistant Secretary for Preparedness and Response (ASPR), NAPAPI working groups bring together subject matter experts from the U.S., Canada and Mexico to address policy issues involving pandemic influenza. Output from NAPAPI working groups is integrated into updates of the 2012 NAPAPI document. |
| Northwest Portland Tribal Registry Project | Resource Development | IHS | NCI | Over the past 10 years, health care delivery for Northwest American Indians and Alaska Natives has evolved from a centralized system maintained by the Indian Health Service (IHS) to a diverse and complex environment. The Northwest Tribal Registry Project was developed in January 1999 by the Northwest Tribal Epidemiology Center, a tribally operated program located at the Northwest Portland Area Indian Health Board (NPAIHB) in Portland, Oregon. |
| Nutrition Coordinating Committee (NCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, IHS, OS | NIDDK, CC, CIT, CSR, FIC, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI, OD/DPCPSI/OBSSR | The Nutrition Coordinating Committee (NCC) operates as an National Institutes of Health (NIH)-wide forum to review, stimulate, and encourage the support of nutrition research and training to better define the role of nutrition in the promotion and maintenance of health and in the prevention and treatment of disease. The NCC also plays a key role in the development of nutrition research policy at the NIH. NCC membership includes a representative and alternate from the 20 NIH Institutes and 7 Centers. In addition, offices and agencies within the U. S. Department of Health and Human Services (HHS), U.S. Department of Agriculture (USDA), and the Department of Defense (DOD) have also appointed liaison representatives to the Committee. The NCC meets monthly to provide an open forum for members to report on current and future nutrition research, policy activities, and research funding and training opportunities. |
| Occupational Exposure to Bisphenol A in the United States | Research Initiative | CDC | NIEHS | The purpose of this project is to assess occupational exposure to bisphenol A (BPA) in a cross-section of industries and jobs where BPA is either produced or processed. |
| Office for Human Research Protections/Office of Extramural Research Training Initiative | Meeting/ Workshop | OS | OD/OER | The National Institutes of Health (NIH) Office of Extramural Research (OER) collaborated with the Office for Human Research Protections (OHRP) to provide comprehensive training at both NIH Regional Meetings for the extramural community and to NIH staff on Human Research Participant Protections. |
| Office of AIDS Research Advisory Council (OARAC) | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/OAR, NICHD | The Office of AIDS Research Advisory Council (OARAC) provides advice to the Director of the Office of AIDS Research (OAR) on the planning, coordination, and evaluation of research and other activities in respect to AIDS conducted or supported by the National Institutes of Health (NIH). OARAC also advises the Secretary of Health and Human Services, the Assistant Secretary for Health, the Director of NIH, and the Director of OAR, on AIDS research programs, the development and annual review of the comprehensive plan for the conduct and support of all AIDS activities of the Institutes and Centers of NIH, including research policies and priorities, and the coordination of domestic and international NIH AIDS efforts. |
| Office of Science and Technology Mo99 Stakeholders Working Group | Committee, Work group, Advisory group, or Task Force | CMS, FDA, OSG | NIBIB, NCI | Coordinate the efforts of multiple stakeholders (U.S. Department of State (State), U.S. Department of Energy (DoE), Department of Homeland Security (DHS), U. S. Department of Health and Human Services (HHS), private sector) to establish a stable, long-term domestic supply of Mo99 (molybdenum-99) for medical purposes. Such a supply needs to be consistent with current international goals (to which the US is an active participant) of reduction in the use of high-enriched uranium in all reactors, including Mo99 production facilities, as well as full cost recovery solutions. |
| Oral Health, Cancer Care, and You | Public Education Campaign | CDC | NIDCR, NCI, NINR | A series of publications to inform health care providers and patients about steps they can take before, during, and after cancer treatment to reduce the risk and impact of the often painful side effects. |
| Osteoporosis and Related Bone Diseases—National Resource Center | Resource Development | OS | NIAMS, NIA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ORWH | Provides patients, health professionals, and the public with an important link to resources and information on metabolic bone diseases, including osteoporosis, Paget’s disease of the bone, and osteogenesis imperfecta. |
| Package and Distribution of Nutritional Biochemistry for AREDS 2 | Research Initiative | OS | NEI | The Age-Related Eye Disease Study II (AREDS2) is a multi-center randomized trial designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and/or omega-3 Long-Chain Polyunsaturated Fatty Acids (LCPUFAs; DHA and EPA) for the treatment of Age-Related Macular Degeneration (AMD) and cataract. The primary objective of AREDS2 is to evaluate the effect of dietary xanthophylls (lutein/zeaxanthin) and/or omega-3 LCPUFAs (DHA and EPA) on progression to advanced AMD. This objective will be accomplished by collecting and assessing the data on approximately 4,000 AREDS2 participants aged 50 to 85 years, who at the time of enrollment have either: 1) bilateral large drusen or 2) large drusen in one eye and advanced AMD (neovascular AMD or central geographic atrophy) in the fellow eye. |
| Paternal Involvement in Pregnancy: Outcomes from Preconception to First Year of Life | Meeting/ Workshop | ACF, HRSA | NICHD, OD/DPCPSI/OBSSR | Numerous efforts have been initiated to promote responsible fatherhood as a way to enhance children’s development. However, less attention has been paid to the role of fathers during pregnancy through the first year of life. This workshop brought together researchers and community representatives to address the impact of fathers’ involvement on pregnancy, birth outcomes, and the health and development of children during the first year of life. This workshop was hosted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and co-sponsored by the Administration for Children and Families, the Maternal and Child Health Bureau, Health Resources and Services Administration, and the National Institutes of Health Office of Behavioral and Social Sciences Research. The purpose of the meeting was to develop a transformative, transdisciplinary research agenda that would translate into good public policy. The workshop consisted of a series of research-based presentations on various aspects of paternal involvement in pregnancy and birth outcomes. Participants broke into four working groups to consider both research questions and methods in their assigned topics. On day 2 of the workshop, these groups reported their findings and recommendations. This workshop included a new investigator poster session, which was held on September 25, 2013, at the same location. Attendance at this workshop was by invitation only. |
| Pathways to Prevention Workshop | Health Survey | AHRQ, CDC, FDA, IHS, OS, SAMHSA | NIDA, NCI, NIA, NINDS, OD/DPCPSI/ODP | This is a conference to look at the existing data on the efficacy and safety of opioids for chronic pain. |
| Patient-Reported Outcomes Measurement Information System (PROMIS) | Research Initiative | CDC, CMS, FDA, SAMHSA | OD/DPCPSI, NCCAM, NCI, NHLBI, NIAID, NIAMS, NICHD, NIDA, NIDDK, NIGMS, NIMH, NINDS, OD/DPCPSI/OSC | The Patient-Reported Outcomes Measurement Information System (PROMIS) is a network of National Institutes of Health-funded primary research sites and coordinating centers working collaboratively to develop a series of dynamic tools to reliably and validly measure patient-reported outcomes (PROs). PROMIS provides an opportunity to improve healthcare outcomes by giving decision makers hard data on how healthcare affects what patients are able to do and how they feel. The U.S. Food and Drug Administration has been invited to contribute to the scientific steering committee meetings as an interested partner. The Centers for Medicare and Medicaid Services, Centers for Disease Control and Prevention, and Substance Abuse and Mental Health Services Administration are working with PROMIS to coordinate use of PROMIS tools in programs of mutual interest. |
| Pediatric Abusive Head Trauma-Reviewing the Evidence Advancing Science | Meeting/ Workshop | HRSA | NICHD, NHLBI, NIDA, NIGMS, NIMH, NINDS, NINR | The developmental sequelae of children who suffer maltreatment related injuries are understudied and there is a need to bring together researchers from different disciplines who study and provide a continuum of services to these children. Thus, the purpose of this conference was to build on the 2002 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) sponsored conference on Inflicted Childhood Neurotrauma, review advances in the science from multiple disciplinary perspectives and to address definitional issues as well as implications for treatment, intervention and long-term outcomes for children. This meeting was an advisory to the new Pediatric Trauma & Critical Illness Branch (PTCIB) of NICHD and the proceedings will be used to inform a research agenda. This workshop was sponsored by PTCIB. The purpose of the meeting was to examine current findings on inflicted childhood neurotrauma, or Abusive Head Trauma (AHT), and related priorities. Day 1 of the workshop began with two presentations, one establishing a research agenda for AHT and a broad overview of what is and is not known about AHT, followed by a roundtable discussion. Then there were two sessions, one on basic research in AHT and one on clinical, epidemiological, and translational research, each followed by a roundtable discussion. Day 2 began with a session reviewing highlights from the previous day, followed by a roundtable discussion. Participants then divided into three workgroups: basic science; clinical science; and treatment, outcomes, prevention, and rehabilitation. After completing their discussions, workgroups presented their findings. This workshop was sponsored by the Pediatric Trauma and Critical Illness Branch (PTCIB) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The purpose of the meeting was to examine current findings on inflicted childhood neurotrauma, or AHT, and related priorities. Day 1 of the workshop began with two presentations, one establishing a research agenda for AHT and the a broad overview of what is and is not known about AHT, followed by a roundtable discussion. Then there were two sessions, one on basic research in AHT and one on clinical, epidemiological, and translational research, each followed by a roundtable discussion. Day 2 began with a session reviewing highlights from the previous day, followed by a roundtable discussion. Participants then divided into three workgroups: basic science; clinical science; and treatment, outcomes, prevention, and rehabilitation. After completing their discussions, workgroups presented their findings. |
| Pediatric Emergency Care Applied Research Network (PECARN) | Research Initiative | HRSA | NICHD | PECARN, the Pediatric Emergency Care Applied Research Network, is the first federally-funded pediatric emergency medicine research network in the U.S. PECARN conducts high-priority, multi-institutional research on the prevention and management of acute illnesses and injuries in children and youth of all ages. PECARN is supported by cooperative agreements between seven academic medical centers and the Health Resources Services Administration / Maternal and Child Health Bureau / Emergency Medical Services for Children Program (HRSA / MCHB / EMSC). The PECARN network consists of a data coordinating center; six Research Node Centers (RNCs); an Emergency Medical Services Demonstration node (funded in 2013); and 18 Hospital Emergency Department Affiliates (HEDAs). PECARN sites represent academic, community, urban, general, and children''s hospitals. Studies carried out by PECARN are funded through independent research grants. PECARN studies have been funded by the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and other divisions of the U.S. Department of Health and Human Services (HHS), as well as private foundations, hospitals, and universities. |
| Pertussis Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The objective of the Pertussis Working Group is to share information and promote collaborations among U.S. Department of Health and Human Services (HHS) agencies in order to better understand the recent resurgence of pertussis in the U. S. and identify potential strategies to address the problem. |
| PHS MSM Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NHLBI | The Working Group is developing guidelines and strategies to improve HIV/STD programs for men who have sex with men (MSM). |
| PHS Review Committee: Use of Marijuana in Clinical Research | Committee, Work group, Advisory group, or Task Force | FDA, OS, SAMHSA | NIMH, NCCAM, NIDA, NINDS | Follow-up review of revised application for purchase of research-grade marijuana from the National Institute on Drug Abuse (NIDA) for use in proposed treatment study of refractory post-traumatic stress disorder (PTSD) in military veterans. |
| Physical Activity and Disease Prevention: Identifying Research Priorities | Meeting/ Workshop | AHRQ, CDC, OS | OD/DPCPSI/ODP, NCI, NHLBI, NIA, NIBIB, NICHD, NIDA | This workshop was coordinated and funded by the National Institutes of Health (NIH) Office of Disease Prevention (ODP) to convene NIH and Federal partners to examine: barriers to achieving the Federal Physical Activity Guidelines; effective evidence-based interventions for initiating and sustaining physical activity; NIH’s physical activity research portfolio; and current and emerging research methodologies. The workshop focused on NIH’s interest in supporting innovative research to improve physical activity assessment and research methods used with diverse age and racial/ethnic populations as well as prioritizing the NIH physical activity research agenda. The meeting was held on December 13-14, 2012. |
| Pink Ribbon Red Ribbon | Meeting/ Workshop | CDC | NCI | Pink Ribbon Red Ribbon (PRRR) is a partnership to leverage public and private sector investments to address breast and cervical cancers in developing countries. It is being implemented in several countries in sub-Saharan Africa. The National Cancer Institute and Centers for Disease Control and Prevention provide technical assistance in implementation strategies to the PRRR countries. This assistance involves drafting guidelines for monitoring and evaluation of prevention and treatment services as well as developing communication strategies. |
| Planning and Design for post-acute care assessment instruments and data elements | Resource Development | CMS | NLM | The ultimate goal of this work is to improve quality of care and interoperability of computerized data in acute hospitals and post-acute care (PAC) settings through use of health informatics and real-time transfer of patient information. The National Library of Medicine (NLM) and Centers for Medicare & Medicaid Services (CMS) collaborate on planning and design for the Continuity Assessment Record & Evaluation (CARE) instrument and its data elements, and those of other CMS post-acute care assessment tools; develop logical data model and software applications that promote compliance and compatibility with Federal Health Architecture consolidated health informatics (CHI) standards; adopt Federal government-wide health information interoperability standards associated with Meaningful Use; and improve data and messaging for the Medicare program. This collaboration benefits from NLM''s role as central U.S. Department of Health and Human Services (HHS) coordinating body for clinical terminology standards, and provides NLM specific and usage-based feedback on the utility of such standards in this environment. |
| Planning Committee for the NIH Consensus Workshop on Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain | Meeting/ Workshop | FDA, HRSA | NCI, NHLBI, NIA, NICHD, NIDCR, NIDDK, NINDS, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ORWH | This consensus workshop is designed to determine what data exists or is needed to help improve the clinical treatment of pain with opioids. |
| Pluripotent Stem Cells in Translation: Early Decisions | Meeting/ Workshop | FDA | NINDS, NHLBI, NIDCR, OD/DPCPSI | The National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) are organizing a series of workshops that will engage the broader research community regarding requirements necessary for translation of pluripotent stem cell-derived products into the clinic. The first workshop, held March 2011, focused on establishment of stem cell lines and banks, covering safety and regulatory issues related to how the original cell line derivation is done in the case of embryonic stem cells, and how the cells are reprogrammed in the case of Induced pluripotent stem (iPS) cells. The second workshop, held July 10-11, 2012, focused on preclinical safety and proof of concept testing, including, among other topics, clinical relevance of the animal models, selection of cell dose levels, impact of host microenvironment, and cell fate post-administration. A third, and final, workshop is expected to focus on clinical trial design including safety monitoring, immunogenicity, immunosuppressant use and immune monitoring. |
| Polyhalogenated aromatic hydrocarbons (PHAH) and thyroid cancer | Research Initiative | CDC | NCI | Polyhalogenated aromatic hydrocarbons are being measured in banked serum/plasma samples from cohort studies to evaluate the association with thyroid cancer incidence. |
| Population Assessment of Tobacco and Health Study | Health Survey | FDA | NIDA | The Population Assessment of Tobacco and Health (PATH) Study is the first large-scale National Institutes of Health (NIH)/U.S. Food and Drug Administration (FDA) collaboration since Congress granted FDA the authority to regulate tobacco products in the Family Smoking Prevention and Tobacco Control Act (FSPTCA) in 2009. The PATH Study is a national longitudinal cohort study that will follow an estimated 59,000 U.S. household residents ages 12 years and older for at least three years. Objectives are to assess initiation and use patterns; to study trends in tobacco-product use cessation and relapse; to monitor behavioral and health impacts, including in risk perceptions and other tobacco-related attitudes; and to assess differences in tobacco-related attitudes, behaviors, and health outcomes among racial/ethnic, gender, and age subgroups. The PATH Study will also collect biospecimens from adults to analyze biomarkers of tobacco use and related health outcomes. By measuring and accurately reporting on the social, behavioral, and health effects associated with tobacco-product use in the U.S., the PATH Study will provide an empirical evidence base to help inform FDA’s decisions about changes in tobacco products in meeting the objectives of the 2009 FSPTCA. |
| Post-traumatic Stress Disorder (PTSD)/Trauma Brain Injury (TBI) Workgroup | Committee, Work group, Advisory group, or Task Force | OS | NIMH, NIAAA, NIDA, NINDS | A 2012 White House Executive Order, emphasizing support of service members, veterans, and their families as a “top priority,” called for an urgent increase in the U.S. Departments of Health and Human Services (HHS), Defense (DOD), and Veterans Affairs (VA) research coordination to address the problems of Post-traumatic stress disorder (PTSD), Traumatic brain injury (TBI), and suicide. Section 5 of this Executive Order requested a National Research Action Plan to develop biomarkers, define the pathophysiology, and create new treatments for PTSD. HHS charged the National Institute of Mental Health (NIMH) to lead this effort along with a parallel effort for TBI led by the National Institute of Neurological Diseases and Stroke (NINDS), with both Institutes working closely with the VA and DOD. In 2013, the National Research Action Plan was released in response to the Executive Order. Fortunately, prior investments interrogating the molecular, genomic, and circuitry changes that give rise to PTSD in the context of environmental factors provide the requisite foundation to respond to this White House request for biomarkers for risk prediction, as well as new targets for medications and other therapies to treat PTSD. Such an investment has the potential to revolutionize the care for individuals at high risk for PTSD, and prevent the development of chronic complex treatment resistant PTSD. |
| Potential of Candidate Cell Substrates for Vaccine Production to Propagate the Agents of Transmissible Spongiform Encephalopathies | Research Initiative | FDA | NIAID | Accidental contamination represents a major risk associated with the use of cell-substrate derived biologicals, including vaccines and antibodies, for human use. The possibility for viral contamination exists in primary cultures and established cultures. Sometimes these cells are grown in serum containing fetal calf serum, which can develop into transmissible spongiform encephalopathy (TSE/BSE). This initiative aims to rigorously characterize and safety test these cell substrates. For TSE/BSE infectivity, the long incubation time requires testing over multiple years. An external committee recommended testing for at least 10 years to obtain the maximum information. |
| Practical Oral Care for People with Developmental Disabilities | Public Education Campaign | CDC | NIDCR, NICHD | A series of publications designed to equip dental professionals in the community with the information they need to deliver quality oral health care to people with special needs. |
| President''s Commission on the Study of Bioethical Issues | Committee, Work group, Advisory group, or Task Force | OS | CC | Christine Grady participates as a Commissioner on the Presidential Commission for the Study of Bioethical Issues. The Commission advises the President on bioethical issues arising from advances in biomedicine and related areas of science and technology. The Commission seeks to identify and promote policies and practices that ensure scientific research, health care delivery, and technological innovation are conducted in a socially and ethically responsible manner. The Commission undertakes study of issues presented to them by the President and the Secretary of Health and Human Services. |
| President’s Emergency Plan for AIDS Relief (PEPFAR) Implementation Science / Combination Prevention | Research Initiative | CDC | NIAID, NIDA | This President''s Emergency Plan for AIDS Relief (PEPFAR) activity focuses on testing treatment as prevention on the population level in South Africa and Zambia. This activity was initiated through the HIV Prevention Trials Network (HPTN), with support of multiple National Institutes of Health (NIH) Institutes and Centers, PEFPAR, and the Bill & Melinda Gates Foundation. The Requests for Application (RFA) was issued concurrently with a Centers for Disease Control and Prevention (CDC) RFA for combination prevention, and the agencies have worked together to ensure that the studies are complementary and do not overlap. |
| President’s Emergency Plan for AIDS Relief (PEPFAR) Public Health Evaluation Activities | Research Initiative | CDC, HRSA, SAMHSA | NIAID, FIC, NCI, NIAAA, NIDA, NIMH, OD/DPCPSI/OAR | The President''s Emergency Plan for AIDS Relief (PEPFAR) is governed by intra-agency groups, which include the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Health Resources and Services Administration (HRSA) for the U.S. Department of Health and Human Services (HHS). CDC has a large role as an implementing partner for PEPFAR, while NIH has limited its activities to providing technical expertise on issues related to safety and efficacy of elements for PEPFAR programs, and to facilitating evaluation of PEPFAR through NIH funded investigators. The agencies work together to assist in developing research and evaluation priorities for PEPFAR. Awards through NIH Institutes and Centers address specific questions and data analysis requests. |
| Prevention Research Centers | Research Initiative | CDC | NCI | The Prevention Research Centers program funds community-based research projects at 37 academic research centers across the U.S.; 5 developmental and 32 comprehensive centers. These centers: Conduct research projects that promote health and prevent disease; Build research teams of multidisciplinary faculty; Seek solutions, strategies, and policies that address public health problems; Participate in research networks that address priority health issues, such as healthy aging, cancer prevention & control, and obesity prevention; Build long-term relationships for engaging communities as partners in research; Conduct research in directions guided by advisory boards of community leaders; Develop and deliver trainings that enhance the public health workforce; and Conduct additional research funded by other federal agencies, foundations, and nonprofit organizations. |
| Prevention Research Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, ATSDR, CDC, OS | OD/DPCPSI/ODP, CC, CIT, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, OD/OLPA | The National Institutes of Health (NIH) Prevention Research Coordinating Committee (PRCC) serves as a venue for exchanging programmatic and scientific information of interest to the NIH, as well as for planning and implementation of collaborative activities. The PRCC promotes prevention research designed to yield results directly applicable to identifying and assessing risk, and to developing interventions for preventing or ameliorating high-risk behaviors and exposures, the occurrence of disease/disorder/injury, or the progression of detectable but asymptomatic disease. Prevention research also includes research studies to develop and evaluate disease prevention and health promotion recommendations and public health programs. |
| Prevention Scientists Promoting Global Health: Emerging Visions for Today and Tomorrow | Meeting/ Workshop | CDC | NIAAA, NCI, NHLBI, NICHD, NIDA, NIMH | The Society for Prevention Research (SPR) envisions a wellness-oriented society in which evidenced-based programs and policies are continuously applied to improve the health and well-being of its citizens. The SPR Annual Meeting provides unique opportunities to advance this vision by providing an integrated forum for the exchange of new concepts, methods, and results from prevention and public health-related research, and communication between scientists, public policy leaders and practitioners concerning the implementation of evidence-based preventive interventions. |
| Prevention with Positives Intervention HIV Clinics (Y01-MH-1318) | Research Initiative | CDC | NIMH, NIAID | The Prevention with Positives Intervention HIV Clinics is a contract with the Centers for Disease Control and Prevention to conduct an HIV clinic-based comparison of a comprehensive prevention program for people living with HIV targeting multiple health behaviors (sexual risk, medication adherence, clinic attendance) and health outcomes (viral load, retention in care). |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, OS, SAMHSA | NIAID, NIAMS, NICHD, NINDS, NLM | The Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) determines the various medical countermeasures (MCMs) that are needed and oversees their development and procurement. The PHEMCE also advances national preparedness against chemical, biological, radiological, nuclear (CBRN) and emerging infectious disease (EID) threats, including pandemic influenza, by coordinating medical countermeasure related efforts within U.S. Department of Health and Human Services (HHS) and in cooperation with interagency PHEMCE partners. In order to accomplish this objective, the PHEMCE uses a multitier approach. Each tier comprises multiple agencies within HHS and/or the Department of Homeland Security (DHS) that work together in a collaborative fashion to further the preparedness of the nation. The first tier includes the Biological, Chemical, Radiological/Nuclear Working Groups; the Blood/Tissue MCM Requirements Working Group; and Integrated Program Teams (IPTs). The Working Groups (WG) utilize scenario-based analyses to determine which MCMs are needed for the Strategic National Stockpile (SNS), or affiliated repositories. The IPTs provide an end-to-end vision of MCMs needed for a particular threat type (e.g., anthrax, radiological/nuclear, etc.). The scope of their work includes setting requirements for the stockpiling of MCMs, MCM delivery and dispensing and monitoring MCM development. The IPTs also advise the Enterprise Executive Committee (EEC)as to threat- or capability-specific MCM priorities for improving preparedness, to inform leadership consideration of cross-threat prioritizations and strategic goal setting. Agencies represented on the PHEMCE WGs and IPTs include: National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Department of Defense (DOD), Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), DHS, and Department of Veterans Affairs (VA). The second tier of this process is the EEC. The EEC is comprised of senior program managers across the partner agencies. It provides the critical interface and organizing capability between the strategic focus of the Enterprise Senior Council (ESC) and the tactical-level efforts conducted within the subordinate IPTs and WGs. This committee serves as a Senior Advisor-level coordination mechanism across the Federal agencies involved in PHEMCE-related activities to facilitate vetting and prioritization of policy decision materials to be presented to the ESC. The third and most senior tier of the PHEMCE and the forum for cooperation and overall mission fulfillment is the ESC. Structurally, the ESC is led by the Assistant Secretary for Preparedness and Response and comprised of the senior leadership of National Institute of Allergy and Infectious Diseases (NIAID) within NIH, CDC, and FDA with comparable senior level representatives from the DoD, DHS, VA, and the U.S. Department of Agriculture (USDA). As the most senior level in the PHEMCE structure, this group approves major policies, product requirements, and large-scale procurement actions. It also oversees strategic reviews of the activities in each of the major threat portfolios (e.g., anthrax, smallpox, radiological/nuclear) and is the final reporting body for high priority actions identified as gaps in these reviews. |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Chemical Integrated Product Development Team (IPT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NINDS, NIAID | The U.S. Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats. |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Chemical Requirements Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NINDS, NIAID, NICHD, NIEHS | The U.S. Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats. |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Enterprise Executive Committee (EEC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Enterprise Executive Committee (EEC) is responsible for overseeing Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) operations. The EEC ensures that important PHEMCE programmatic, procurement, requirements, and portfolio actions are fully vetted and that any recommendation or action is clearly delineated and properly approved. Additionally, the EEC manages the work at the various Integrated Program Teams and subgroup levels, directly manages the annual assessment of the Strategic National Stockpile, and composes PHEMCE documents, such as the Strategy and Implementation Plan. |
| Public Health Prevention of HIV Risk Behaviors Technical Working Group | Committee, Work group, Advisory group, or Task Force | CDC, SAMHSA | NIAAA, NIDA | Collaboration with the Office of Global AIDS Coordination, Centers for Disease Control and Prevention to identify and implement effective HIV prevention and treatment interventions among alcohol abusing and dependent populations. |
| Quantitative data mining for drug-adverse event safety signal detection using MEDLINE | Research Initiative | FDA | NLM | The objective of this initiative between the National Library of Medicine (NLM) Cognitive Science Branch and the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA) is to develop a mutually beneficial automated data mining analytical tool in which NLM’s electronic databases and resources (including MEDLINE) are utilized to support the FDA’s mission related to enhancing postmarket drug safety surveillance and safe use. |
| RABRAT (Radiobiology Bioterrorism Research and Training Group) | Meeting/ Workshop | FDA, OS | NCI | Monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications and other events and information related to preparing the U.S. Government to respond to nuclear terrorism. |
| Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008 | Research Initiative | CDC | NCI | An analysis of the National Program of Cancer Registries database to assess census division differences by race (white, black) in trends of prostate cancer. |
| Radiation Emergency Medical Management (REMM) | Resource Development | CDC, OS | NLM, NCI | This activity is to develop a comprehensive web resource. Radiation Emergency Medical Management (REMM) is a mechanism to collect, evaluate, collate, store and make available electronically to health care professionals immediate, up-to-date, evidence-based clinical information they would use to treat civilian patients and others affected by radiation incidents. |
| Radiation/Nuclear Biodosimetry Team | Committee, Work group, Advisory group, or Task Force | OS | NIAID | Team members participate in the review of white papers, full proposals and progress reviews for Biomedical Advanced Research and Development Authority (BARDA)-funded contracts supporting the development of novel biodosimetry platforms. |
| Radiation/Nuclear Technical Evaluation Review Panel | Committee, Work group, Advisory group, or Task Force | OS | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) participates on the Radiation/Nuclear Technical Evaluation Review Panel to review white papers and proposals received by the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) for the development of radiation nuclear medical countermeasures. NIAID provides scientific and programmatic critiques and reviews of selected submissions. |
| Randomized Intervention in Children with Vesicoureteral Reflux (RIVUR) | Research Initiative | OS | NIDDK | The multicenter, randomized, double-blind, placebo-controlled RIVUR trial is designed to determine whether daily antimicrobial prophylaxis is superior to placebo in preventing recurrence of UTI in children with VUR. The study is designed to recruit 600 children (approximately 300 in each treatment group) over an 18-24 month period. The primary endpoint is recurrence of UTI. Quality of life, compliance, safety parameters, utilization of health resources, and change in VUR will be assessed periodically throughout the study. |
| Rapid State Evaluation Reviewer | Research Initiative | FDA | NICHD | The purpose of this interagency agreement was for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to provide the Center for Tobacco Products of the U.S. Food and Drug Administration with an employee to participate in an objective review panel for the Rapid State Evaluation Blanket Purchase Agreement. This includes all activities involved in the preparation and attendance for review. The NICHD employee served on the Project Advisory Group (PAG). The PAG members served as an advisory and review body on technical matters during the acquisition process. Activities for the PAG members, included: Conduct individual review and assessment of each proposal based on the Request for Proposal (RFP) instructions, evaluation criteria; Participate in consensus evaluation sessions to agree upon panel findings and consensus comments, Clarification questions, and factor, sub-factor, and proposal adjectival ratings; Participate in the oral presentations; Review and approve delivery of PAG report to the Contract Officer; and Perform a technical review of the Business Proposals. In addition the employee performed the following activities: Examine each proposal in detail including any additional material such as draft project management and staffing plans; Assess how well the proposal and additional material satisfy each Evaluation Factor, Sub-Factor, and Criteria; Document the assessment – criteria by criteria and factor by factor – by citing specific proposal references and writing rationale detailed comments; Assign the appropriate comment ratings; and Craft clarification/discussion questions for Offerors if appropriate. |
| Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study - Occupational Supplement | Health Survey | CDC | NINDS | The goal of this study is to identify the extent to which occupational exposure contributes to cardiovascular disease in a racially diverse, population-based sample, with emphasis on health disparities secondary to racial/ethnic characteristics. |
| Reciprocal Educational and Training Partnerships between FDA/CDER and the NIH Clinical Center | Training Initiative | FDA | CC, NCI, NIAID, NIMH, NINDS | This activity is sponsored by the Clinical Pharmacology Program, Office of Clinical Research Training and Medical Education (OCRTME) at The National Institutes of Health (NIH) Clinical Center (CC) and it consists of elective rotations at the Office of Clinical Pharmacology (OCP) and the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research for NIH staff with a primary focus on clinical fellows and research fellows who expressed an interest in learning more about FDA regulatory sciences applicable to drug development research. Rotating fellows are mentored by FDA staff on the required elements of an Investigational New Drug (IND) application and the key elements of the FDA review process from a regulatory perspective. This program also established a mechanism for FDA scientific reviewers at the OCP to rotate at the NIH CC and to interact with members of a clinical research team, thus acquiring a better perspective on clinical research protocol implementation and the requirements of an Institutional Review Board (IRB) at the NIH. |
| Reentry Research Network | Committee, Work group, Advisory group, or Task Force | ACF, SAMHSA | NIDA, OD/DPCPSI/OBSSR | This is a subgroup that reports to the Federal Interagency Reentry Council. The purpose of this group is to bring together numerous federal agencies to make communities safer, assist those returning from prison and jail to becoming productive, tax-paying citizens, and save taxpayer dollars by lowering the direct and collateral costs of incarceration. |
| Regional Grant Writing and Scientific Peer Review Workshop | Meeting/ Workshop | CDC | NCI, CSR, FIC, NHLBI, NIAID, NICHD, NIDA, NIMH, NINDS, OD/DPCPSI/OAR, OD/DPCPSI/ODP | The Center for Global Health of the U.S. National Cancer Institute (NCI) in collaboration with the South African Medical Research Council (SAMRC) will hold regional grant writing and peer review workshops to encourage investigators to address public health issues through research. The objectives of the workshops are to (1) increase the participation of scientists from mid- to low-resource countries in the research grant process; (2) develop strategies for sustainable research support and collaborations, and; (3) use competitive research as a tool to address global health issues. |
| Registry of Patient Registries (RoPR) Project | Resource Development | AHRQ | NLM, NIDDK | The Agency for Healthcare Research and Quality''s (AHRQ) Registry of Patient Registries (RoPR) is a system for tracking “patient registries” that is compatible with the ClinicalTrials.gov clinical study registry operated by The National Library of Medicine. Since November 2012, data providers registering “observational studies” at ClinicalTrials.gov can indicate (1) whether the studies also meet AHRQ’s definition of a “patient registry” and, (2) provide more detailed (optional) information about the patient registry using the separate RoPR Data Entry System. Users of the ClinicalTrials.gov Web site are able to search for registered observational studies that are identified as patient registries. In the future, users will also be able to link from a record at ClinicalTrials.gov to the corresponding record containing a detailed description of the patient registry at RoPR, if available. As part of this project, broad consultations were carried out with relevant groups. National Institute of Diabetes and Digestive and Kidney Diseases staff participated extensively in these consultations. |
| Report on Carcinogens (RoC) Evaluation of 1-Bromopropane | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | Collaborated on preparing the Report on Carcinogens (RoC) evaluation of 1-bromopropane for possible listing in the RoC. The RoC is a congressionally mandated, science-based, public health report that identifies substances in our environment that are cancer hazards for people living in the U.S. |
| Report on Carcinogens (RoC) Evaluation of ortho-Toluidine | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | Collaborated on preparing the Report on Carcinogens (RoC) evaluation of ortho-toluidine for possible listing in the RoC. The RoC is a congressionally mandated, science-based, public health report that identifies substances in our environment that are cancer hazards for people living in the U.S. |
| Report on Carcinogens (RoC) Evaluation of Pentachlorophenol and Byproducts of its Synthesis | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | Collaborated on preparing the Report on Carcinogens (RoC) evaluation of pentachlorophenol and byproducts of its synthesis for possible listing in the RoC. The RoC is a congressionally mandated, science-based, public health report that identifies substances in our environment that are cancer hazards for people living in the U.S. |
| Research in diabetes mellitus, its complications, and obesity | Research Initiative | IHS | NIDDK | he objectives are to identify the determinants and understand the progression of type 2 diabetes, obesity, and other chronic diseases in Pima Indians. |
| Research on Research Integrity Program | Research Initiative | OS | NIEHS, NIDCR | Handles the administrative responsibilities for soliciting, reviewing, funding, and managing the Research on Research Integrity program in collaboration with the U.S. Department of Health and Human Services Office of Research Integrity. |
| Research to Risk Assessment Workgroup | Committee, Work group, Advisory group, or Task Force | ATSDR | NIEHS | Developed to bring together scientists knowledgeable in critical research areas such as "omics" and cumulative risk with risk assessment scientists and practitioners who develop/evaluate site-specific risk assessments to create an opportunity for experts to work collaboratively on how best to apply new science in the short term for site risk assessments. |
| Research-Tested Intervention Program Database (RTIPs) | Resource Development | SAMHSA | NCI | The Research-Tested Intervention Program Database (RTIPs) is a searchable database of cancer control interventions and program materials and is designed to provide program planners and public health practitioners easy and immediate access to research-tested materials. |
| Revision of CDC Guidelines | Committee, Work group, Advisory group, or Task Force | CDC | CC | The collaboration serves to revise guidelines for managing occupational exposures to HIV and managing healthcare workers infected with hepatitis B. |
| RuSH (Registry and Surveillance System in Hemoglobinopathies) | Resource Development | CDC, HRSA, OS | NHLBI, NICHD, NIDDK | The Registry and Surveillance System in Hemoglobinopathies (RuSH) is a database of information on people living with hemoglobinopathies (sickle cell disease and thalassemia) in six states.. |
| Ruth L. Kirschstein National Research Service Award Program | Training Initiative | AHRQ, HRSA | OD/OER | Predoctoral and postdoctoral training in biomedical, behavioral, and clinical research, including health services and primary care research, is supported by a portion of the National Institutes of Health''s (NIH) Kirschstein-National Research Service Award Program (NRSA) funds. These funds are annually transferred to the Agency for Healthcare Research and Quality and Health Resources and Services Administration by the NIH Budget Office in accordance with Public Law 111-8, Section 219 of the Health Service Act. |
| Sabbatical in Clinical Research Management Program | Training Initiative | FDA, OS | CC, FIC, NCATS, NEI, NHLBI, NIAID, NLM | Experienced investigators come to the National Institutes of Health (NIH) to learn about management of a clinical research enterprise, including topics such as planning and budget development, protocol writing and tracking and scientific review. Sabbaticals are self-directed, meaning that the participant chooses from a list of electives and helps determine how much time to spend studying each topic. The electives are offered by leaders at the NIH and other U.S. Department of Health and Human Services agencies with the NIH Clinical Center being the most heavily involved. |
| Safety and Efficacy Evaluations of Topical Microbicide (TM)/Biomedical Prevention (BP) Products in the Repeat Low-Dose Macaque SIV/SHIV Infection Model | Research Initiative | CDC | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) and Centers for Disease Control and Prevention (CDC) recognize the need to perform preclinical safety and efficacy evaluations of candidate products in the repeat low-dose (RLD) macaque SIV/SHIV infection model that has been established by CDC. NIAID established an interagency agreement with CDC to: 1) conduct safety and efficacy evaluations of Topical Microbicide/Biomedical Prevention products in the RLD macaque model, including pharmacokinetic/pharmacodynamic analyses of candidate biomedical prevention products; 2) utilize relevant macaque species, virus strains, and routes of infection to accomplish the proposed evaluations; and 3) perform other macaque studies as needed. |
| Safety Reporting Portal | Resource Development | FDA | OD/OSP | Development of a portal to streamline the process of reporting pre- and post-market safety data to the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) and to serve as a prototype for a federal-wide system. The Portal is an important policy innovation and major step forward in the effort to eliminate unnecessary complexities and inefficiencies associated with the current system of reporting adverse events. The Portal uses a harmonized set of terms, the Basal Adverse Event Report, to provide a single, web-based interface for standardized electronic reporting of adverse events and unanticipated problems to NIH and FDA and also enables the transmission of reports to local oversight bodies such as institutional review boards (IRBs) and data and safety monitoring boards (DSMBs). |
| SAMHSA Recovery Month | Public Education Campaign | SAMHSA | NIDA | The Substance Abuse and Mental Health Services Administration''s annual public health observance for people in recovery from substance abuse; The National Institute on Drug Abuse (NIDA) is part of SAMHSA''s inter-agency planning committee and a promotional partner. |
| SEARCH for Diabetes in Youth | Research Initiative | CDC | NIDDK | SEARCH is a multi-center study that identifies cases of diabetes in children/youth, providing data on incidence and prevalence in the U.S. as well as data on diabetes management and complications. |
| Sequencing Quality Control (SEQC) Toxicogenomics (TGMX) Study | Research Initiative | FDA | NIEHS | TO compare TGMX results between microarray and RNA-seq |
| Sex differences in esophageal cancer incidence rates by census region in the United States, 1999-2008 | Research Initiative | CDC | NCI | An analysis of the National Program of Cancer Registries database to assess census region sex differences in trends of esophageal squamous cell carcinoma and esophageal adenocarcinoma. |
| Sleep Disorders Research Advisory Board | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI, NCATS, NCCAM, NCI, NIA, NICHD, NIDA, NIDDK, NINDS, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | The Advisory Board shall advise, assist, consult with, and make recommendations to the Director of the National Institutes of Health, through the Director of the Institute, and the Director of the Center concerning matters relating to the scientific activities carried out by and through the Center and the policies respecting such activities, including recommendations. (42 USC § 285b–7) |
| Smokefree.gov | Resource Development | CDC, OS | NCI, OD/DPCPSI/OBSSR | Smokefree.gov is intended to help individuals quit smoking. Different people need different resources as they try to quit. The information and professional assistance available on this Web site can help to support both immediate and long-term needs as individuals become, and remain, a nonsmoker. Smokefree.gov allows individuals to choose the help that best fits their needs. This collaboration also includes a number of smoking cessation text message programs throughout the world: China, Caribbean, Guam, American Samoa, and Samoa. |
| Smoking Cessation Services during CDC TIPS II Campaign | Public Education Campaign | CDC | NCI | To assist in ensuring that 1-800-QUIT-NOW''''s counselling services and the National Cancer Institute''s text messaging service and web site (Smokefree.gov) have adequate capacity to meet the expected increased demand for services during the Centers for Disease Control and Prevention TIPS Campaigns |
| Social Determinants of Health Working Group for Healthy People 2020 | Committee, Work group, Advisory group, or Task Force | CDC, SAMHSA | NIAAA, NCI, NHLBI, NIAMS | The overarching goals for Healthy People 2020 incorporate a focus on social determinants of health as well as on health outcomes and risk factors. The Working Group intends to develop objectives for the social determinants and methods to ensure their integration across all Healthy People 2020 objectives. |
| Society for Prevention Research Annual Meetings | Meeting/ Workshop | ACF, CDC | NIDA, NCI, NIAAA, NICHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The Society for Prevention Research was formed in 1991 and has grown from a small group of researchers focused on drug and alcohol abuse prevention and mental health to become a leading scientific organization devoted to advancing prevention science, with 700+ members and a multidisciplinary prevention focus that emphasizes drug abuse, mental health and HIV/AIDS prevention in addition to diverse, public health domains (e.g., obesity, violence, translational science). The annual meetings promote cross-fertilization of theory, methods, and intervention and provide an opportunity to enhance understanding of the underlying mechanisms of health-related issues with the goal of building the science of effective strategies, and for prevention and health promotion. |
| Specialized Centers of Research (SCOR) on Sex and Gender Factors Affecting Women''s Health | Research Initiative | FDA | OD/DPCPSI/ORWH, NIAMS, NICHD, NIDA, NIDDK, NIMH | The Specialized Centers of Research (SCOR) programs are large Center Programs (P50) that consist of 11 Centers that conduct interdisciplinary research focused on health issues that affect women and examine sex/gender contributions to health and disease. The currently funded SCORs are interdepartmental, intercollegiate, interinstitutional and focus on sex differences in musculoskeletal health, tobacco, addiction, substance abuse, reproductive health, urinary tract, depression, metabolic disorders and pain. The SCOR mechanism promotes collaborative research among scientists with varied expertise in order to achieve research objectives that are less likely to occur through other grant mechanisms. |
| Standardization of Methods to Generate Spiked Clinical Samples for Use in Studies to Support FDA Clearance of Diagnostics for Low Prevalence Pathogens | Research Initiative | FDA | NIAID | The National Institutes of Health (NIH) has been working with the Food and Drug Administration (FDA) to develop standardized methods to generate clinical samples to assess the performance of diagnostic tests. |
| Standards for Genetic Testing Report | Research Initiative | AHRQ, CDC, OS | NLM, NHGRI | This activity aims to develop a standard reporting format, using Logical Observation Identifiers Names and Codes (LOINC) and HL7, for electronic medical records health information exchange, the National Library of Medicine''s Personal Health Record Project and activities of the Office of the Secretary. |
| State Cancer Profiles | Resource Development | CDC | NCI | The objective of the State Cancer Profiles Web site is to provide a system to characterize the cancer burden in a standardized manner in order to motivate action, integrate surveillance into cancer control planning, characterize areas and demographic groups, and expose health disparities. The focus is on cancer sites for which there are evidence based control interventions. Interactive graphics and maps provide visual support for deciding where to focus cancer control efforts. |
| Strategic Multisite Initiative for the Identification, Linkage and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) | Research Initiative | CDC | NICHD, NIDA, NIMH | The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) was awarded grant money to expand their project of increasing availability of HIV testing for adolescents 12-24 and the provision of adolescent-focused healthcare services for those adolescents who are diagnosed with HIV infection. The project''s expansion includes all the ATN sites across the U.S. The Eunice Kennedy Shriver National Institute of Child Health and Human Development is collecting data to evaluate the effectiveness of adolescent oriented linkage to care services for the HIV infected adolescents. This collaboration has the potential to improve the health of American youth, both by identifying those with undiagnosed HIV and bringing them into adolescent-friendly treatment programs and by reducing the chances of them further spreading the virus to others. There is a committee "SMILE in CARING for YOUTH" that monitors activities related to the National Institutes of Health-Centers for Disease Control and Prevention collaboration on enhancing treatment and retention in care of HIV youth. |
| Structured Data Capture Forms and Common Data Element Working Groups | Committee, Work group, Advisory group, or Task Force | OS | NCI, NLM | Help design a standard form and data element structure, developing XML artifacts and implementation guide |
| Studies in the Treatment of Anthrax Edema Toxin Associated Shock: The Role of Conventional Hemodynamic Support Alone or Together with a PA Directed mAb | Research Initiative | FDA | CC | Production of edema toxin by B. anthracis is a key pathogenic component in the hemodynamic compromise and resistance to conventional hemodynamic support leading to death during all severe forms of anthrax infection, including inhalational disease. The aim of the present collaboration was to define employing a large animal model the efficacy of conventional hemodynamic support for anthrax edema toxin induced shock and to determine whether the use of protective antigen directed monoclonal antibody (PA-mAb) can increase the efficacy of conventional hemodynamic support. |
| Study of Cancer Among United States Firefighters | Research Initiative | CDC | NCI | A retrospective cohort study to evaluate the relationship between occupational exposures of firefighters and cancer risk. |
| Subcommittee on Nanoscale Science, Engineering, and Technology | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIBIB, NCI, NIEHS, OD/OSP | This subcommittee of the National Science and Technology Council''s Committee on Technology is responsible for coordinating the National Nanotechnology Initiative (NNI). The NNI was established in 2001 to coordinate federal research and development in nanotechnology by providing a vision of the long-term benefits and opportunities offered by nanotechnology and acting as a locus for communication, cooperation, and collaboration between Federal agencies involved in nanotechnology research and development. In 2011, the Nanoscale Science, Engineering, and Technology Subcommittee developed a strategic plan that encompasses a comprehensive nanotechnology R&D initiative built on shared goals, priorities, and strategies that complement agency-specific missions and activities. |
| Subpopulations and Intermediate Outcome Measures in Chronic Obstructive Pulmonary Disease (COPD) | Research Initiative | FDA | NHLBI | SPIROMICS (SubPopulations and Intermediate Outcome Measures In Chronic Obstructive Pulmonary Disease Study) is an observational study of COPD (Chronic Obstructive Pulmonary Disease) that seeks to identify practical intermediate outcome measures and mechanistically homogeneous subgroups of patients with the disease. The study was developed in cooperation with the U.S. Food and Drug Administration and will be implemented with industrial partners. |
| Sudden Death in the Young (SDY) Registry | Resource Development | CDC | NINDS, NHLBI | Collaboration between the National Heart, Lung, and Blood Institute, National Institute of Neurological Disorders and Stroke, and Centers for Disease Control and Prevention to develop a registry of cases of sudden death in the young (to age 24), including sudden cardiac death and sudden unexpected death in epilepsy. |
| Suicide Research Consortium | Committee, Work group, Advisory group, or Task Force | CDC, IHS, SAMHSA | NIAAA, NIMH | The consortium coordinates program development in suicide research, stimulates extramural research on suicide, and disseminates science-based information on suicidology. |
| Surveillance, Epidemiology and End Results (SEER) - Medicare Database | Resource Development | CMS | NCI | The Surveillance, Epidemiology, and End Results (SEER)-Medicare data are a unique resource that can be used for research related to the health care provided to persons with cancer. The database results from the linkage of two large population-based data sources: the SEER cancer registries data and the Medicare enrollment and claims files. |
| Surveillance, Epidemiology, and End Results (SEER) Program | Resource Development | CDC | NCI | The Surveillance, Epidemiology, and End Results (SEER) program is the premier source for cancer statistics in the U.S. It collects information on incidence, prevalence and survival from specific geographic areas representing 26 percent of the US population. Through SEER, we develop reports on all of these information areas plus cancer mortality for the entire country. The site is intended for anyone interested in U.S, cancer statistics or cancer surveillance methods. |
| Targeting of Interleukin-13 Receptor a2 for Treatment of Head and Neck Squamous Cell Carcinoma Induced by Conditional Deletion of TGF-ß and PTEN Signaling | Research Initiative | FDA | NIDCR, NIDCD | The activity will test new animal models of head and neck squamous cell cancer with targeted treatments using Interleukin-13 Receptor alpha 2 antagonists. |
| Task Force on Environmental Health Risks and Safety Risks to Children: Coordinated Federal Action Plan to Reduce Racial and Ethnic Asthma Disparities | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG | NHLBI, NCMHD, NIAID, NICHD, NIEHS, NINR | The Action Plan to Reduce Asthma Disparities promotes collaboration and coordination among Federal agencies to leverage existing resources to address the multi-leveled causes of asthma disparities. The Action Plan outlines four key strategies to improve the quality of care for children who have asthma and promote community programs and resources to support clinicians, children, and their families in following best practices for asthma management. |
| TB Diagnostics Research Forum | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The purpose of the forum is to communicate, coordinate, and collaborate to address issues of tuberculosis (TB) diagnostics, especially drug susceptibility testing (DST) for new drugs and regimens. The initial focus was to bring together researchers, clinicians, clinical trial groups, government, and non‐government organizations with both the drug and diagnostic industry to advance the field of pyrazinamide DST to meet the needs of clinical trials. In addition, the Forum will expand to other drugs including new anti-tuberculosis drugs in the pipeline. |
| TB Therapeutics Research Coordination Forum | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The purpose of the TB (Tuberculosis) Therapeutics Research Coordination Forum (“the Forum”) is to support and sustain discussion, information sharing, and decision making to coordinate clinical trials of new TB drug combinations. The overall goal is to advance new therapies rapidly and cost-effectively while maintaining the highest standards of scientific rigor. The Forum will work to coordinate planning among the major non-commercial sponsors and their research groups to ensure rapid and efficient Phase II evaluations of drug combinations. |
| Technical and Clinical Consultation to Indian Health Service in Kidney Disease | Public Education Campaign | IHS | NIDDK | A National Institute of Diabetes and Digestive and Kidney Diseases senior staff member serves as Chief Clinical Consultant for Nephrology for the Indian Health Service. |
| Technical Consultation on HCV Infection in Young IDUs | Meeting/ Workshop | CDC, OS, SAMHSA | NIDA, NIAID, NIDDK | Bring Federal and non-Federal clinician/researchers from academia, state public health departments and community to present and discuss current research and other information on an emerging epidemic of viral hepatitis (HCV) infection in the 15-30 year group. |
| Text 4 Baby Program Evaluation Technical Advisory Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS, SAMHSA | NICHD | Formal program evaluation of the Text 4 Baby initiative, which provides health info to pregnant women and young mothers via text message. |
| Text4baby | Public Education Campaign | ACF, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA | NIDCR, NICHD, NIDA, NIDDK | Free health text messaging service for pregnant women and new mothers. Those who text "BABY" (or “BEBE” for Spanish) to 511411 receive weekly text messages, timed to their due date or their baby''s birth date through the baby’s first year. Messages, which have been vetted by both government and non-profit health experts, deal with topics such as nutrition, immunization, birth defect prevention, and oral health. |
| The CDC Dental, Oral, and Craniofacial Data Resource Center (DRC) | Resource Development | CDC | NIDCR | Publicly accessible database, query system, and survey catalog for population-based oral health surveys |
| The Environmental Determinants of Diabetes in the Young (TEDDY) | Research Initiative | CDC | NIDDK, NIAID, NICHD, NIEHS | This consortium is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people. The study enrolled over 8,000 newborns and is following them for 15 years to identify environmental triggers of type 1 diabetes. |
| The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) | Research Initiative | CDC | NCI | EMBLEM provides a unique infrastructure to obtain valuable data and samples to study Burkitt’s lymphoma (BL) epidemiology. Study data will help characterize or investigate: 1. The association of malaria-resistance genes with endemic BL. 2. Host genetic polymorphisms associated with BL using genome-wide association methods. 3. The role of the Epstein-Barr virus (EBV) genetic variants in endemic BL. 4. The role of malaria immunology and phenotype of inflammation in BL. 5. The complexity of coinfection with different P. falciparum malaria genotypes in BL. 6. The interaction between helminthic parasites, HIV, malaria, and EBV in BL. 7. The immunohistochemistry and molecular pathology of BL. 8. The impact of malaria, helminthic parasites, and HIV on childhood BL. |
| The Federal Tuberculosis Task Force | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIAID, FIC, NCATS, NHLBI, NIAAA, NICHD, NIDA | The Federal Tuberculosis (TB) Task Force is a coalition composed of the Federal agencies and organizations involved in U.S. TB control efforts. Established in 1991, the Task Force facilitates coordination of activities between Federal agencies. It was created by the Director of the Centers for Disease Control and Prevention (CDC) to address the outbreaks of multidrug-resistant (MDR) TB occurring during the 1985-1992 surge in TB cases. |
| The Foundation for the NIH Biomarkers Consortium | Research Initiative | CMS, FDA | NIBIB, NCI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDDK, NIMH, NINDS | The Biomarkers Consortium develops, validates, and qualifies biological markers (biomarkers) to speed the development of medicines and therapies for detection, prevention, diagnosis, and treatment of disease and improve patient care. The National Institutes of Health (NIH) Public Private Partnership Program coordinates NIH participation in the sponsored Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium. The Consortium is an umbrella which encompasses research projects, ongoing working groups, as well as occasional workshops and conferences. |
| The Healthy Brain Initiative | Public Education Campaign | ACL, CDC | NIA | A call to action and a guide to assist in implementing a coordinated approach to moving cognitive health into public health practice. |
| The Impact of Tobacco Use on Oral Health and the Oral Microbiome | Research Initiative | CDC, FDA | NCI | .U.S. Food and Drug Administration Intramural Center of Tobacco Regulatory Science Award Program funded a project examining how tobacco affects oral health and the oral microbiome in the National Health and Nutrition Examination Survey (NHANES) study. |
| The Incidence of Breast and Other Cancers Among Female Flight Attendants | Research Initiative | CDC | NCI | A cohort study of approximately 10,000 Pan Am flight attendants to determine cancer incidence (primarily breast cancer) associated with cosmic radiation and circadian disruption from their work. |
| The Interagency Committee on Human Nutrition Research (ICHNR) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDDK | The Interagency Committee on Human Nutrition Research (ICHNR) provides a mechanism for communicating among the various Federal agencies to enhance the coordination of human nutrition research activities. |
| The Intersection of Violence and HIV Risk in Women Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS | OD/DPCPSI/OAR | This Working Group established to address the research issues on violence and HIV in women including research gaps, current knowledge and current interventions. The Working Group conducted meetings separately and together with the White House Working Group in which they provided information and recommendations to the White House Violence against Women and HIV Initiative. |
| The National Ambulatory Medical Care Survey (NAMCS) | Health Survey | CDC | NCCAM | The National Ambulatory Medical Care Survey (NAMCS) is a national survey designed to meet the need for objective, reliable information about the provision and use of ambulatory medical care services in the U.S. Findings are based on a sample of visits to non-federal employed office-based physicians who are primarily engaged in direct patient care. In 2012, a series of questions were added to assess what types of complementary health practices are used physician offices and the referral patterns to complementary health care providers such a chiropractors and acupuncturists. |
| The National Committee on Vital and Health Statistics | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS | OD/DPCPSI/OBSSR | The National Committee on Vital and Health Statistics (NCVHS) serves as the statutory [42 U.S.C. 242k(k)] public advisory body to the Secretary of Health and Human Services in the area of health data and statistics. In that capacity, the Committee provides advice and assistance to the Department and serves as a forum for interaction with interested private sector groups on a variety of key health data issues. |
| The NIH Bone Marrow Stromal Cell Transplantation Center | Research Initiative | FDA | NIDCR, CC, NCI, NHLBI, NIAID, NIAMS, NIBIB, NINDS | The mission of the NIH Bone Marrow Stromal Cell (BMSC) Transplantation is to develop clinical grade bone marrow stromal cells for use in clinical trials that utilizes the ability of these cells to exert immunomodulatory and immunosuppressive effects that are beneficial for the treatment of a number of diseases and disorders, and to provide assistance to clinical investigators in the preparation of regulator documents for institutional review boards and the U.S. Food and Drug Administration. |
| The Pharmacology Research Associate (PRAT) Program | Training Initiative | FDA | NIGMS | Funding provided for the support of a Pharmacology Research Associate (PRAT) Program Associate as a second year fellow in the laboratory at the U.S. Food and Drug Administration. |
| The Science of Sex and Gender in Human Health | Training Initiative | FDA | OD/DPCPSI/ORWH | This is a Web-based course that offers a basic scientific understanding of the major physiological differences between the sexes; their influence on illness and health outcomes; and their implications for policy, medical research, and health care. |
| The Trans-NIH Rare Diseases Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCATS, CC, CSR, FIC, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM | The Trans-NIH Rare Diseases Working Group was established in 2004. This Working Group assists the Office of Rare Diseases Research in carrying out its mission by addressing a set of goals that build on partnerships the Office of Rare Diseases Research has developed with National Institutes of Health (NIH) Institutes, Centers, and Offices, U.S. Department of Health and Human Services Agencies, and other organizations that address issues in rare diseases research such as identifying research opportunities and advances in rare diseases research; promoting coordination and cooperation in joint research efforts among the NIH Institutes, Centers and Offices and the research entities they support. |
| The United Nations 57th Session of the Commission on the Status of Women (CSW) | Committee, Work group, Advisory group, or Task Force | ACF, CDC | NIDA | The U.S. Department of Health and Human Services (HHS) Office of Global Affairs–International Health Action for a Healthier U.S. is the lead office for HHS efforts. This office invited representatives from several HHS agencies to prepare for representing HHS at the Commission on the Status of Women meeting in March 2013. |
| The United States Renal Data System (USRDS) | Resource Development | CMS, HRSA | NIDDK | The United States Renal Data System (USRDS) is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the U.S. The missions of the USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients. |
| Therapeutics for Rare and Neglected Diseases (TRND)/FDA Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCATS, CC, NHGRI, NHLBI, NICHD, NINDS | A group of Therapeutics for Rare and Neglected Diseases (TRND) staff and U.S. Food and Drug Administration (FDA) staff from the Center for Drug Evaluation and Research (CDER) meet on a semi-monthly basis to discuss projects for the TRND program. The purpose of this working group is to discuss the scientific progress on each project toward the eventual goal of an Investigational New Drug Application for each project. Results of experiments are discussed, and TRND staff takes the feedback of FDA/CDER staff into consideration when developing future project plans. |
| Tobacco and Nicotine Research Interest Group (TANRIG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | NIDA, NCI, NHGRI, NHLBI, NIAAA, NIAID, NICHD, NIEHS, NIMH, NINR, OD/DPCPSI/OBSSR | The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant U.S. Department of Health and Human Services agencies. |
| Tobacco Regulatory Science Program (TRSP) | Research Initiative | FDA | OD/DPCPSI/ODP, NCI, OD/OER | Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources. |
| Toxicology in the 21st Century (Tox21) Program | Research Initiative | FDA | NCATS, NIEHS | The Toxicology in the 21st Century (Tox21) initiative, championed by the National Center for Advancing Translational Sciences (NCATS), the National Institute of Environmental Health Sciences (NIEHS), the U.S. Environmental Protection Agency (EPA), and the U.S. Food and Drug Administration (FDA), was formed to develop high-throughput screening tests that measure cellular harm caused by environmental chemicals. The goals of the Tox21 initiative are to identify patterns of compound-induced biological response in order to characterize toxicity and disease pathways, facilitate cross-species extrapolation, and model low dose extrapolation, to prioritize compounds for more extensive toxicological evaluation, and finally, to develop predictive models for biological response in humans. |
| Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us”. The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of U.S. and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination and co-operation. |
| Trans-HHS Intimate Partner Violence Screening and Counseling: Research Symposium | Meeting/ Workshop | ACF, ACL, AHRQ, CDC, HRSA, IHS, SAMHSA | NIDA, NIA, NIAAA, NIMH, NLM, OD/DPCPSI/ORWH, OD/OER | The Coordinating Committee on Women''s Health represents U.S. Department of Health and Human Services (HHS) agencies and offices throughout the Department. It has identified the prevention and intervention of domestic/intimate partner violence (IPV) as a priority focus for its cross-federal work. There is a critical need for guidelines for health practitioners to effectively screen patients for IPV and provide appropriate counseling. At the request of Dr. Howard Koh, HHS convened a research symposium at the National Institutes of Health (NIH) in December 2013 with the purpose of identifying gaps in research in screening and counseling for IPV in primary health care settings and to shape priorities in the national research agenda moving forward. Ultimately, the Department’s goal is to promote effective strategies for health care practitioners for screening and counseling. |
| Trans-NIH American Indian and Alaska Native Health Communications and Information Workgroup | Committee, Work group, Advisory group, or Task Force | IHS | NIAMS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORWH | The workgroup provides a forum for National Institutes of Health (NIH) health education and communications staff to share effective communication approaches to develop and disseminate health information for American Indian and Alaska Native communities. The Work Group partners with the Indian Health Service to conduct outreach to 1,600 Community Health Representatives (CHRs) nationwide through a regular mailing of NIH health information in order to increase awareness among CHRs about the availability of NIH health information for patients and the general public. |
| Trans-NIH Plan for HIV-Related Research | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS | OD/DPCPSI/OAR, CC, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORIP, OD/DPCPSI/ORWH | Authorized by section 2353 of the Public Health Service Act, this annual collaborative planning process establishes scientific priorities for all National Institutes of Health (NIH) AIDS research. Broad input is solicited from scientists from NIH, other government agencies such as the U.S. Department of Veterans Affairs, U.S. Agency for International Development, Department of Defense, and U.S. President''s Emergency Plan for AIDS Relief, and non-governmental organizations, as well as community representatives and other experts from the U.S. and abroad. |
| Translational Research to Help Older Adults Maintain their Health and Independence in the Community | Research Initiative | ACL | NIA | The National Institute on Aging (NIA) is soliciting applications using the National Institutes of Health R01 and R21 award mechanisms for translational research that move evidence-based research findings toward the development of new interventions, programs, policies, practices, and tools that can be used by community-based organizations to help elderly individuals remain healthy and independent, and living in their own homes and communities. The goal of this initiative is to support translational research involving collaborations between academic research centers and community-based organizations with expertise serving the elderly, specifically encouraging connections with Area Agencies on Aging, organizations affiliated with the Corporation for National and Community Service, and other entities that will enhance our understanding of practical tools, techniques, programs and policies that communities across the nation can use to more effectively respond to needs of their aging populations. |
| Transplant Cancer Match Study | Research Initiative | HRSA | NCI | A study linking databases of U.S. transplant recipients, donors, and wait list candidates to multiple U.S. cancer registries to evaluate the spectrum of cancer risk in transplant recipients. |
| Traumatic Brain Injury Common Data Elements Standards - Interagency Steering Committee | Resource Development | CDC | NINDS, CIT | The Traumatic Brain Injury (TBI) Common Data Elements (CDE) Standards – Interagency Steering Committee provides oversight to a Federal scientific initiative to develop and utilize common data elements for TBI. |
| Treating for Two: Safe Medication Use in Pregnancy Initiative | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | OD/DPCPSI/ORWH, NICHD | The initiative provides expert input for the development of a conference on systematic, evidence-based review of specific medications used during pregnancy and adverse fetal outcomes. |
| Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) | Research Initiative | CDC | NIDDK | Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) is a multi-center clinical research study examining the safety and efficacy of three treatment options for type 2 diabetes in the pediatric population. TODAY was initiated due to the increase in type 2 diabetes in children and adolescents, which itself is linked to the rise in obesity. |
| Trends in Hormone Concentrations in U.S. Men and Relationship to Endocrine Disrupting Chemicals in the National Health and Nutrition Examination Survey (NHANES) Population | Research Initiative | CDC | NCI | An examination of serum hormone levels of men in the National Health and Nutrition Examination Survey (NHANES) population to determine whether levels have declined over time and whether they correlate with serum levels of endocrine disrupting chemicals. |
| Tribal Epidemiology Centers Program | Research Initiative | IHS | NIMHD | To develop Epidemiology Centers and public health infrastructure for American Indian/Alaska Native communities. |
| Tribal Health Research Advisory Council (HRAC) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, OS, SAMHSA | NIMHD | To support the activities of the Council, including obtaining input from tribal leaders on health research priorities and needs, and dissemination of information. |
| Two-dose H7N9 Vaccination Project | Research Initiative | OS | NIAID, NIGMS | The National Institute of Allergy and Infectious Diseases (NIAID) is working with the National Institute of General Medical Sciences (NIGMS) and the Biomedical Advanced Research and Development Authority (BARDA) on a project to use a previously developed mathematical model to determine the best use of a limited supply of H7N9 vaccine. |
| U. S. Government Interagency Working Group on Nanotechnology Environmental, and Health Implications (NEHI), of the Nanoscale Science, Engineering, and Technology Subcommittee (NSET) of the National Science and Technology Council (NSTC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB, NIEHS | The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee and Nanotechnology Environmental, and Health Implications (NEHI) Working Group provide leadership in establishing the national nanotechnology environmental, health, and safety research agenda and in communicating data and information related to environmental and health aspects of nanotechnology between National Nanotechnology Initiative (NNI) agencies and with the public. NNI activities support the development of new tools and methods required for the research that will enable risk analysis and assist in regulatory decision-making. NNI agencies engage and interact with regional, state, and local groups, educational institutions, industry-supported groups, and non-governmental organizations to enhance the impact and value of NNI efforts and to provide a collaborative approach. |
| U.S. Government Interagency Working Group on Nanotechnology Environmental, and Health Implications (NEHI), of the Nanoscale Science, Engineering, and Technology Subcommittee (NSET) of the National Science and Technology Council (NSTC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIBIB, NCI, NHGRI, NIEHS | The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee and Nanotechnology Environmental, and Health Implications (NEHI) Working Group provide leadership in establishing the national nanotechnology environmental, health, and safety research agenda and in communicating data and information related to environmental and health aspects of nanotechnology between National Nanotechnology Initiative (NNI) agencies and with the public. NNI activities support the development of new tools and methods required for the research that will enable risk analysis and assist in regulatory decision-making. NNI agencies engage and interact with regional, state, and local groups, educational institutions, industry-supported groups, and non-governmental organizations to enhance the impact and value of NNI efforts and to provide a collaborative approach. |
| U.S. Government response to Fukushima nuclear crisis | Public Education Campaign | OS | NCI | Scientists were deployed in 2011 for two weeks to the U.S. Embassy in Tokyo, Japan, as part of the U.S. Government response to protect U.S. citizens abroad during a nuclear crisis. The National Cancer Institute continues to collaborate on research involving the response and recovery efforts. |
| U.S. Preventive Services Task Force (USPSTF) | Resource Development | AHRQ | NCI, NINR, OD/DPCPSI/ODP | The U.S. Preventive Services Task Force (USPSTF) is an independent panel of non-Federal experts in prevention and evidence-based medicine and is composed of primary care providers. The USPSTF conducts scientific evidence reviews of a broad range of clinical preventive health care services (such s screening, counseling, and preventive medications) and develops recommendations for primary care clinicians and health systems that are published in the form of "Recommendation Statements." |
| United State Government (USG) Interagency Forensics Advisory Board | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | The purpose of the Interagency Forensics Advisory Board is to discuss strategies for the U.S. Government (USG) in the area of microbial forensics and attribution investigations. One of the first agenda items concerned microbial repositories across the USG with a focus on challenges and gaps. |
| Urology Interagency Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA | NCCAM, NCI, NIA, NICHD, NIDDK, NINDS | Public law 99-158 establishes a need for the Urology Interagency Coordinating Committee and emphasizes the importance of interagency coordinating meetings. Meetings focus on interagency collaboration to elicit ideas from meeting participants to enhance current research directions within the National Institutes of Health and form partnerships among agencies. |
| US-Ireland Research & Development Partnership | Research Initiative | OS | NHGRI, NHLBI, NIBIB, NIDDK | The goal of the partnership is to stimulate collaborative research between the U.S. and Ireland in the area of cystic fibrosis (CF), diabetes, and nanotechnology. Government agencies and non-profit organizations, including National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Science Foundation; Cystic Fibrosis Foundation; R&D Office (Northern Ireland); Department of Enterprise, Trade, and Employment; Health Research Board; Science Foundation Ireland; and Inter-Trade Ireland, participate. As an outgrowth of the U.S.-Ireland R&D Partnership, a grant proposal on the role of anaerobic bacterial infection in CF was submitted to the National Institutes of Health which involves U.S.-Ireland tripartite scientific collaboration. |
| Ventilator-Associated Pneumonia | Meeting/ Workshop | CDC | CC | A series of meetings were held to develop a practical new national surveillance definition for ventilator-associated pneumonia. |
| We Can! (Ways to Enhance Children’s Activity and Nutrition) | Public Education Campaign | CDC, HRSA | NHLBI, NCI, NICHD, NIDDK | Through the We Can! (Ways to Enhance Children’s Activity and Nutrition) program, the National Institutes of Health and other U.S. Department of Health and Human Services partner agencies disseminate strategies, tools, and resources to community organizations, the general public, healthcare providers, and other groups. Strategies focus on three behaviors: eating right, moving more, and reducing screen time to help prevent obesity in youth. Parents and caregivers of 8-13 year olds are the primary focus of the program''s outreach. |
| We Can! Health Education Campaign and the Program Media-Smart Youth: Eat, Think, and Be Active! | Meeting/ Workshop | OS | NICHD, NHLBI | In FY13, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) held a conference for organizational leaders and partnered with the National Heart, Lung, and Blood Institute (NHLBI) and the U.S. Department of Health and Human Services’ Center for Faith-Based and Neighborhood Partnerships to promote the We Can! (Ways to Enhance Children’s Activity and Nutrition) health education campaign and the program Media-Smart Youth: Eat, Think, and Be Active! NICHD and NHLBI staff co-led a series of training webinars, hosted by the Partnership Center, to train hundreds of community leaders across the country in implementing We Can! programs, including Media-Smart Youth. |
| White House Interagency Committee on the Implementation of the US Strategy to Prevent and Respond to Gender-Based Violence Globally | Committee, Work group, Advisory group, or Task Force | ACF, CDC | NIDA, OD/DPCPSI/ORWH | This is an interagency working group to address gender-based violence, which shall coordinate implementation of the strategy by the Departments and Agencies that are members of the Working Group (member agencies) in accordance with the priorities set forth in section 3 of the Executive Order 13623. |
| White House Office of National Drug Control Policy (ONDCP) Electronic Health Records (EHRs) Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA, IHS, OS, SAMHSA | NIDA, NIAAA, NIMH | This interagency working group coordinates initiatives across the U.S. Department of Health and Human Services to improve efforts to leverage meaningful use of electronic health records, health information technology, and related research and implementation activities as a means to improve quality, safety, and efficiency for substance use disorder research and treatment. |
| Wireless Medical Technologies | Committee, Work group, Advisory group, or Task Force | FDA, OS | NIBIB, CIT, NIA, NIAAA, NIAID, NICHD, NIMH, NINDS, NLM | The Wireless Medical Technologies Working Group was launched as follow-up to the Personal Motion Technologies for Healthy Independent Living workshop in 2010. The working group provides a forum for information sharing among Federal agencies to better understand challenges and barriers to wireless medical technology adoption including issues of engineering development, regulatory issues governing safety, effectiveness and communication, relevant standards, and reimbursement. |
| Women''s Health Research In-Focus: Violence Against Women | Resource Development | ACF, CDC | NIDA, OD/DPCPSI/ORWH | Led by the National Institute on Drug Abuse (NIDA), the Office of Research on Women''s Health recently published a fact sheet focused on violence against women. The fact sheet highlights the research and activities of the National Institutes of Health in this area as well as the various federal programs addressing violence against women. |
| Work Group on Harmonizing Hemoglobinopathy Data Sets | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NLM, NCATS, NHLBI, NICHD, NIGMS, OD/OER | The mission of the Workgroup for Harmonizing Hemoglobinopathy Data Sets is to create a resource for federal programs and extramural communities to use in data systems which incorporate data elements in hemoglobinopathies. Specifically this entails establishing a Hemoglobinopathies Uniform Medical Language including: identifying specific goals and objectives for the kind of data that are required by these programs; case definitions for electronic data systems at all levels; consensus about conditions and data elements to be included; and differentiation between data needs for surveillance and for registries/biorepository. |
| Work, Family and Health Network | Research Initiative | ACF, CDC | NICHD, NIA | The Administration for Children and Families'' Office of Planning, Research and Evaluation is providing the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) funds to partially support the "Work, Family, and Health Network," a research project of NICHD. This project is examining the effects of a workplace intervention designed to reduce work-family conflict and thereby improve the health and well-being of employees and their families. There is a modification agreement and the purpose of the modification agreement is to provide continuation of research support for the Work, Family and Health Network (WFHN) "Limited Competition for Evaluating the Health Benefits of Workplace Policies and Practices." The WFHN evaluated the health benefits of workplace policies and practices aimed at ameliorating work-family conflict. |
| Workgroup on Research Related to Evidence Based Policy | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, OS, SAMHSA | NIDA | This workgroup focuses on research issues surrounding evidence-based policy. Discussions generally include cross cutting questions-- e.g., What is evidence-based? What are key lessons that have been learned as evidence-based policy has been rolled out? In addition, this group provides updates on meetings and projects related to evidence-based policy. |
| Working Group on the Intersection of HIV/AIDS, Violence Against Women and Gender-related Health Disparities | Committee, Work group, Advisory group, or Task Force | ACF, CDC | NIDA, OD/DPCPSI/OAR, OD/DPCPSI/ORWH | This working group is in response to the Presidential Memorandum calling for executive departments and agencies to build on their current work addressing the intersection of HIV/AIDS, Violence Against Women, and Girls and Gender-related Health Disparities by improving data collection, research, intervention strategies, and training. |
| Working Groups to Develop Federal HIV/AIDS Prevention and Treatment Guidelines | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | OD/DPCPSI/OAR, NICHD, NIMH | Working Groups of HIV experts from across the country, including physicians, pharmacists, researchers, and HIV treatment advocates responsible for writing, reviewing, and updating HIV/AIDS prevention and treatment guidelines. |
| Yale Specialized Center of Research (SCOR) on Gender-Sensitive Treatment for Tobacco Dependence | Research Initiative | FDA | NIDA | The Yale-Specialized Center of Research (SCOR) is bringing together leading basic and clinical science experts to establish an interdisciplinary, translational, cross-species program of research aimed at identifying novel therapeutics to address the critical health disparity that female smokers face. |
An official website of the United States government
Here's how you know
Official websites use .gov
A .gov website belongs to an official government
organization in the United States.
A .gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.